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Abstract 
Behçet Syndrome (BS) is a multisystem disorder characterized by mucocutaneous lesions (oral 
ulcers, genital ulcers, and skin pustules), arthritis and intraocular inflammation. The 
pathogenesis of BS is poorly understood but it is considered a complex polygenetic syndrome, 
with environmental triggers. A Th1 skew has been reported. Recent genome wide association 
studies have confirmed the association with HLA B51, as well as identifying novel single 
nucleotide polymorphisms including IL-10, IL23/12R, STAT4, ERAP1 and CPLX1.  Aims:  
This project aimed to dissect abnormal cutaneous inflammatory response in BS to gain an 
understanding as to which pathways are responsible for the pathergy response. Secondary aims 
were to dissect any observations in more detail in vitro. In Chapter 3, the hypothesis that the 
abnormal cutaneous inflammatory response to "non-specific" stimulation in BS is associated 
with a failure of deactivation of macrophages during the resolution phase of inflammation was 
explored using human in vivo models of inflammation (MSU injections and skin blisters). In 
Chapter 4, the hypothesis that the abnormal cutaneous inflammatory response may involve 
neuropeptides was explored. We applied capsaicin topically to BS and HC, and measured the 
resultant change in dermal blood flow using laser doppler imaging to evaluate non-invasively if 
neuropeptides such as CGRP may play a role in the abnormal cutaneous inflammatory response 
in BS. Chapter 5 summarizes key in vitro experiments undertaken alongside in vivo 
experiments. The IFN-γ / chemokine pathways were explored in detail in CD14+ monocyte 
populations in BS, HC and disease control subjects.  Results: CXCL10 was identified as a 
chemokine of interest using the Cantharidin skin blister model of inflammation. We did not find 
statistically significant differences in neuropeptide responses between BS and HC, although 
there was a trend towards less CGRP in the BS cohort. In vitro work focused on peripheral 
blood derived monocytes stimulated with IFN-γ. BS monocytes produced significantly more 
CXCL10 protein versus healthy control (HC) monocytes from two hours onwards, despite 
equivalent quantities of mRNA, revealing a significantly increased protein:mRNA ratio. This 
increased protein:mRNA ratio was found to be a specific response. Other IFN-γ induced 
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chemokines examined did not show this response profile (CXCL9,CXCL11, CCL2); monocytes 
stimulated with other cytokines (e.g. TNF-α) did not show this specific response; and the 
increased CXCL10 protein mRNA ratio was  not observed in either Rheumatoid Arthritis (RA) 
or Systemic Lupus Erythematosus (SLE) patients. Sucrose density gradients, to segregate cell 
lysate mRNA into free RNA or polysome-associated RNA, did not further differentiate HCs 
from BS, with equal quantities of mRNA in BS and HC samples being found in association with 
polysomes, possibly implicating microRNAs as translation control factors of interest. 
Conclusions: We have discovered that BS monocytes have dysfunctional post-transcriptional 
regulation of CXCL-10 mRNA, resulting in overexpression of CXCL-10 protein upon IFN-γ 
stimulation. This may contribute to the exaggerated inflammatory responses that characterises 
BS and could also be diagnostically useful. 
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1. Introduction 
 
Hippocrates of Cos (460–377 BC) described an illness with fevers, orogenital ulceration, 
pustules and eye disease in the 5th Century BC, “but there were also other fevers, as it will be 
described. Many had their mouths affected with aphthous ulcerations. There were also many 
defluxions about the genital parts, and ulcerations, boils (phymata), externally and internally 
about the groins. Watery ophthalmies of a chronic character, with pains; fungous excrescences 
of the eyelids, externally and internally, called fici, which destroyed the sight of many persons” 
[1]. From 1700 onwards, several reports were published of cases very similar to Behçet 
syndrome [2]. In one of these cases, reported in 1930 by the Greek ophthalmologist Benediktos 
Adamantiades [3], genital ulcers, arthritis and ocular inflammation were brought together as a 
single disease. In 1937, Hulusi Behçet, a Professor and Director of Dermatology and 
Syphilology at the University of Istanbul, published details of two patients with recurrent oral 
ulcers, genital ulcers, and ocular lesions [4]. During the following 3 years he published reports 
on five further patients in different languages, thereby promoting cultural awareness of the 
syndrome. Moreover, he added other clinical findings, including acneiform skin lesions, 
erythema nodosum, and arthralgia, to the so-called triple symptom complex [2]. He was 
convinced of the autonomy of this multi-system illness and succeeded in drawing the attention 
of the scientific community to it. 
The condition has been given many names, the two most widely accepted being Behçet disease 
and Behçet syndrome (BS). Given the heterogeneity of clinical manifestations, we prefer the 
term syndrome rather than disease, thereby avoiding the implication of a single aetiology. BS 
has a complex polygenetic pre-distribution, with probable environmental triggers resulting in 
abnormal inflammatory responses [5-8]. Classification of this syndrome as an autoinflammatory 
or an autoimmune condition, however, has been heavily debated. Autoinflammatory diseases 
are a group of inherited disorders characterized by episodes of seemingly unprovoked recurrent 
inflammatory attacks triggered by the innate immune system. Their underlying genetic basis 
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relates to mutations and/or polymorphisms of genes that encode proteins involved in the 
regulation of apoptosis, cytokine processing and inflammation [9]. In contrast to classical 
autoimmune disorders, autoinflammatory diseases show no female predominance, and evidence 
of antigen-specific T cells or high-titre specific autoantibodies is relatively lacking. In BS, no 
female preponderance is observed, HLA class II associations have not been demonstrated and 
no strongly associated autoantibodies have been found. Furthermore, many manifestations of 
BS overlap with autoinflammatory conditions (Table 1). However, BS does not fit perfectly into 
the autoinflammatory disease category, as fevers do not tend to be a prominent feature, and 
onset in children is unusual. If autoinflammatory disease classification is extended to include 
many polygenetic disorders, including Crohn’s disease, gout and Still’s disease, it may be 
reasonable to include BS in this broader grouping [10]. However, it may be best classified as a 
complex polygenetic syndrome.  
The complexity of BS makes dissecting the underlying pathogenesis a challenging prospect. 
Indeed, BS remains a relatively poorly understood syndrome. Recent genetic studies have shed 
some light on underlying mechanisms but much work remains to be done. Furthermore, there is 
a huge unmet clinical need, with no diagnostic test, no biomarkers to monitor disease activity or 
assess response to treatments and no specific treatments. This chapter reviews the clinical 
presentation of this syndrome as well as our current understanding of the pathogenesis of BS 
with emphasis on insights gleamed from recent genetic advances. It also highlights some of the 
excellent hypothesis-driven cellular research undertaken over the past 5 decades, trying to marry 
this to recent genetic insights. The evidence for environmental triggers in genetically susceptible 
individuals is also touched upon. Finally I outline my research aims. Detailed introductions for 
the three arms of this research project are found in later chapters.  
 
 
 
 
 24 
 
Table 1-1. Overlapping features of autoinflammatory conditions and BS 
Overlapping features of autoinflammatory conditions and Behçet Syndrome 
Clinical finding Associated autoinflammatory condition 
Aphthous ulcerations HIDS 
Genital ulcerations HIDS 
  PAPA 
Acneiform lesions PAPA 
Pathergy  PAPA 
Uveitis Blau Syndrome  
  NOMID 
  TRAPS 
Non deforming arthritis FMF 
  TRAPS 
  PAPA 
  Blau Syndrome 
  Muckle Well's Syndrome 
  HIDS 
Meningoencephalitis FMF 
  NOMID 
Abbreviations: HIDS, Hyperimmunoglobulinemia D with Periodic Fever Syndrome; NOMID, 
Neonatal Onset Multisystem Inflammatory Disease;  PAPA, Pyogenic Sterile Arthritis, Pyogenic 
Gangrenosum and Acne Syndrome; TRAPS, TNF Receptor Associated Periodic Syndrome. 
Table adapted from paper by Ambrose, Haskard[11] 
 
1.1 Epidemiology and prevalence 
BS is found throughout the world, with the highest prevalence in countries bordering the Silk 
Route, an ancient network of interlinking trade routes that connected Asia with the 
Mediterranean world. BS is linked with HLA B51 and the high frequency of this tissue antigen 
along the Silk Route indicates that a genetic risk migrated with population movement [12]. Not 
only is BS more common in countries related to the Silk Route than those further away, but the 
clinical manifestations also seem to be more severe [13]. National epidemiological studies of 
BS have been undertaken in Iran (6,500 cases)[14], Japan (3,316) [15], China (1,996) [16], 
Korea (1,527) [17] and Germany (590) [18], in addition to large case series from several 
countries [19-23]. From these reports, prevalence seems to vary from 80–421 per 100,000 
individuals in Turkey, 80 in Iran, 8.6 in the USA and 7.2 in France to 4.2 in Germany [14-24]. 
Precise figures are not available for the UK, but the UK Behçet’s Syndrome Society (the 
national patient group) have in excess of 600 members who report having ‘confirmed Behçet 
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syndrome’, leading to a possible prevalence of 10 per 100,000 individuals [25]. The male to 
female ratio in the larger national studies shows some variability, but overall no outright 
worldwide gender predominance is evident (Iran, 1.19; Japan, 0.97; China, 1.34; Korea, 0.57; 
Germany, 1.4; and Turkey, 1.03) [14-26]. The onset of BS is typically in early–middle adult life 
(that is 20–40 years of age) but, in rare instances, it also presents during childhood or in the 
elderly [27]. 
1.2 Clinical manifestations 
BS is a multisystemic disorder, with mucocutaneous involvement being almost universal. 
Musculoskeletal symptoms are also common. Less commonly, ocular, vascular, gastrointestinal 
and/or neurological involvement occurs, with potentially serious consequences. The frequency 
of manifestations shows geographical variation. Additionally, at least two clusters of disease 
manifestations have been observed: that of superficial vein thrombosis, deep vein thrombosis 
and dural sinus thrombus; and that of acne, arthritis and enthesitis. 
1.2.1 Orogenital ulceration 
Recurrent oral aphthae are the hallmark of BS; they are almost always evident and can precede 
other manifestations by months or years. Ulcers can be small (minor ulcers, <10 mm), large 
(major ulcers, >10 mm) or, occasionally, herpetiform. Ulcers normally occur in crops on the 
buccal mucosa and mucosa of the inner lips but can also occur on the tongue, hard and soft 
palate and in the pharynx. Ulcers in BS do not typically form on the external lips, and lesions 
there should lead one to think of other disorders such as herpes virus or Stevens–Johnson 
syndrome. The ulcers are usually painful and occasionally scar. The most common differential 
is recurrent aphthous stomatitis, which affects up to 10% of the population. Oral ulcers in BS 
may be surrounded by an erythematous halo, although this observation is not sufficiently 
specific or sensitive to aid in diagnosis. Importantly, many other conditions can be associated 
with oral ulceration (a non-exhaustive list is shown in Table 2). Most oral ulcers in BS resolve 
within 10–14 days. Occasionally oral ulcers in BS can be persistent, but non-healing ulcers 
should be considered for biopsy to exclude an alternative diagnosis, such as Crohn’s disease or 
 26 
 
carcinoma. Interestingly, cigarette smoking may provide some protection from oral ulceration 
[28]. 
Genital ulcers occur less frequently than oral ulcers (Iran, 65% of patients; Japan, 73%; China, 
76%; Korea, 83%; Germany, 64%; and Turkey, 88%)[14-26]. They resemble oral ulcers in 
appearance, are usually painful and, when deep, may heal with scarring. Genital ulcers in 
females affect the vulva and vagina and, occasionally, the cervix. In males, ulcers occur 
classically on the scrotum. Ulceration on the penis may occur in BS but should raise the 
possibility of HLA B27-related spondyloarthritis, particularly if situated around the glans penis. 
As with oral lesions, non-healing ulcers should be biopsied. 
Table 1-2.  Differential diagnosis of recurrent oral ulcerations 
Differential diagnosis of recurrent oral ulcerations 
Aphthous ulcerations ('recurrent aphthous stomatitis') affects 10% population 
Rheumatological disease Systemic Lupus Erythematosus 
  Spondyloarthropathy 
  Rheumatoid Arthritis 
Gastrointestinal disease Inflammatory Bowel Disease 
  Coeliac Disease 
Autoinflammatory conditions HIDS 
Infectious disease Herpes Simplex 
  HIV 
Dermatological disease Stephens Johnson 
  Pemphigoid 
  Pemphigus 
  Lichen Planus 
Haematological Cyclic neutropenia 
Other Drugs 
  
        methotrexate, other chemotherapy, 
nicorandil 
  nutritional deficiencies 
          Vitamin B12, Iron, Folic acid 
Table adapted from paper by Ambrose, Haskard[11] 
1.2.2 Pathergy 
Pathergy refers to an exaggerated response to minor trauma, and is often experienced as a 
prolonged cutaneous erythematous inflammatory response to day-to-day insults, such as needle 
or thorn pricks or nettle stings. Pathergy is a hallmark feature of BS and can be very helpful in 
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differentiating BS from other conditions with overlapping clinical features such as Crohn’s 
Disease (CD) and Systemic Lupus Erythematosus (SLE). Examining the pathergy response in 
BS was one of the main arms of this research project. The Pathergy test and histology of the 
pathergy response is discussed in more detail later in this chapter and in Chapter 3. 
1.2.3 Skin lesions 
Cutaneous lesions are very common in BS, occurring in 65–87% of patients (Iran, 65%; Japan, 
87%; China, 69%; Korea, 84%; and Germany, 81%) [14-26]. Usual features include papules 
and pustules resembling acne, although care must be taken during diagnosis to consider whether 
pustules are an adverse effect of corticosteroid therapy. Acneiform lesions are more common in 
patients with BS with arthritis and are indistinguishable from acne vulgaris except that lesions 
may also occur on limbs [29]. The lesions are not sterile and have a similar microbiologic flora 
to acne [30]. Erythema nodosum may occur in BS, but is also a strong indicator of inflammatory 
bowel disease or sarcoidosis. Subcutaneous nodules may also be caused by superficial 
thrombophlebitis. 
1.2.4 Ocular inflammation 
The onset of ocular inflammation is usually within 2–3 years of the diagnosis of BS and is the 
presenting manifestation in 10–15% of cases. The eye is the most commonly involved vital 
organ (Iran, 57%; Japan, 69%; China, 35%; Korea, 51%; and Germany, 58%) [14-26]and tends 
to be most severely affected in males and in individuals less than 30 years of age [31]. Ocular 
disease is characterized by unpredictable, repetitive inflammatory attacks, which can subside 
spontaneously without treatment, with little inflammation between attacks. Bilateral panuveitis 
and retinal vasculitis are the typical manifestations of ocular disease [31]. Recurrent attacks 
eventually result in complications such as cataract, posterior synechiae, macular oedema, optic 
atrophy and glaucoma. Isolated anterior uveitis occurs in only ~10% cases, and is more common 
in females (22.3% patients) than males (5.8% patients) but is more typical of HLA B27-related 
diseases than BS [31]. It may present with a hypopyon (that is, an accumulation of white blood 
cells in the anterior chamber of the eye), which is visually dramatic but is rarely sight 
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threatening. Conjunctivitis, scleritis, episcleritis and sicca syndrome are uncommon and should 
also lead one to consider alternative diagnoses. 
1.2.5 Neurological system 
Headache is a common symptom in BS, occurring in over 80% of patients [32]; the vast 
majority of instances are a result of primary headache syndromes rather than detectable 
structural central nervous system (CNS) disease. Migraine is the most common problem 
(characterized by unilateral throbbing pain, visual or sensory aura), although a small number of 
patients have tension type headaches (characterized by a dull, constant, occipitovertebral 
ache)[32]. In patients complaining of headache, symptoms that warrant further investigation 
include severe or incapacitating pain, a change in character of the headache and particularly the 
presence of neurological signs [33]. 
Excluding headaches, neurological complications of BS (nBS) occur in less than 12% of cases 
(Iran, 3.5%; Japan, 11%; China, 6.5%; Korea, 4.6; and Germany, 11%) [14-26], often a few 
years after the onset of the other systemic features. Parenchymal disease occurs more frequently 
than neurovascular, and both types are more common in males than females [34]. By contrast, 
involvement of the peripheral nervous system is uncommon, and was seen in only 0.8% of 
patients in one large case series [33]. In parenchymal disease, meningoencephalitis occurs, with 
a mixed inflammatory cell infiltrate leading to necrosis and apoptotic neuronal loss [35]. 
Inflammatory infiltration, rather than fibrinoid necrosis, is seen around small vessels [35, 36]. 
The brainstem and mid-brain are the most commonly affected areas, but spinal cord lesions and 
cerebral involvement may also occur and, occasionally, nBS presents as a pseudotumour 
cerebri. Brainstem involvement usually presents subacutely, with headache, cranial neuropathies 
or cerebellar or corticospinal tract dysfunction [37]. Sensorineural hearing loss can occur, 
resulting in sudden deafness, balance disturbances and dizziness [38]. The characteristic MRI 
lesion in parenchymal nBS is a unilateral upper brainstem lesion extending into the thalamus 
and basal ganglia [39]. Analysis of cerebrospinal fluid shows a neutrophilic (in early disease) or 
lymphocytic (in late disease) pleocytosis, but usually no oligoclonal bands [40]. 
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Neurovascular disease accounts for approximately 20% of cases of nBS and symptoms include 
dural sinus thrombosis, intracranial aneurysm and extracranial aneurysm and/or dissection. 
Aneurysms of the cerebral, vertebral and carotid arteries can also occur. The prognosis of nBS 
varies—those with a nonparenchymal process, such as dural sinus thrombosis, are unlikely to 
have recurrent disease, disability, or premature death if they survive the initial event. By 
contrast, patients with parenchymal disease have a less certain outcome [33, 40]. 
1.2.6 Musculoskeletal system 
Musculoskeletal symptoms are extremely common in BS (Iran, 37%; Japan, 57%; China, 30%; 
Korea, 38%; and Germany, 53%) [14-26] . Arthritis is asymmetric and palindromic, potentially 
affecting most joints, but particularly the knees, ankles, and wrists. Erosive arthritis is very 
unusual and should suggest another diagnosis, such as spondyloarthritis (SpA) [41]. At one 
stage BS was classified in the spectrum of SpA [42, 43]. The distinction created much debate, 
and prospective studies of joint involvement in BS showed sacroiliac joint involvement to be 
rare in BS [41, 43]. As discussed in more detail later in the chapter, recent genome wide 
association studies (GWAS) have identified overlapping single nucleotide polymorphisms 
(SNPs) of interest in the two conditions (e.g. ERAP1).  Fibromyalgia coexists in many patients 
with BS and is associated with anxiety and depression, but not necessarily with the activity of 
other manifestations [44]. Although chrondritis is not a usual feature of BS, the rare mouth and 
genital ulcers with inflamed cartilage (MAGIC) syndrome overlaps with features of BS and 
relapsing polychrondritis [45]. Osteitis and hyperostosis are also not features of BS and their 
presence should lead one to suspect synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) 
syndrome[46]. 
1.2.7 Gastrointestinal manifestations 
Many patients with BS experience abdominal pain, and symptoms similar to irritable bowel 
syndrome.  Demonstrable gastrointestinal ulceration, with lesions in the terminal ileum, caecum, 
and ascending colon are less common (Iran, 7%; Japan, 15%; China, 9%; Korea, 7%; and 
Germany, 12%) [14-26, 47]. Ulceration may also occur in the small intestine [48]. 
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Distinguishing BS with gastrointestinal ulceration from inflammatory bowel disease (e.g. CD) 
with extra-enteric involvement can be difficult, unless granuloma are visible in biopsy samples 
(CD) [49]. 
1.2.8 Cardiovascular system 
The vasculopathy of BS is distinct from other forms of vasculitis as it predominantly affects 
veins and pulmonary arteries, both of which transport deoxygenated blood under low pressure. 
Vascular involvement shows wide geographic variability (Iran, 8.9%; Japan, 8.9%; China, 
7.7%; Korea, 1.8%; Germany, 23%; and Turkey, 17%) [14-26]. When present, vascular 
pathology is frequently the presenting complaint [50], most commonly in male patients and 
those with a positive pathergy test or ocular involvement [51]. Superficial thrombophlebitis 
presents as tender superficial nodules and can be difficult to distinguish clinically from 
erythema nodosum. Besides sometimes having a linear appearance localizing to a peripheral 
vein, superficial thrombophlebitis can also be recognized by ultrasonography showing a central 
lumen. Deep vein thrombosis (DVT) usually affects veins of the legs [52], but may involve the 
superior and/or inferior vena cava, or, less commonly, the mesenteric, portal, hepatic, splenic, 
iliac, subclavian, axillary and retinal veins and/or dural sinuses. Venous thrombosis is 
considered to be partially accounted for by activated vascular endothelium, and no intrinsic 
abnormality of coagulation has been reported. 
Arterial aneurysm formation is much less common than venous thrombosis. Aneurysms have a 
predilection for the pulmonary arterial tree, although aneurysms of the systemic circulation also 
occur. The association of pulmonary artery aneurysms with peripheral DVT is known as 
Hughes–Stovin syndrome, and is important to distinguish from pulmonary embolism in any 
patient with BS presenting with haemoptysis and DVT, as anticoagulation could be fatal [53]. In 
fact, embolism of venous thrombi is thought to be unusual in BS, perhaps because clots tether 
along a length of inflamed vein. 
Unlike other inflammatory conditions, acceleration of atherosclerosis does not seem to be a 
feature of BS [54].  
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1.2.9 Genitourinary system 
Besides genital ulceration, urogenital pathology is uncommon, and, in particular, parenchymal 
renal disease is rare. Young men may experience attacks of epididymitis, which is often 
misinterpreted as infective. Bladder mucosal ulceration may be responsible for urinary 
symptoms, and is probably underdiagnosed [55]. 
1.2.10 Constitutional symptoms 
Patients with BS often have constitutional symptoms. Fatigue is almost universal and has a huge 
effect on patient quality of life [25]. Fevers are often self-reported but less commonly 
substantiated, and demonstrable recurrent fevers should lead one to consider other conditions 
such as autoinflammatory disorders, cyclical neutropenia (characterized by monthly fevers, 
mouth ulcers, pharyngitis and cervical lymphadenopathy), or sepsis. 
1.3 Reaching the diagnosis 
No diagnostic test currently exists for BS and markers of inflammation such as C reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) may be only modestly elevated or even 
normal in patients with active disease. One of the aims of this research project was to study skin 
models of inflammation to assess their potential usefulness for diagnosis or measuring disease 
activity.   
HLA B51 expression occurs with increased frequency in patients with this syndrome, depending 
on ethnicity [56]. However, expression of this antigen is neither sensitive nor specific as a 
diagnostic test. The diagnosis therefore has to be decided on clinical grounds, with due 
diligence in excluding other conditions. The Classification criteria published by the 
International Study Group in 1990 are helpful for this purpose, and require the presence of 
recurrent oral aphthous ulcerations plus two other major manifestations (Table 3) [57]. It is 
important to note that these criteria are intended for research and should not be applied 
dogmatically to clinical management. A thorough history and examination is essential. 
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Table 1-3. The International Study Group Criteria for diagnosis of BS 
The International Study Group Criteria for diagnosis of BS 
Symptom The detail 
Oral ulcerations 3 times a year 
Plus 2 of the following: in the absence of other systemic diseases 
recurrent genital aphthae   
eye lesions  
including anterior or posterior uveitis, cells in vitreous on slit lamp examination, or 
retinal vasculitis, observed by an ophthalmologist 
skin lesions  
including erythema nodosum, pseudo vasculitis, papulopustular lesions, or acneiform 
nodules consistent with BS 
a positive pathergy test  
a papule 2 mm or more in size developing 24 to 48 hours after oblique insertion of a 
20 to 25 gauge needle 5mm into the skin, generally performed on the forearm 
Table adapted from paper by Ambrose, Haskard [11]. 
 
1.4 The pathergy test and monosodium urate crystal test 
The pathergy test is usually performed by inserting a 20 gauge needle into the forearm skin and 
is considered positive if a papule or pustule is present after 48 hours. In national studies, 
pathergy phenomenon was seen in 34–57% of cases (Iran, 53%; Japan, 44%; Korea, 15%; 
Germany, 34%; and Turkey, 57%) [14-26].  Pathergy seems to be less common in non-endemic 
regions with only 10% of UK patients having a positive response [58]. Furthermore, the 
frequency of a positive test has declined over time, possibly owing to more effective prior 
cleaning of the test site [59]. Despite the low sensitivity, the pathergy test has a high specificity 
(>90%) and remains useful [59]. The neutrophilic dermatoses, such as Sweet’s syndrome and 
pyoderma gangrenosum, and pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) 
syndrome may also give a positive pathergy test. Additionally, a positive pathergy test has been 
reported in patients with chronic myeloid leukaemia treated with IFN-α [60]. The pathology of 
pathergy reactions resembles that of other skin lesions in BS, with neutrophils, monocytes and 
lymphocytes present in large numbers, together with increased mRNA transcripts for the 
cytokines IFN-γ, IL-12 p40 and IL-15; the chemokines CCL20, CXCL10, CXCL9, and 
CXCL11; and adhesion molecules ICAM-1, and VCAM-1,  at 48 hours in BS versus HC [61, 
62]. Cytokine response to needle injury in the skin in BS is qualitatively different from that 
occurring in healthy individuals [62]. 
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An alternative method to elicit an exaggerated response is to inject monosodium urate crystals 
(2.5 mg) into the dermis. The usual response consists of erythema and induration, which are 
maximal at ~24 hours. In healthy individuals there is an erythematous reaction at 24 hours 
which has usually largely resolved by 48 hours. In contrast,  a prolonged response is observed in 
BS [63], with a sensitivity for BS of 78%, whereas the classical pathergy test had a sensitivity of 
28% [64].  Moreover, the cutaneous response to MSU crystals appears to be more reproducible 
than pathergy (95% concordant response after one year, compared to 73% for pathergy) [64]. 
This unit has been able to show that UK patients also demonstrate a prolonged inflammatory 
response to MSU crystals [65]. The great advantage of the MSU crystal reaction over the 
pathergy reaction as an investigational approach is that it is a graded rather than a categorical 
(present/absent) response and can be quantified in all individuals. Moreover, the large literature 
on the inflammatory response to MSU crystals in the context of hyperuricaemia and gout 
provides an excellent mechanistic frame-work for exploring how the response is abnormal in BS 
[66, 67]. This is discussed in detail in Chapter 3.  
1.5 Prognosis 
Severity is generally greater in men, the young and those with genetic links to endemic regions 
[13].The greatest morbidity and mortality occurs with ocular, vascular and CNS disease. Young 
Turkish males (15–24 years of age) with ocular, vascular or CNS disease can have as much as a 
tenfold increase in mortality when compared with age and sex matched controls. In certain 
patients, disease may become less severe over time. Females and those with isolated 
mucocutaneous disease have a relatively good prognosis [13]. 
1.6 Inflammation and genetics  
Most complex diseases are caused by the combination of genetic risk variants and 
environmental factors. Although there are many different types of genetic variation, current 
state of the art technology is most effective at identifying single nucleotide polymorphisms 
(SNPs), sites that differ by only one nucleotide among individuals in a population. 
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Early genetic work (1980s) was based on candidate gene association studies (CGAS) to 
investigate genes of interest. Recent technological advances now allow us to study thousands to 
millions of SNPs along the entire genome – Genome Wide Association Studies (GWAS), in 
large human samples. The advantage of the CGSA is its affordability and minimization of false 
negatives, whereas GWAS has the advantage of producing fewer false positives, being unbiased 
with regard to gene function, having the ability to correct for population stratification, and 
having coverage of variations across the genome. GWAS have a good track record of 
reproducibility.  GWAS fail regarding identification of associated genes rather than genomic 
regions, identification of associated rare variants and studies can still have problems related to 
selection and misclassification bias. It also remains expensive, although costs continue to come 
down. Table 4 shows a simplified summary of some available genetic tests.  
In general, genetic studies have revealed that regulatory variants are much more likely to cause 
disease than non-synonymous coding single nucleotide polymorphisms (SNPs) (i.e. SPNs that 
code for an alternative amino acid), and may be transcriptional or posttranscriptional (e.g. 
polymorphisms in post transcriptional regulatory elements related to micro RNAs (miRNA)).  
Although genome wide association studies (GWAS) offer powerful means for identifying 
common variants associated with complex disease, they have been generally ineffective in 
identifying associations resulting from rare (minor allele frequency <1%) and low frequency (1-
5%) variants. Next generation sequencers (HT-NGT) are becoming ever more sophisticated, 
offering analysis of single molecules of DNA (no PCR required), and using longer read lengths, 
which in combination with deep sequencing (reading the same strand of DNA multiple times) 
and advanced technology tools for re-assembly and analysis, result in ever more accurate and 
informative information becoming available for complex genetic syndromes such as BS. 
 
 
 
 
 35 
 
Table 1-4 A summary of some common genetic tests 
Genetic test
 
Description
 
Advantages
 
Disadvantages
 Classic linkage studies of 
multicase families
 
Selected markers co-
segregate with disease
 
Good for rare mutations with 
strong/obvious effect.
 
Need predictable inheritance pattern 
for analysis.
 
Allele sharing methods (e.g. 
affected sibling pairs, ASP)
 
Markers shared more than 
expected between disease 
siblings
 
No controls required. Model of inheritance 
not required.
 
Large numbers of siblings required. 
Low power to detect genes of modest 
risk.
 CGAS
 
Assessment for presence of 
SNPs or VNTRs (e.g. 
microsatellite markers) in 
area of interest
 
Cheaper than GWAS. Less false negatives 
than GWAS. 
 
Selection bias. False positives. 
 
GWAS: HT and HT-NGS
 
1000s of SPNs studied at 
regular intervals 
throughout the genome
 
Relatively unbiased. 3rd generation 
sequencing: single DNA molecule, 
increasing accuracy (no PCR), longer read 
lengths.
 
Large study numbers. Miss rare 
variants. Multiple hypothesis testing. 
False positives (control selection). 
 
Ultra-deep sequencing of 
genomic DNA 
 
Combined with GWAS or 
CGAS: Depth = number of 
times a nucleotide is read 
during sequencing.
 
Identification of rare single-nucleotide 
polymorphisms (SNPs). Enables distinction 
between sequencing errors and true SNPs.
 
 
 
Abbreviations: CGAS, candidate gene association studies; SNP,single nucleotide polymorphism; VNTR, variable number of tandem repeats; 
GWAS, genome wide association study;    HT, high throughput; HT-NGS, high throughput next generation sequencing 
1.6.1 Genetics and BS 
There is strong evidence for a genetic contribution to BS. Having a sibling with BS confers a 
10-50 fold increased risk of developing the syndrome relative to the general population [68]. 
Affected offspring of patients may have an earlier onset of disease (genetic anticipation) [69]. 
No single gene mutation is responsible for BS; rather, there appears to be a complex polygenic 
predisposition to its development, which reflects the heterogeneity of the clinical presentation. 
There is geographical variation in the distribution of symptoms, such as a high incidence of 
gastrointestinal involvement in the Far East [16, 17].  These observations support the hypothesis 
that BS may entail several distinct genetic mechanisms and that ‘Behçet syndrome’ is an 
umbrella term for clinically similar, but not identical illness, with the common denominator of 
oral ulceration. 
In such a complex polygenetic disorder, numerous genes may be involved, regulating pro- or 
anti-inflammatory pathways. As BS is rare in children, it is likely that a trigger or burden of 
triggers in the environment is encountered in genetically predisposed individuals, resulting in 
development of the syndrome. This trigger(s) may differ, depending on the underlying genetic 
susceptibility. While genetics and gene regulation may hold the key to understanding this 
complex syndrome, there is also much to learn from hypothesis-driven research as well as from 
analysis of environmental interactions.  
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1.6.2 Innate immune dysfunction 
The innate immune system is primed to recognise pathogen associated molecular patterns 
(PAMPs, e.g. lipopolysaccharide (LPS)) and danger associated molecular patterns (DAMPs, 
e.g. heat shock proteins (HSP)) via cell membrane receptors such as Toll-like receptors (TLRs), 
scavenger receptors, and intracellular receptors such as the NOD-like receptors (NLRs e.g. 
NLRP1 which activates the inflammasome, resulting in IL-1β and IL-18 production). Cells 
include phagocytic populations (e.g. dendritic cells, macrophages, neutrophils) and the natural 
killer cells (NK cells). Phagocytic cells ingest and display antigens, and secrete cytokines such 
as IL-1β, TNF-α, IL-6, IL-8 and IL-12 which up-regulate the response and recruit inflammatory 
cells. NK cells recognise infected or damaged cells displaying stress molecules and having 
down-regulated MHC Class I molecules, via killer activation receptors (KARs) and killer 
inhibition receptors (KIRs) respectively. B-1 B cells and non-activated B cells secrete natural 
antibodies and also take part in innate immunity.  
1.6.2.1 Innate immune dysfunction in BS 
Clinical manifestations of BS, such as episodic inflammation and clinical overlap with auto-
inflammatory diseases, as well as the histological feature of neutrophil recruitment to sites of 
inflammation suggest that the innate immune response is important in BS. Recent genetic 
studies, discussed below, support the hypothesis that dysregulation of innate immunity is 
involved.  
1.6.3 The inflammasome / IL-1β pathway  
The inflammasome / IL-1β pathway is one of the cardinal pathways of innate immunity. In BS, 
studies have demonstrated polymorphisms within the IL-1β gene [70-72] as well as identifying 
polymorphisms within the Mediterranean fever 1 gene (MEFV1) [73-77].  In a study published 
in 2013, non-synonymous variants (NSVs) identified by deep exonic re-sequencing of candidate 
genes, in pooled samples of almost 2,500 BS patients and controls (48 samples per pool), found 
that carriage of the MEFV mutation Met694Val conferred BS risk in the Turkish population 
(OR 2.65). This gene is also implicated in Ankylosing Spondylitis (AS) [78] and Inflammatory 
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Bowel Disease (IBD) [79] in Turkish populations. They also found several Nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) SNVs (Arg702Trp; Gly908Arg; 
Leu1007fsinsC) associated with BS, which were present in Turkish but not Japanese cohorts. 
These SNVs associated with reduced response to Muramyldipeptide (MDP) (a peptidoglycan 
constituent of gram positive and negative bacteria). These NOD2 SNVs have been shown to be 
associated with risk in Crohn’s Disease (CD) but interestingly were found to be protective in 
BS. The same study assessed several other ‘inflammasome’ genes without finding any 
significant association, including CASP1 and PYCARD. Clinical studies  support the role of IL-
1β pathways in BS, with elevated IL-1β observed in the sera [80] and synovial fluid [81] of BS 
subjects. 
1.6.4 Toll-like receptors and cytokines 
TLR-4 stimulation (e.g. with LPS) results in activation of Interferon regulatory factor (IRF)/ 
Interferon (IFN), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
Mitogen-activated protein kinase (MAPK)-activator protein (AP)-1 pathways resulting in 
activation of multiple cytokine pathways, including IL-6, TNF-α, IL-1 and IL-12. Two TLR-4 
NSVs identified by deep exonic re-sequencing (D299G & T399I) were found to be protective 
for BS, and resulted in a reduced response to LPS. Interestingly, the same markers are risk 
SNVs for CD [73]. A separate study, found that monocytes of active BS subjects demonstrated 
increased activity of toll-like receptors (TLR)-2 & -4 and furthermore, monocytes from 
intestinal lesions in BS subjects expressed increased TLR-2 and -4 mRNA compared to health 
controls (HCs) [82].   
TNF-α polymorphisms were reviewed in a meta-analysis and this report substantiated the 
association of BS with the -1031C, -857T and the - 238A TNF-α promoter polymorphisms in 
multiple ethnic groups [83]. Clinical studies have found elevated TNF-α in serum [80] and 
aqueous fluid [84] and certainly anti-TNF-α monoclonal antibodies have an established role in 
the treatment of BS [85].  
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Significant differences in IL-6 variable nucleotide tandem repeats (VNTRs) and allele 
frequencies were found in BS subjects. These differences were particularly apparent in the 
HLA-B51 negative and female subjects [86]. IL-6 protein has been shown to be elevated in 
serum and CSF fluid [87, 88]. Serum from BS subjects stimulate a classic pro-inflammatory 
response in macrophages [89].  
1.6.5 Matrix metalloproteinases 
Matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) are secreted enzymes that regulates cell-
matrix composition. Their main substrate is gelatin (a denatured collagen). They are produced 
by keratinocytes, monocytes, tissue macrophages, and neutrophils. They cleave denatured 
collagen (gelatins) and type 4 collagen which facilitates lymphocyte recruitment. They are also 
involved in cytokine and chemokine processing [90, 91]. These enzymes have been implicated 
in multiple inflammatory conditions including vasculitis [92], aggressive periodontitis [93] and 
aneurysmal formation [94].  It is thought that MMP-2 and -9 have anti- and pro- inflammatory 
roles respectively. MMP-2 has been shown to maintain gut barrier function [95]. Candidate 
gene analysis of MMP-2 and MMP-9 polymorphisms found the lower MMP-2 -1575 *G/*G 
and -735*C/*C which correlated to lower levels of MMP2 in erythema nodosum (EN) lesions 
on immunohistochemistry. Furthermore, they found significantly higher MMP-9-1562-*C/*C 
which correlated to more MMP-9 in EN biopsies. A clinical study has found serum MMP-9 
levels to be higher in active BS versus HCs [96].  
1.6.6 Natural killer cells and receptors 
Natural killer (NK) cells are a group of circulating cytotoxic lymphocytes that play a role in 
nonspecific toxicity against virus-infected cells and tumour cells [97]. They are considered cells 
of innate immunity, but share some receptors with NK T cells and γδ T cells. These later two 
cells are described as transitional cells, straddling innate and adaptive immunity. NK cells also 
share some receptors with cytotoxic T cells, the natural killer cells of adaptive immunity. 
A SNP (KLRC4, rs2617170) was identified by GWAS within the KLRK1-KLRC1 locus on 
chromosome 12  [98]. This haplotype block (the ‘NKG2D’ haplotype) contains 5 natural killer 
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cell receptor genes. The KLRC4 gene codes for the NKG2F C-type lectin receptor. Two non-
synonymous variants in KLRC4 encoding KLRC4pIle29ser and pAsn104Ser alterations 
respectively were found on this BS protective haplotype of this Linkage disequilibrium (LD) 
block [98]. This haplotype has been associated with reduction of peripheral blood leukocyte 
cytotoxicity [99]. Furthermore, the LD NKG2D gene encodes an activating homodimeric C-
type lectin receptor, which is expressed on NK cells, CD8+αβ T cells, γδ T cells, and activated 
macrophages. The NKG2D receptor triggers cell-mediated cytotoxicity upon the recognition of 
self-ligands, such as MICA and MICB (induced by cellular stress, e.g. virus / tumour). 
Interestingly these MICA and MICB genes are in LD with HLA B*51 [99].  In support of this 
haplotype’s importance in BS, a Turkish whole genome linkage analysis study in multi-case BS 
families (using 395 microsatellite markers), found the strongest linkage peak (OD 3.94) was on 
chromosome 12p12-13 which includes the KLRK locus [100].  
Non-genetic research also supports a role for these genes/pathways. CD69+ activated NK1 cells 
mainly produce IFN-γ and IL-10, two cytokines found in abundance in BS, and these cells 
express high levels of IL-12β receptors. NK2 cells produce IL-5 and express low levels of IL12-
Rβ [101]. A study found CD69+-activated NK cells were significantly increased in active BS 
compared to inactive BS and healthy controls. Inactive disease was associated with the NK2 
phenotype. Also of interest was that NK cells from inactive BS subjects, but not NK cells from 
controls, suppressed IFN-γ expression by CD4+ T cells from active BS subjects in vitro, 
suggesting that NK cells control a Th1 response in BS [102]. 
1.6.7 γδ T cells 
γδ T cells represent a small subset of T cells that possess a distinct TCR on their surface. These 
cells are found at their highest abundance in the gut mucosa, skin and the respiratory tract. They 
do not require antigen processing and MHC presentation of peptide epitopes although some 
recognize MHC class IB molecules. They have a very limited set of V, D and J genes, but 
respond quickly. The antigens recognized by γδ T cells include heat shock proteins (HSP) and 
the non-peptide antigens prenyl pyrophosphates (PPP). The PPP isopentenyl pyrophosphate 
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(IPP) is a precursor for a variety of biological molecules, such as cholesterol and some vitamins. 
Peripheral blood γδ T cells have been found to be elevated in BS, with a polyclonal activation 
[103, 104]. They have been associated with active disease, with higher expression of CD69 and 
production of IFN-γ and TNF-α [105]. IPP-specific TCRVγ9Vδ2+ Th1-like cells from intra-
ocular fluid have been isolated from BS uveitis subjects [106]. TCRVγ9δ2+ T lymphocytes are 
relatively expanded in active disease [107]. A recent paper found significantly increased CD16 
expression, and less CCR7 expression in the peripheral blood (PB) γδ T cells of BS versus HC.  
CD16 expression represents an active phenotype (high cytolytic activity, inflammatory 
cytokines production) of the γδ T cells. CCR7 is used to distinguish tissue-homing effector 
(CCR7-) from lymph node-homing non-effector memory cells (CCR7+). γδ T cells also express 
inhibitory and activating members of the NK receptor family. TCRVγ9Vδ2+ T cells can be 
activated through NKG2D by stress ligands such as MICA. In this study, NKG2D receptors on 
the γδ T cells were decreased in subjects with BS compared to HC [108]. 
Table 1-5. Summary of innate immunity genetic markers identified in BS  
Inflammasome 
pathway 
Gene marker Study type Population Reference 
IL-1α and IL-1β 
IL-1α-889C; IL-1β+3953 T; IL-1α -
889C/IL-1β +5887T  
CGAS Turkish [70-72] 
MEFV Met694Val, Met680Ile CGAS; DER of NSVs Multiple [73, 74] 
NOD2 
Arg702Trp; Gly908Arg; 
Leu1007fsinsC 
DER of NSVs 
Turkish,  
not Japanese 
[73] 
Non-inflammasome pathway       
TNFA 
 -1031C (OR 5 1.35, ); - 238A (OR 
5 1.51);   - 857T (OR 5 0.76) 
Metanalysis GCAS Multiple [83] 
IL-6 VNTR in 3'region IL-6 gene CGAS Korean [86] 
TLR4 D299G; T399I; rs1927906 DER of NSVs Multiple [73, 109] 
Other pathway         
MMP2  -1575G, -735C  CGAS Korea [110] 
MMP9  - 1562 C  CGAS Korea [110] 
Natural Killer genes       
KLRC4 /NKG2F rs2617170  GWAS  Turkish, Japanese [98] 
KLRK 12p12-13 Familial linkage study Turkish  [100] 
NKG2A 
NKG2A c.-4258*C, c.338-90*G, 
and CD94 c.-134*T alleles 
CGAS Korea [111] 
NKG2C NKG2C c.305*T (risk) CGAS Korea [111] 
Abbreviations: CGAS, candidate gene association studies; SNP, single nucleotide polymorphism; VNTR, variable number of tandem 
repeats; GWAS, genome wide association study;    HT, high throughput; HT-NGS, high throughput next generation sequencing 
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1.6.8 Adaptive Immunity 
The immune system has to defend the organism against ever evolving pathogens, necessitating 
an almost unlimited repertoire of receptors to recognise invading pathogens. Antigen-specific 
recognition by receptors on B and T cells leads to clonal expansion. The receptors are generated 
in a random process and T cells with receptors against self are usually eliminated in the thymus. 
T cell receptors (TCRs) recognize a specific peptide epitope contained within a MHC molecule. 
B cells synthesize immunoglobulin of a single specificity that binds a single epitope. 
Engagement of BCR or TCR leads to initiation of signal transduction pathways and expression 
of cytokines, chemokines and other proteins.  
1.6.8.1 HLA B51 and other HLA markers  
Human Leukocyte Antigens (HLA) are a cluster of genes on chromosome 6, which, amongst 
other functions, code for the HLA class І and ІІ cell surface antigen recognition molecules. 
Expressed on the surface of virtually all cells, class I molecules (HLA A, B and C) display 
antigens from inside the cell. If a cell is infected or damaged, antigen is displayed via class I 
molecules and the cell is targeted by circulating cytotoxic T cells (CD8+).  
HLA B5 has 2 alleles: HLA B51 and HLA B52.  HLA B51 allele binds peptides with 8-11 
amino acids [112] and differs only by 2 amino acids from B52, where asparagine and 
phenylalanine are replaced by glutamic acid and serine in B52  [113]. These two amino acids 
are located in the B pocket of the antigen binding grove of the HLA molecule, which holds the 
second amino acid of the peptide being presented. HLA B51 may only hold a small amino acid 
in this grove (alanine or proline).  HLA B51 is the strongest known genetic susceptibility factor 
for BS [6, 114-116]. The pooled odds ratio for developing BS associated with the presence of  
HLA B51 is 5.8  [117], but shows geographical variation (1.5 in Portugal to 16 in Italy [12, 
118]). HLA B51 may contribute to disease severity, but its presence does not confirm BS [119]. 
28% of Amerindian Eskimo population are HLA B51 positive, yet there are no reported cases of 
BS in this population [3].  
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The mechanisms by which HLA B51 may contribute to BS remains unknown, although there 
are a number of theories including linkage disequilibrium (LD) with genes such as MICA [6, 
120]; misfolding (B51 is a slow folding molecule, which binds low affinity peptides. This 
binding may cause slow assembly and misfolding of the HLA B51 molecule possibly causing 
endoplasmic reticulum stress thereby inducing an inflammatory response) [121]; Low affinity 
binding of peptides (leading to enrichment of CD8+ and γδ T cell repertoires) [122, 123];  HLA 
B51 interacting with Natural Killer (NK) cells, CD8 and γδ T cells, through its HLA Bw4 
epitope which it shares with HLA B27 [124, 125]; or peptides derived from digestion of the 
HLA B51 protein being presented by other HLA class II molecules and inducing an adaptive 
immune response (e.g. retinal s antigen, shares amino acid sequence homology with B27PD 
which is also found in B51) [126, 127]. 
Recent genetic work has made two exciting discoveries which may shed some light on the 
mechanism for pathogenesis of HLA B51. Endoplasmic reticulum aminopeptidase 1 (ERAP1) 
encodes an endoplasmic reticulum aminopeptidase, responsible for trimming peptides that are 
9-17 amino acids long to 9 in preparation for HLA Class I presentation. It is also involved in 
cytokine receptor shedding. It was identified previously in GWAS studies in AS and psoriasis 
[128, 129]. A GWAS using a recessive model and fine mapping recently identified ERAP1 in a 
Turkish BS population. The mutations identified have been shown to confer protection against 
psoriasis (in HLA C06 individuals) and AS (in HLA B27 individuals) but conferred risk for BS 
in HLA B51 individuals.[98].  
Another recent paper genotyped over 8000 variants in the extended HLA locus, and carried out 
imputation and metalysis of 24,834 variants in 2 BS cohorts from ancestry groups. Using this 
fine mapping they identified the most significant association to be rs116799036 (OR 3.74) 
which was located approximately 24kb upstream of HLA B and 18kb upstream of MICA[130]. 
To determine whether the genetic effect of rs116799036 can be explained by the association 
with HLA B51, they performed pairwise conditional analysis to control for HLA B5101. The 
genetic association remained significant independent of HLA B5101. Notably, when adjusted 
by conditioning on rs116799036 the genetic association with B5101 disease was completely 
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abrogated. Therefore this study strongly suggests that the association between HLA B51 and BS 
can be explained by rs116799036, found upstream of B51. This data is also consistent with a 
previous microsatellite study which identified the region to a 46kb DNA segment centromeric to 
HLA B [130].  The exact function of this region is not known. Some other HLA associated 
markers that have been identified are shown in Table 6. 
Table 1-6. Summary of some HLA genetic markers identified in BS 
Inflammasome 
pathway 
Gene marker Study type Population Reference 
HLA B*51 rs116799036 GWAS, dense genotyping Multiple [130] [5, 6] ERAP1 rs10050860 (encoding p.Asp575Asn) and  rs17482078(p.Arg725Gln) 
GWAS discovery, fine 
mapping validation 
Turkish  [98] 
PSORS1C1 rs12525170 GWAS, dense genotyping Turkish& Italian [130] 
HLA-F-AS1 rs114854070 GWAS, dense genotyping Turkish& Italian [130] Abbreviations: CGAS, candidate gene association studies; GWAS, genome wide association study. 
1.6.8.2 T helper cells 
There has been extensive interest in the role of T cells, and their interactions with APCs in BS.  
Drugs such as cyclosporine, mycophenolate, thalidomide and azathioprine, all of which act at 
least in some way through T cell inhibition, can be highly effective treatments. T helper (Th) 
cells, upon activation, can be directed towards a Th1, Th2, Th17 or the more recently described 
Th9 skew depending on their environment.  
1.6.8.3 Th1 cells 
Th1 cell defence is directed against intracellular pathogens. Initially cells require IFN-γ to 
upregulate IL-12Rs. IL-12 then stimulates differentiation towards a Th1 skew. Transcriptional 
factors involved include Signal Transducers and Activators of Transcription (STAT) 1, T-box 
transcription factor TBX21 (T bet) and STAT4. Th1 cells secrete IFN-γ and lymphotoxin, and 
induce chemokines such CXCL9, CXCL10 and CXCL11 which attract more T cells to the area 
and aid development of cytotoxic T cells.  
STAT4 polymorphisms have been found to be associated with BS in the Turkish, Japanese, Han 
Chinese and Korean populations [98, 131, 132]. Furthermore the IL23R-IL12RB2 is a common 
variant SNP that was identified in the first two GWAS studies published in 2010 [6, 116]. In 
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clinical studies, IL-12 was found to be elevated in peripheral blood of BS subjects and 
correlated with disease activity[133]. High levels of IFN-γ were found in BS aqueous humour 
fluid as compared with fluid from subjects other causes of uveitis [84].  High levels of CXCL9, 
CXCL10 and CXCL11 have been observed in BS associated uveitis versus other forms of 
uveitis, and high CXCL10 was found in CSF fluid of BS subjects [134, 135].  
1.6.8.4 Th17 cells 
Th17 differentiation initially requires the presence of Transforming growth factor beta (TGFβ) 
plus either IL-6 or IL-21. Later IL-17 is required and then IL-23 is required for terminal 
differentiation and effector function. Signalling pathways involve STAT3, Interferon regulatory 
factor (IRF) 4, RAR-related orphan receptor gamma (RORγT), TLR2/4 and pSTAT3. IL-17 
elicits an innate response with neutrophil recruitment, and promotes growths. It also induces 
secretion of CXCL9, CXCL10 and CXCL11, attracting Th1 cells [136, 137].  Both Interferon-α 
and Cylcosporin A inhibit the production of IL-17 in BS, and both have efficacy in the 
treatment of BS [138, 139].  
The IL-12R/IL-23RB2 and STAT4 as well as the TLR4 SNPs already discussed in the Th1 
paragraph above,  may equally be implicated in the Th17 pathway [6, 73, 98, 116, 132, 140]. 
Additionally, a recent GWAS study in a Korean population identified interactions between IL-
17a, IL-23R, and STAT4 polymorphisms, which confer susceptibility to intestinal BS [132]. A 
SNP (rs2397084) was identified in a Korean population within the IL-17 gene [141], and a 
STAT3 SNP (rs2293152) was found to be a risk factor for BS in Han Chinese population [142]. 
This SNP is also a risk factor for IBD.  
In clinical studies, serum concentrations of IL-17, and production of IL-17 and IL-23 by 
stimulated peripheral blood derived mononuclear cells (PBMCs) has been shown to be elevated 
in active BS [143, 144]. 
1.6.8.5 Co-stimulatory molecules 
T cell activation is enhanced by some co-stimulatory molecules e.g. CD28 (on T cells) 
interacting with CD80/CD86 (on APCs) and CD40L (on T cells) with CD40 (on APCs) and 
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inhibited by others, e.g. cytotoxic T lymphocyte antigen-4 (CTLA-4, on T cells) interacting with 
CD80 (on APCs), programmed death-1 (PD-1, on APCs) and programmed death-ligand 1 (PG-
L1) [145].   
Two candidate SNPs were identified in the CD40 gene (rs4810485TT, rs1883832TT) in Han 
Chinese population [146]. Candidate CD28 and CTLA4 SNPs were investigated in a Turkish 
cohort. The CTLA-4 +49AGG allele was found to be significantly lower in BS versus HC. This 
G allele has been found to be associated with the impaired control of T cell proliferation. The 
CD28 IVS3 +17T/C allele was found to be more prevalent in the BS population [147]. Clinical 
studies have shown a reduced expression of three co-stimulatory inhibitors (CTLA-4, CD86 and 
PL-L1) in active disease, as well as high levels of  Inducible co-stimulator (ICOS), a member of 
the CD28 co-stimulator family [148].   
Table 1-7. T helper cell populations 
Th cells Stimulus Signalling pathway Effect Th1 IFN-γ initially, then IL-12 
STAT1 ;  T bet; 
STAT 4 
Secrete IFN-γ and lymphotoxin, MIP-1, CXCL9/10/11. 
Attract and activate macrophages. Defence against 
intracellular pathogens.  Th2 IL-4 initially,  then IL-5/IL-13 
STAT6, GATA3 Defence against extracellular pathogens e.g. parasites; helminths. Stimulate IgE and Mast cells, B cells to produce 
antibodies.  Th17 TGFβ and IL-6/IL-21 initially,  
then IL17, IL23 
STAT3, IRF4, 
RORγT; TLR2/4; 
pSTAT3 
IL-22; IL-17, acts on endothelial and parenchymal tissues, 
illicit an immune response including acute phase response, 
and promoting growth. Induce CXCL9/10/11 which attract 
Th1. 
1.6.9 Chemokines 
Chemokines are involved in leukocyte recruitment to sites of inflammation. The CCR1-CCR3 
locus contains a cluster of chemokine receptor genes within a LD block. Haplotype analysis of 
this region revealed 3 SNPs (rs13085057, rs13092160CC and rs13075270) associated with BS.  
rs13092160 TT was associated with less CCR1 and CCR3 expression [98, 149]. SNPs have also 
been found in association with the chemokine CCR5 in Italians [150]; and the chemokine CCL4 
(MIP-1) [151]. In clinical studies CCL2 (MCP) levels in the blood of BS subjects were found to 
be significantly higher than HC or thrombotic controls [152, 153]. CCR5 and CXCR3 receptors 
have also been shown to be highly expressed in BS biopsies from oral ulcers[154]. The 
pathology of pathergy reactions shows increased mRNA transcripts for the chemokines CCL20, 
CXCL10, CXCR3, and CXCL11 [61, 62].  
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Table 1-8. Summary of T helper and chemokine markers identified in BS 
Adaptive immunity Gene Study type Population Reference 
Th1         
IL23-IL12RB2 
rs924080 ;  rs1495965 ;  rs17375018, 
rs11209032 
GWAS Multiple [5, 6] 
STAT 4 rs7574070, rs7572482  GWAS Multiple 
[73, 132, 
140] 
Th17         
STAT 3 rs2293152 GG CGAS Chinese [142] 
IL23-IL12RB2 
rs924080 ;  rs1495965 ;  rs17375018, 
rs11209032 
GWAS Multiple [5, 6] 
IL-17 gene rs7771466 CGAS Korean [141] 
Costimulatory molecules       
CD40 rs4810485TT, rs1883832TT CGAS Chinese [146] 
CD28 rs1181389 
C 
GAS 
Turkish [147] 
CTLA4 rs10497873 CGAS Turkish [147] 
Chemokines         
MCP-1  -2518A/G GWAS Chinese [151] 
CCR1-CCR3  
rs7616215; rs13084057; rs13092160, 
rs13075270 
GWAS  Multiple, Chinese [73] [149] 
CCR5 ccr5-403AA, ccr5 delta32 CGAS Iranian, Italian [150] 
Abbreviations: CGAS, candidate gene association studies; GWAS, genome wide association study. 
1.6.10 Dampening inflammation 
The immune system has developed many mechanisms to avoid sustained, over-zealous and 
auto-reactive inflammatory responses. These include thymic positive and negative selection; 
feedback loops; co-activation of pro- and anti- inflammatory signalling pathways; requirement 
of second signals; as well as anti-inflammatory pathways involving IL-10; TGFβ; resolvins; 
lipoxins; T-regs; Tr1 cells; T suppressor cells; debris clearance mechanisms; de-activated / M2c 
macrophages; glucocorticoids; transcriptional and post-transcriptional control pathways, to 
name just a few. In BS, there is a prolonged or sustained activation or possibly a failure to 
deactivate responses. The clinical hallmark of sustained inflammation in BS is the pathergy 
response.  
1.6.10.1 IL-10 
GWAS studies have found SNPs associated with IL-10 [6, 116]. The IL-10 disease allele 
(rs1518111 AA) was associated with a reduction in IL-10 mRNA expression and protein 
production in purified monocytes 24hr after LPS stimulation [6].  
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1.6.10.2 Treg cells 
A recent study identified a SNP within the TGF-β gene [155]. Although no functional data is yet 
available regarding this TGF-β SNP, less TGF-β production would reduce Treg differentiation. 
A cellular study showed increased Th17 cells and decrease in frequency of CD4+foxp3+ Tregs 
in peripheral blood, which correlated with BS activity. BS serum causes a shift to high Th17 
and towards lower numbers of TregsFoxp3 cells [156].  
1.6.10.3 MicroRNAs 
MicroRNAs (miRNA) play a role in post-transcriptional repression of protein production. A 
miRNA-146a polymorphism (rs2910164GG>CC) was identified in a Chinese BS cohort, and 
this was associated with higher IL-17, TNF-α and IL-1β, suggesting the disease associated SNP 
resulted in less negative feedback [157]. A clinical study found decreased miRNA-155 
expression in PBMCs and DCs from BS subjects with active uveitis. Overexpression of this 
miRNA was shown to inhibit production of IL-6 and IL-1β; furthermore miRNA-155 
transfected DCs significantly inhibited intracellular IL-17 expression in CD4+ T cells. 
Therefore, the lack of repression by miRNA-155 in BS may contribute to the pro-inflammatory 
/ Th-17 response [158]. 
1.6.10.4 Apoptosis 
Apoptosis is an important mechanism to dampen inflammation. A study has shown that 
activated T cells from BS showed resistance to CD95 induced apoptosis, with high level 
expression of  B-cell lymphoma-extra large (Bcl-xl) in BS T cells. Thalidomide, a suppresser of 
NF-κB via IKK, was able to reverse this [159].  
1.6.10.5 Ubiquitin and SUMO4 
Ubiquitin and Small ubiquitin-related modifier 4 (SUMO4) (an ubiquitin like protein) SNPs 
have been found to be associated with BS in 3 genome wide association studies [160-162].  
Ubiquitins are small regulatory proteins found in almost all tissues of eukaryotes. Amongst 
other roles, they direct proteins to the proteasome for destruction.  
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Table 1-9. Summary of anti-inflammatory markers identified in BS 
Dampening 
inflammation 
Gene Method Population Reference 
IL-10 rs1518111, rs1800872, rs1800871 GWAS Multiple [5, 6] 
TGFbR3 rs1805110(Chinese) GWAS Chinese [155] 
Other         
MicroRNA-146a  rs2910164GG  CGAS Chinese [157] 
SUMO4 rs237012 GWAS Chinese [160] 
UBAC2 rs3825427,rs9517668,rs9517701 
(Chinese), rs9513585, 
GWAS Chinese, 
Turkish 
[161, 163] 
UBASH3B  rs4836742 GWAS Chinese [163] 
Abbreviations: CGAS, candidate gene association studies; GWAS, genome wide association study. 
1.6.11 The role of neuropeptides in inflammation 
Two of the best characterised neuro-immune systems are: (i) The hypothalamic-pituitary-
adrenal (HPA) axis: Acute physical or psychological stress activates the HPA axis resulting in 
increased plasma ACTH and cortisol concentrations. Cortisol is a potent anti-inflammatory 
agent. (ii)The cholinergic anti-inflammatory pathway: The nervous system has been shown to 
act via the parasympathetic vagus nerve to inhibit cytokine release. Afferent vagal nerves sense 
pathogens, ischaemia and cytokines. Efferent nerve activation of the vagus nerve results in local 
release of acetylcholine (ACh) in organs including the spleen. Macrophages have ACh receptors 
which upon activation inhibit pro-inflammatory cytokine synthesis and release. The efferent 
neural signalling pathway is termed the cholinergic anti-inflammatory pathway [164-169]. The 
nervous system has been shown to play a role in several inflammatory conditions from psoriasis 
to arthritis [170-175]. 
There is ample clinical evidence suggesting that emotional stress can influence the course and 
disease activity of BS [176, 177]. The association between stressful life events and various 
dermatological diseases is explained by the concept of neuro-immuno-cutaneous system [178-
182]. It was reported that neuropeptides, especially Substance P (SP), Calcitonin gene related 
peptide (CGRP) and neurotrophins such as nerve growth factor (NGF) affect the pathogenesis 
of skin disorders like atopic dermatitis and psoriasis vulgaris.  
Recent genome wide association studies in BS have suggested a possible neuropeptide link. In 
one study, they identified near genome-wide significance for one non-MHC SNP, rs936551 
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(P=5.29 x 10 – 8) located at the telomeric end of the short arm of chromosome 4 within the 
promoter region of CPLX1, which encodes complexin-1 [6]. Complexins play a critical role in 
the control of fast synchronous neurotransmitter release. They operate by binding to trimeric 
SNARE complexes consisting of the vesicle protein Synaptobrevin and the plasma membrane 
proteins Syntaxin and SNAP-25, which are key executors of membrane fusion reactions [183]. 
SNARE complex binding by complexins is thought to stabilize and clamp the SNARE complex 
in a highly fusogenic state, thereby providing a pool of readily releasable synaptic vesicles that 
can be released quickly and synchronously in response to an action potential and the 
concomitant increase in intra-synaptic Ca(2+) levels [184]. Genetic elimination of complexins 
from mammalian neurons causes a strong reduction in evoked neurotransmitter release.  
One study has formally investigated neuropeptides in BS [185] using immunohistochemistry of 
skin biopsies and protein quantification of serum samples.  Strong immunoreactivity of SP was 
seen in the epidermis, panniculitis lesion and vasculitis lesion of BS subjects versus HCs. The 
concentration of CGRP measured by ELISA was decreased in BS subjects. CGRP was recently 
revealed to promote IL-10 production and suppress LC antigen-presenting function, T 
lymphocyte proliferation and production of IL-2, IL-12 or IFN [186]. 
1.6.12 Environmental Triggers  
It is very unlikely that genetic risk wholly accounts for BS development. BS is a syndrome that 
typically develops in the 3rd or 4th decade, implying a further trigger is required to cause disease 
in those who are genetically susceptible. Environmental agents have been extensively 
investigated including bacteria (especially the Streptococcal species), viruses and other 
environmental agents such as chemicals, heavy metals and smoking. It is possible that the 
development of BS is related to the burden of triggers rather than one specific trigger for 
disease, as no superantigen has been identified to date. Alternatively, different triggers may 
result in the development of BS, depending on the presence of specific genetic abnormalities.  
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1.6.12.1 Streptococcal species 
Streptococcal species have been extensively studied.  Strep. sanguinis is a gram positive 
facultative aerobic coccus and member of the viridans streptococcus group. It is a normal 
inhabitant of the human mouth, especially in plaque, where it modifies the local environment 
making it less hospitable to cavity forming bacteria such as Strep. mutans. Strep. sanguinis 
antigens have been found in the skin and monocytes of BS subjects, but not in healthy controls.  
These antigens share a sequence of amino acids (homology) with the stress induced heat shock 
proteins (HSPs). Studies have shown that Strep. sanguinis and HSP (HSP 60/65kDa) activate γδ 
T cells in BS, but not in healthy controls. Studies suggest that following bacterial exposure, 
cells express HSPs that are antigenic and reactivate γδ T cells in susceptible individuals 
(molecular mimicry model) [187]. The relationship between streptococcal infections and BS is 
also suggested by clinical observations such as the aggravation of BS symptoms by dental 
treatment [188] and that oral ulcers precede the establishment of BS by months to years. In 
Turkish populations there is a higher rate of Strep. mutans salivary colonization compared  with  
controls and colonization is associated  with  low levels of serum mannose binding lectin 
(MBL) compared to controls [189]. Elevated levels of antibodies against epitopes of 
mycobacterial HSPs, some of which have significant homology to human HSPs, have been 
observed amongst subjects with BS [190]. Exacerbations of ocular disease coincided with 
enhanced levels of these autoimmune antibodies. Furthermore these peptides can induce uveitis 
when injected into Lewis rats [191].  
1.6.12.2 Intestinal permeability 
Increased intestinal permeability may lead to chronic immune stimulation [192].  The 
gastrointestinal epithelial cells normally form a relatively impermeable physical barrier to 
luminal contents, facilitated by tight junctions [193]. A thick layer of mucus overlies the 
epithelial cell layer. Several studies have reported increased intestinal permeability in CD 
subjects [194]. Diversion of the faecal stream in such subjects is associated with the induction 
of remission.  Intestinal permeability in BS  subjects without gastrointestinal disease have been 
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assessed using Cr-EDTA and found to be significantly increased compared to healthy controls 
[195].  
1.7 Summary  
BS is a complex, heterogeneous condition. In addition to orogenital ulceration, pathergy is one 
of the hallmark features of the condition. There is no diagnostic test and there are no reliable 
biomarkers to monitor response to treatments or disease activity. Owing to the current 
limitations of our understanding of the underlying disease process, treatments are nonspecific. 
Further basic research is required to improve our understanding of this condition and more 
clinical research is needed to provide support for our current approach to patient management. 
Young males are most likely to develop severe ocular, CNS and vascular complications and 
need to be closely watched and aggressively treated. 
BS is a complex disorder. There appears to be a polygenetic susceptibility, and in susceptible 
individuals a trigger or burden of triggers activates the immune system which becomes 
hyperactive and disordered, resulting in disease.  This is not a ‘pure T cell’ or ‘ pure 
inflammasome’ syndrome, but appears to be one characterised by generalised hyperactivity of 
many components of immune system, both innate and adaptive, and a slowness switching off 
inflammation. Rather than grouping all patients together as one disease, this is a syndrome that 
has a variety of genetic abnormalities and a variety of triggers all of which result in a similar, 
but not identical, clinical syndrome in individuals.  
Dissecting the abnormal inflammatory response may potentially open window to the 
pathogenesis of the condition and may also provide the potential to discover a diagnostically 
useful tool or identify useful biomarkers.  
1.8 Project  Aims overview 
This project aimed to dissect abnormal inflammatory responses in BS to gain an understanding 
as to which pathway(s) are responsible for the phenomena.   
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In Chapter 3, the hypothesis that the abnormal cutaneous inflammatory response to "non-
specific" stimulation in BS is associated with a failure of deactivation of macrophages during 
the resolution phase of inflammation was explored using human in vivo models of inflammation 
(MSU injections and skin blisters). Secondary aims were to classify what other cells and 
cytokines were present in blister fluid. We studied cantharidin-induced skin blisters in 12 BS 
and 12 Healthy controls (HC), analysing blister fluid cells and cytokines using flow cytometry 
and multiplex bead cytokine analysis respectively. 
In Chapter 4, the hypothesis that the abnormal cutaneous inflammatory response may involve 
neuropeptides was explored. We applied capsaicin topically to BS and HC, and measured the 
resultant change in dermal blood flow using laser doppler imaging to evaluate non-invasively if 
neuropeptides such as CGRP may play a role in the abnormal cutaneous inflammatory response 
in BS. The primary question was to assess if there is a difference in capsaicin response between 
HC and BS. We also wished to assess if subjects with a large MSU skin reaction and subjects 
who had an erythematous response to the cantharidin blisters also had an abnormal capsaicin 
skin test, as this could offer the possibility of a quicker and simpler test than the MSU injection. 
Finding a simpler test to replace MSU /pathergy testing would be a useful advance.  
Chapter 5 summarizes key in vitro experiments undertaken alongside in vivo experiments. The 
IFN-γ / chemokine pathways were explored in detail in CD14+ monocyte populations in BS, 
HC and disease control subjects. We found significant differences in response in BS as 
compared to other groups and CXCL-10 was a chemokine of interest identified by these 
experiments. We found that following IFN-γ stimulation, monocytes from BS produced 
equivalent mRNA but more CXCL10 protein, indicating differential post-transcriptional 
regulation. This was further explored using sucrose density gradients.  
Detailed introductions to each of these tests are found in the relevant chapters.  
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2. Materials and Methods 
2.2 Study subjects and study design 
2.2.1 Ethics 
The study was conducted according to the principles of the Declaration of Helsinki and all 
participants gave written informed consent. Ethical approval was obtained from the 
Hammersmith, Queen Charlottes and Chelsea Research Ethics Committee. 
2.2.2 Subject evaluation  
Both male and female individuals aged over 18 years were included. Subjects with significant 
co-morbidities (e.g. asthma, diabetes mellitus) were excluded. (i) Behçet Syndrome (BS) 
subjects were recruited from the Hammersmith Hospital rheumatology clinic, and through the 
UK Behçet’s Syndrome Society. All subjects satisfied the 1990 ISG Behçet Diagnostic Criteria 
[57]. A clinical history including medication history was obtained and disease activity was 
assessed using the Leeds Behçet's Disease Activity Form, which gives an activity score on a 0-
12 point scale (>4 indicates active disease) [196]. (ii) Age- and sex-matched healthy volunteers 
were recruited locally by word of mouth and were required to be free of significant acute or 
chronic inflammatory disease, and to be on no medications (women taking oral contraception 
were not excluded). (iii) Rheumatoid arthritis (RA) subjects were recruited from Hammersmith 
Hospital and Charing Cross Hospital general rheumatology clinics. All subjects fulfilled the 
2010 American College of Rheumatology (ACR) / European League Against Rheumatism 
(EULAR) criteria for RA [197].  A clinical history including medication history was obtained 
and disease activity was quantified using DAS28 (ESR) scoring which gives a score on a 1-10 
point scale (>5.1 indicates active disease) [198]; (iv) Systemic lupus erythematosus (SLE) 
subjects were recruited from a combined renal-rheumatology clinic at the Hammersmith 
Hospital. All subjects fulfilled the ACR criteria for SLE having at least the presence of 4 of the 
11 diagnostic criteria[199]. A clinical history including medication history was obtained and 
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disease activity was quantified using the SLE disease activity score (SLEDAI) which gives a 
score on a 1-105 point scale (>6 indicates active disease, rare to have score >20)[199]. 
2.2.3 Study design  
The project used a cross-sectional observational approach to investigate cutaneous inflammation 
in healthy individuals, in subjects with BS and in subjects with other inflammatory diseases 
(RA, SLE). 
2.2.4 Statistical methodology  
Analysis was carried out using PRISM software. Medians with range were calculated unless 
otherwise stated. Mann-Whitney or Students t-tests were used to compare two outcomes. 
Kruskal-Wallis analysis of variance calculations were used to look for variance between groups. 
Where required, Dunn’s test was used to correct for multiple comparisons in non-parametric 
groups.  
2.3 Monosodium urate crystals (MSU) 
2.3.1 Protocol for MSU crystal preparation  
To eliminate confounding due to inter-batch variability of MSU crystals, a batch was made prior 
to commencement of the study (batch 12/04/2010) and this was used for all experiments. MSU 
crystals were prepared by a modification of the protocol used by Denko and Whitehouse, 1976 
[200]. All equipment was sterilized overnight with 1% E-toxa (Sigma) clean solution then 
autoclaved, following which all other steps were undertaken under a laboratory hood. 12.2ml 
1N NaOH was added to 400ml sterile water (endotoxin free, Sigma) and brought to boil on a 
hot plate. 1g Uric acid (Sigma) was added, stirring constantly with magnetic stirrer to dissolve. 
The solution was cooled on a hot plate to 60oC and pH adjusted to 8.9, while stirring constantly. 
The mixture was then allowed to cool to room temperature for 4-5 hours while stirring, during 
which time it turned milky white. It was then kept at 4oC overnight. The following day, crystals 
were poured over Whatman filter paper using a filter bottle attached to a suction pump.  Filter 
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papers were kept in Petri dishes and dried at room temperature for 24 hours. The crystals 
formed thin brittle wafers, which were broken up and stored in a glass container.  A portion of 
crystals was baked at 200oC, either for 2 hours or overnight to ensure they were LPS free. 
Batches were compared by in vitro monocyte stimulation, looking at TNF production, to ensure 
they were equally pro-inflammatory post-baking. This was found to be the case, and all crystals 
were then baked overnight. Crystal sizing was performed by light microscopy using a Zeiss 
Photomicrograph III (Oberkochen, Germany) equipped with polarizing filters. The average size 
of crystals was 7.96 m, standard deviation 3.67m.   
2.3.2 Endotoxin testing  
Endotoxin levels were tested using an endotoxin assay purchased from Bio Whittaker, UK. 
Levels were < 35 pg/ml per 1mg/ml of solution. Crystals were stored in sterile containers. 
2.3.3 MSU administration and size measurement 
 Following cleansing of the skin with alcohol, sterile MSU crystals (2.5 mg in 100µl sterile 
water) were injected into the upper dermis of the volar aspect of the forearm. At 24 and 48 
hours the injection site was digitally photographed together with a scale marker and maximal 
diameter of erythema measured. 
 
Figure 2-1 Erythema at the site of a MSU injection, 24 hours after the crystal was injected. 
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2.4 Skin blister models 
2.4.1 Suction blisters 
Skin was injected intradermally with 2.5mg MSU. 24-48 hours later the site was photographed, 
following which a suction cup was placed over the injection site and secured. Gentle suction 
(150-200mm Hg) was applied. Suction cups of 5mm, 7.5mm and 10mm diameter were used. 
Blisters took 60-180 minutes to form. The fluid was gently aspirated using a 200μl pipette tip 
into a siliconized ependorf, and placed on ice.  
2.4.2 Cantharidin blisters   
2.4.2.1 Cantharidin mode of action 
Cantharidin is an acantholytic agent. On application to skin, it is absorbed by the lipid layers of 
epidermal cell membranes leading to release of serine proteases that cause degeneration of the 
desmosmal plaque, leading to detachment of tonofilaments from desmosomes. This in turn leads 
to intraepidermal blistering and nonspecific lysis of the skin. The blister causes the tissues 
containing the protein to separate from the surrounding skin. Since acantholysis is 
intraepidermal, healing occurs without scarring, although hyperpigmentation may occur, 
especially in darker skin.  
2.4.2.2 Cantharidin skin blisters 
Skin was cleaned with an alcohol wipe. A 25µl droplet of fluid containing 0.1% cantharidin 
collodion (‘Cantharone’ 0.7% Dormer Laboratories, USA, DIN 00619035 diluted in acetone) 
was applied to a 1cm circle of filter paper on the volar aspect of the subject’s forearm. This was 
covered with a 2cm x 2cm piece of paraffin and a bandage.  At 24-48 hours blisters were 
photographed, then gently punctured with a 200µl siliconised pipette tips and fluid was 
collected into siliconised ependorfs and kept on ice.  
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Figure 2-2 A cantharidin elicited skin blister. 
2.4.3 Blister fluid processing 
Fluid recovered from the suction or cantharidin skin blister was immediately transferred to a 
siliconized ependorf and placed on ice. The volume was recorded and then 10μl was aspirated 
and applied to a haemocytometer for a total cell count. The remainder was spun in a 
microcentrifuge at 300g, after which interstitial fluid was separated, aliquoted and stored in 
siliconized ependorfs at -80oC for future analysis of blister fluid protein content. Cells were 
resuspended in FACS buffer (phosphate buffered saline (PBS) with 0.5% bovine serum albumin 
(BSA) (Sigma-Aldrich, UK) and 0.05% sodium azide (Sigma-Aldrich, UK)) for immediate 
characterization by flow cytometry. 70µl was set aside a for white cell differential slide. 
2.4.3.1 Cytospin 
A labelled slide was added to the cytospin metal container, along with filter paper and the 
plastic cover. 50 µL of fluid was applied and the slide was spun for 5 minutes at 300g. The slide 
was removed and left to dry, then stained with Quick Diff (IHCworld, USA), and then washed 
gently in water, then air dried. Once dry, a cover slip was applied with glue in the fume hood. 
Differential counts were performed by light microscopy.  
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2.5 Monocytes isolation and culture 
2.5.1 Peripheral venous blood sampling 
 Peripheral venous blood was collected using an aseptic technique and anti-coagulated with 10% 
sodium citrate (Sigma-aldrich, UK). The blood sample was diluted (1:1) with Hanks Buffered 
Saline (Sigma-aldrich, UK), layered carefully onto Histopaque (Sigma Aldrich, UK) and then 
spun with deceleration turned to 0, for 20 min at 700g. The interface containing peripheral 
blood mononuclear cells (PBMCs) was removed and washed three times with PBS (500g for 10 
min, then 400g x 10 min, then 300g x 10min). Deceleration was set to 9 for these 3 spins. The 
cells were then re-suspended in FACS buffer for immunostaining, or in MACS buffer for 
CD14+ cell isolation. 
2.5.2 CD14+ monocyte positive selection 
PBMCs were re-suspended in 80µL of MACs buffer (PBS with 0.5% BSA and 0.05% 0,5M 
EDTA (Sigma-Aldrich)) and 20µL CD14 microbeads (Miltenyi, Germany) per 10x7 cells. The 
solution was mixed well and incubated for 15 minutes then washed by adding 1.2mL buffer per 
10x7 cells and centrifuging at 300g for 10 min. Up to 10x8 cells were resuspended in 500µL of 
buffer and applied to a MS column which had been pre-rinsed with 500µL of buffer (Miltenyi, 
Germany) in the magnetic field. The column was washed with 1500µL buffer, and once the 
reservoir was empty, the column was removed from the magnet and immediately placed on a 
10mL falcon tube. 1000µL of buffer was applied to the column and immediately flushed by 
firmly pushing the plunger down. Cells were counted, washed and plated at 1million cells/mL in 
DMEM (Invitrogen, UK) with 10% fetal calf serum (FCS) (Biosera, UK), 1% penicillin-
streptavidin (Sigma-aldrich, UK). Cell purity was confirmed as 98% pure by flow cytometry. 
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2.6 Flow cytometry 
2.6.1 Flow cytometry theory 
Flow cytometry is a cellular analysis technology in which a beam of light is directed onto a 
focused stream of fluid passing through the flow cytometer. The scatter of light is analysed to 
reveal characteristics of the cells passing through that stream of buffer. Cells labelled with a 
fluorescent antibody will cause a distinct pattern of light scattering at a specific wavelength 
which can then be detected by the flow cytometer. By using antibodies to specific cell markers, 
this method can be applied to determine whether the cell population is expressing a given 
antigen. If multiple antibodies are being used to assess a cell population, it is imperative to 
identify the threshold above which a value is interpreted as positive. This can be achieved with 
isotype control antibodies or by using ‘Fluorescence minus one’. It is also useful to use 
compensation beads for single staining with each fluorescent antibody to aid adjustments for 
compensation during analysis.  
2.6.2 Fluorescence minus one 
The fluorescence minus one (FMO) technique controls for all fluorescent dyes for which the 
threshold is in question; that is, where spectral overlap correction may lead to greater 
uncertainty as to what constitutes background staining. In an FMO control stain set, all reagents 
used in a given multicolor stain are included except the reagent for which the threshold is to be 
determined. To show the threshold that distinguishes fluorescent cells from cells that do not 
express the determinant detected by the reagent omitted from the FMO control, data are 
collected for cells stained with FMO control stain sets and are compensated, displayed and 
gated in the same way as cells stained with the full stain set. The background fluorescence for 
each subset in the display is demonstrated by the upper boundary of the subset in the FMO 
control. An example is to assess for CD163, we had one tube of cells stained with all antibodies 
from row 1, and on tube stained with all antibodies except anti-CD163. 
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2.6.3 Antibodies for flow cytometry 
Table 2-1. Antibodies used for flow cytometry experiments 
Row Antibody Company Country 
1 Anti-human CD163 IgG1 FITC  conjugate Bachem UK 
  Anti-human CD16 IgG1 R-PE conjugate Invitrogen USA 
  Anti-human CD14 IgG2a Pacific Blue conjugate Invitrogen USA 
  Anti-human HLA DR (class II) IgG2b APC conjugate Invitrogen USA 
2 Anti-human CD4 iGg2a biotin Caltag USA 
  Anti-human anti-γ/δ TCR IgG1 PE conjugate Pharmigen Becton Dickinson USA 
  Anti-human CD3 IgG1 PC7 PE Cy7 conjugate Beckman Coulter USA 
  Anti-human CD8 IgG2a pacific blue conjugate Invitrogen USA 
3 Anti-human CD56 FITC conjugate Invitrogen USA 
  Anti-human CD16 IgG1 R-PE conjugate Invitrogen USA 
  Anti-human CD3 IgG1 PC7 PE Cy7 conjugate Beckman Coulter USA 
  Anti-human CD8 IgG2a pacific blue conjugate Invitrogen USA 
Other Streptavidin Alexa fluor 488 conjugate  Invitrogen USA 
  Live/dead fixable aqua dead cell stain kit Invitrogen USA 
 
(i) Row 1: antibodies for examining monocyte/macrophage population. Anti-CD14 antibodies 
were used to identify the monocyte/macrophage population. Use of anti-CD16 (FcγRIII) was 
intended to separate CD14+ monocytes into CD14highCD16low and CD14lowCD16high. 
CD14+CD163+ cells and CD14+HLA-DR+ expression were measured as markers of 
deactivated or activated populations. (ii) Row 2: antibodies for examining T cell subsets. CD3 
was used as the marker for all T cells, as it is present on cells expressing either αβ or γδ T cell 
receptors. γδ T cells was measured directly in the FL2 channel, whilst the proportion of CD3+ 
αβ T cells was deduced by subtracting the number of CD3+ γδ T cells from the total CD3+ 
population. (iii) Row 3: antibodies for examining NK cells. NK cells express CD56 (a 
homophilic adhesion molecule of the immunoglobulin superfamily (NCAM)) and CD16. The 
absence of CD3 but the presence of CD56 and CD16 were deemed the most reliable markers for 
pure NK cells in humans. Two functional subsets of NK cells exist: the more mature CD56dim 
CD16high population is potently cytotoxic, whereas the CD56bright CD16low/neg NK cells 
have low cytotoxicity but produce much greater amounts of cytokines.  
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2.6.4 Flow cytometry protocol 
Flow cytometry was used to quantify and characterise leukocyte subsets in blister fluid and 
peripheral blood. Cells (from blisters or PBMCs) were re-suspended in FACS buffer and 
blocked with 10% human pooled plasma for 20 minutes on ice. 1x105 cells were applied to 
wells pre-prepared with antibodies (1µl antibody per 1x105 cells) and incubated on ice for 15 
minutes. Wells were then washed for 5 minutes at 300g with 200µL FACS buffer, 3 times. The 
secondary antibody was applied and after a further 15 minute incubation, and repeat 3 washes 
the cells were transferred to FACS tubes for analysis. Cells were analysed with on a Beckman 
Coulter CyAn ADP 9 colour, 3 laser high performance analyser.  
2.7 Neuropeptide investigation 
2.7.1 Thermal threshold testing (TTT) 
A thermal threshold testing system (NeuroSensory Analyzer, Merdoc Ltd Israel) with a rate of 
rise in temperature of 1 degree/second was used. The thermode was placed at on the volar 
aspect of the forearm. The baseline temperature was set at a neutral point (30oC). Thermal 
thresholds are determined for cool and warm sensation, and for heat and cold perceived as pain. 
Four consecutive tests are carried out for each modality. The mean temperature was recorded as 
the threshold.   
2.7.2 Capsaicin mode of action 
Capsaicin occurs naturally as the pungent compound in hot chilli peppers. It is a highly selective 
and potent exogenous agonist for the TRPV1 receptor on nerve endings. The TPRV1 receptor 
(transient receptor potential cation channel subfamily V member 1, also known as the capsaicin 
receptor and the vanilloid receptor 1) is a non-selective transmembrane cation channel found on 
small nerve fibre terminals [201]. It is activated by a wide variety of exogenous and endogenous 
physical and chemical stimuli.  The best-known activators of TRPV1 are: heat greater than 
43°C, capsaicin and allyl-isothiocyanate (the pungent compound in mustard and wasabi).  
Activation causes neurogenic inflammation and vasodilation via the local release of vasoactive 
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mediators including CGRP and substance P and possibly also by the activation of dorsal root 
reflexes [201].  TPRV1 receptor activation causes vasodilation via the local release of 
vasoactive mediators including CGRP.  This reaction can be blocked by CGRP antagonists. 
2.7.2.1 Capsaicin preparation and administration 
Capsaicin powder was obtained from Sigma-Aldrich N.V. (Bornem, Belgium) and was 
dissolved in a 3:3:4 mixture of ethanol 100%, Tween-20 and distilled water. Capsaicin was 
diluted so that 20mL of the mixture contained 100, 300 or 1000µg capsaicin. Capsaicin 
responses were assessed in BS and HC subjects. All subjects were asked to abstain from non-
essential drugs including antihistamines for 3 days, as well as from chocolate, caffeine and 
alcohol for 12 hours before the test. All measurements were performed while the subjects rested 
in a semirecumbent position on a comfortable recliner in a quiet, temperature-controlled room. 
10-mm rubber O-rings (McMaster-Carr, New Brunswick, NJ, USA; 8 mm inner diameter) were 
placed onto the volar surface of the forearm. The rings were positioned so that their distal edges 
were 20cm proximal to the wrist crease, within approximately 1 cm of the midline and avoiding 
visible veins. After placement of the O-rings, a laser Doppler imager was used to obtain 
baseline scans of the Dermal Blood Flow (DBF) in the areas deﬁned by the rings. Subsequently, 
these O-rings served as reservoirs to contain the topically applied 20-ml capsaicin or placebo 
solutions.  
2.7.3 Real-time blood flow imaging system: Laser-doppler 
Real-time blood flow imaging (BFI) was undertaken with a Perimed Laser Doppler Perfusion 
Imager (HR-LDPI system, PeriScan PIM II®; Perimed, Järfälla, Sweden) that had an X-Y 
scanning laser probe, allowing two-dimensional mapping of the blood ﬂow variability over an 
extended skin surface using doppler technology. The red light of a 633-nm helium-neon laser 
penetrates the skin variably to a depth of about 1mm. The vasculature within these layers 
comprises vessels of variable size, orientation and function. For this reason, it is not meaningful 
to express the cutaneous ﬂow in absolute terms, but rather as arbitrary ‘perfusion units’. These 
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calculations were performed using the built-in statistical function of the HR-LDPI system 
(LDPIwin; Perimed).  
2.7.3.1 Real-time blood flow imaging system: Laser-Speckle Flowmetry 
Laser speckle contrast imaging exploits the fact that a random speckle pattern is generated when 
tissue is illuminated by laser light (wavelength 780nm), and this speckle changes when blood 
cells move within the region of interest. When there is a high level of movement (fast flow) the 
changing pattern becomes more blurred and the contrast in that region reduces accordingly. 
Therefore low contrast is related to high flow, high contrast to low flow. The contrast image is 
processed to produce a colour-coded image that correlates with blood flow in the tissue. This 
technique gives a video frame rate of blood flow images (25 per second). The zoom function 
enables resolutions exceeding 1M pixels per cm. The resulting image is mainly of blood flow in 
the microvessels in the surface layers of the tissue being sampled. The effective sampling depth 
is small (0-2mm). Flux (PU) is the scale of blood flow (0-1000PU). The scale is arbitrary 
because it is impossible to be precise about the sample volume.  Data may be represented as 
total or % change in flux once the area of interest is defined. Another output is to assess the flare 
area i.e. how many pixels are above the mean flow post intervention. Laser speckle flowmetry is 
effectively still a Doppler technique because high speed results in suppression of contrast and 
low speed is an expansion of contrast, in the same way that sound waves get compressed with 
higher speeds in the typical Doppler illustrations. Laser Doppler is a slightly different to laser 
speckle as different algorithms are used to calculate flow. 
2.8 Protein analysis 
2.8.1 ELISA 
Inflammatory mediators in blister fluid were determined by capture ELISA using a matched 
antibody pair (DuoSet; R&D Systems, Abingdon, UK) according to the manufacturer’s 
recommendations. Capture antibodies were diluted to the working concentration in PBS and 
100µL was added per well. The plate was sealed and incubated overnight at room temperature. 
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Plates were washed 3 times then blocked for1 hour then washed again 3 times. Samples and 
standards were applied and incubated for 2 hours then plates were washed again 3 times. 
Detection antibodies were applied for 2 hours plates were washed 3 times. Streptavidin (R&D, 
UK) was applied for 20 minutes then plates were washed 3 times. Tetramethylbenzidine 
Substrate solution (TMB) (Sigma-Aldrich) was applied. Once an adequate blue colour had 
developed the reaction was stopped with H2SO4 (Acros organics) and Optical Densities (OD) 
were determined using the microplate reader set to 450nm. Standard curves for each cytokine 
(in duplicate) were generated by using the reference cytokine concentrations supplied in this kit. 
All samples were measured in duplicate and the results were calculated against the standard 
curve, and expressed as the mean ± SEM cytokine concentration (pg or ng/ml). 
2.8.2 Multiplex bead analysis – Cytokine analysis of blister fluid 
Soluble mediators in blister fluid were analysed using FlowCytomix beads (eBioscience, 
country) on the Cyan FACS machine. Multiplex bead analysis allowed the measurement of 
multiple cytokines in small volumes of blister fluid (25µl.) The following cytokines were 
assayed: IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-22, 
TNF-α and IP-10. Briefly, beads were labelled with antibodies which specifically react with 
each of the analytes to be detected in the multiplex system. The beads could be differentiated by 
their sizes and by their distinct spectral addresses. A mixture of coated beads for each analyte to 
be measured was incubated with the samples or standard mixture. The analytes present in the 
sample bound to the antibodies linked to the fluorescent beads. A biotin-conjugated second 
antibody mixture was then added, the specific antibodies binding to the analytes captured by the 
first antibodies. Streptavidin-Phycoerythrin was then added, binding to the biotin conjugate and 
emitting fluorescent signals. Fluorescence was measured by flowcytometry. Standard curves for 
each cytokine (in duplicate) were generated by using the reference cytokine concentrations 
supplied in this kit.  
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2.9 RNA extraction and cDNA generation  
2.9.1 RNeasy protein extraction method 
Cells were harvested and frozen in 350 μL RLT buffer (Qiagen, UK) containing 3.5 μL 2-
mercaptoethanol (Sigma-Aldrich, UK). The lysate was passed 5 times through a blunt 20-gauge 
needle (0.9 mm diameter) fitted to an RNase-free syringe, or pipetted into a QIAshredder spin 
column (Qiagen, UK) and centrifuged x 2 min at full speed. One volume of 70% ethanol was 
applied to the homogenized lysate and mixed well. The sample was transferred to an RNeasy 
spin column (Qiagen) placed in a 2 mL collection tube, and centrifuged for 30 secs at 8000g. 
The flow-through was discarded. 700 μL buffer RW1 (Qiagen) were added to the RNeasy spin 
column. The column was centrifuged for 15 seconds at 8000g, and the flow-through was 
discarded. 500 μL of buffer RPE was added and centrifuged for 15seconds at 8000g, twice. The 
spin column was placed in a new collection tube and spun on full speed for 1 minute. The spin 
column was placed in a new 1.5ml collection tube and 30μL RNase free water was added and 
spun for 1 minute x 8000g.  
2.9.2 Trizol RNA extraction 
Homogenization: 1mL of Trizol Reagent (Invitrogen, UK) was added to sample and 
homogenized by pipetting the suspension up and down several times. The samples were 
incubated for 5 minutes at room temperature to permit complete dissociation of the 
nucleoprotein complex. Phase separation: Chloroform (200µL of chloroform for every 0.75mL 
of TRIzol LS) was added. Samples were vortexed for 15 seconds then incubated for 2-3 
minutes. Samples were centrifuged at 12,000g for 15minutes at 4 oC. Following centrifugation, 
the mixture separates into lower red, phenol-chloroform phase, and interphase, and a colourless 
upper aqueous phase. The upper aqueous phase, containing RNA, was separated into a fresh 
tube. RNA precipitation: RNA was precipitated by adding 1mL of isopropyl alcohol. Samples 
were incubated at room temperature for 10 minutes and centrifuged at 12,000 x g for 10 minutes 
at 4°C. The RNA precipitate formed a visible pellet. The supernatant was completely removed 
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and the RNA pellet was washed twice with 1mL 75% ethanol. The pellet dried by incubating a 
37°C incubator for 5-10 minutes. RNA was dissolved in 20µL RNase free water (Sigma) by 
passing the solution up and down several times then left on ice for 30 minutes. 
2.9.3 Trizol LS RNA extraction  
Homogenization: 0.75 ml of TRIzol LS Reagent (Invitrogen, UK) was added to each 0.25 ml of 
sample (0.75 ml of TRIzol LS Reagent per 5-10 x 106cells) and homogenized by pipetting the 
suspension up and down several times. The samples were incubated for 5 minutes at room 
temperature to permit complete dissociation of the nucleoprotein complex. Phase separation:  
Chloroform (200µL of chloroform for every 0.75mL of TRIzol LS) was added. Samples were 
inverted and mixed well for 15 seconds then incubated for 10 minutes. Next the samples were 
centrifuged at 12,000g for 15minutes at 4oC to get phase separation. The aqueous phase of the 
sample was removed and placed in a new tube. RNA isolation: 2µL of glycoblue was added to 
samples to act as a carrier to the RNA. 800µL of 100% isopropanol was added and incubated at 
room temperature for 10minutes. The samples were centrifuged at 12,000g for 10 minutes at 4 
oC. The supernatant was removed leaving only the RNA pellet. This was washed with 1mL 75% 
ethanol and the sample was vortexed. The samples were then centrifuged at 7,500 g for 5 
minutes at 4 oC and the supernatant was discarded. The pellet was air dried for 10 minutes then 
resuspended in 20µL RNase-free water by passing the solution up and down several times  then 
left on ice for 30 minutes.  
2.9.4 RNA purification and concentration analysis 
The purity and the concentration of the RNA were analysed using the Nanodrop 
spectrophotometer (Thermo Scientific). 
2.9.4.1 RNA purification 
At this step, the sample contained RNA and DNA. DNA-Free (Ambion, UK) was used to purify 
the sample. Samples were diluted in the provided buffer in a 1:10 dilution and incubated for 
30minutes at 37oC. The DNase Inactivation Reagent was vortexed before us then added to all 
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samples (10% volume). Samples were mixed and incubated for 2 minutes, then centrifuged at 
10,000g for 1.5minutes. The supernatant was carefully aspirated into a fresh tube, leaving the 
beads pelleted at the bottom. Samples were nanodropped. 
2.9.4.2 cDNA synthesis  
cDNA was synthesised using the SuperScript® III RT kit (Invitrogen) following manufacturer’s 
instructions. Briefly, 1ug of total RNA was added to 1μl oligo(dT)20 (50μM) (Eurofins, 
Promega) and 1 μl 10 mM dNTP Mix (Promega), and adjusted to a final volume of 13 μl with 
water. The mixture was heated to 65°C for 5 mins and incubated on ice for 5 mins. 4 μl of 5x 
first-strand buffer (Invitrogen), 1 μl of 0.1M dithiothreitol (DTT) (Invitrogen), and 1 μl of 
SuperScript III reverse transcriptase were added to the mixture. The reaction was incubated at 
25°C for 5 min, 50°C for 50 mins and inactivated by heating it to 70°C for 15 mins then stored 
in freezer or on ice. 
2.9.5 Quantitative real-time PCR  
2.9.5.1 Quantitative real time PCR theory 
Quantitative real time PCR (qRT-PCR) works via the generation of a fluorescent signal which is 
measured after each cycle to detect the replication of an amplicon [202]. The readout is given as 
the number of cycles required for the fluorescent signal to surpass the threshold level set by the 
user. This output is called the cycle threshold (Ct), and the fewer cycles required to surpass 
threshold, the more of the specific mRNA is present in the sample. Housekeeping genes allow 
normalisation of results. Data was analysed using the comparative Ct method, where the Ct of 
each sample for the gene of interest is normalised to its own housekeeping gene Ct, in order to 
calculate ΔCt. ΔCt = Ct (target gene) – Ct (Housekeeper)  
2.9.5.2 Quantitative real time PCR protocol 
5 µl of template cDNA (pre-diluted 1:20) was amplified using the following reagents; 12.5 µl 
SYBR green fastmix IQ (Quanta perfecta, Invitrogen); 6.5 µl H2O, 0.5 μL forward primer (pre-
diluted 1:10), 0.5 μL reverse primer (pre-diluted 1:10). The cDNA or DNA was denatured by 
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heating the mixture at 95°C for 3 minutes, and amplified according to the following conditions, 
repeated for 40 cycles: 95°C for 10 secs, 56°C for 30 secs. Real-time PCR were performed 
using the iCycler thermocycler (Biorad). The results were analysed using iCycler IQ optical 
system software (Biorad).  
Table 2-2. Oligonucleotides used for qRT PCR 
Oligonucleotides used for qRT PCR 
CXCL-9 F 5' TTG CTG GTT CTG ATT GGA GTG 3' 
  R 5' CCT TGG TTG GTG CTG ATG C 3' 
CCL-2 F 5' AGT CAC CTG CTG TTA T 3' 
  R 5' TCA AGT CTT CGG AGT T 3' 
CXCL-10 F 5' GCT ATG TTC TTA GTG GAT GTT C3' 
  R 5' AGG ATG GCA GTG GAA GTC 3' 
HPRT F 5' TTG GTC AGG CAG TAT ATT CC 3' 
  R GGG CAT ATC CTA AA CA AC 3' 
ACTIN F GAG CTA CGA GCT GCC TGA CG 3' 
  R GTA GTT TCG TGG ATG CCA CAG GAC T 3' 
GAPDH F 5' CAA CAG CCT CAA GAT CAT 3' 
  R 5' GAG TCC TTC CAC GAT ACC 3' 
Oligo dt   5' CGA CTC GAG TCG ACA TCG ATT TTT TTT TTT TTT TT 3' 
 
2.9.5.3 Validation of qRT-PCR product with agarose gel  
On completion of the first qRT-PCT run for each new primer set, the product was validated with 
an agarose gel. Product with gel loading dye, and a ladder was loaded on to a 2.5% agarose gel 
(2.5g agarose in 100mls TAE buffer and 1.5µL ethidium bromide) and run at 100V x 20 
minutes. Products were assessed to ensure only a single band was present and that the band was 
the expected size.  
2.10 Sucrose-density-gradient polysome experiment 
2.10.1 Sucrose-density-gradient polysome experiment theory 
RNA from cells was isolated and layered on top of a tube containing a sucrose density gradient 
(sucrose 50% at the bottom to 20% at the top of the tube). It was then spun at very high speeds 
which resulted in ‘heavy’ polysomes travelling further down the tube then 80S or 40S subunits. 
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Free RNA travelled the least far. A needle pierced the bottom of the tube and very even denser 
sucrose was introduced slowly (60%) to push the contents of the tube into a collecting tube and 
past a laser (which fed to a graph tracer giving an image of passing fluid contents), and finally 
the sucrose was fed into collecting ependorfs, which allowed the sample to be collected in 
fractions and analysed.  
2.10.2 Establishing the sucrose density gradient 
Buffer was prepared as follows: 0.3 M NaCL (Ambion, USA), 15mM MgCl2 (Ambion, USA), 
15mM Tris HCL 7.6 (Calbiochem, Germany) in molecular grade water (Sigma-Aldrich, UK). 
Falcon tubes of buffer were prepared with the following concentrations of molecular grade 
sucrose (Sigma-Aldrich): 50%, 44%, 38%, 32%, 26% and 20%. Polyallomer tubes (Beckman 
Coulter, USA) were placed into a secure rack. 1.5mL of the highest concentration of sucrose 
was added. Tubes were snap frozen in liquid nitrogen. 1.5mL of the reducing concentrations 
were added sequentially, freezing the tube between each one to establish a density gradient from 
50% to 20% in the tube.  Tubes were covered with parafilm and stored in -80oC  freezer until 4 
hours before they were required. 
2.10.3 Cell lysis and ultracentrifugation 
Cell lysis buffer was prepared as follows: 0.3 M  NaCL (Ambion, USA), 15mM  MgCl2 
(Ambion, USA), 15mM Tris  HCL 7.6 (Calbiochem, Germany), 1% 1% Triton x-100 355mM 
(Sigma-Aldrich, UK), 10µL/mL superase (Superase.IN, Ambion, USA) and 10 µL/mL protease 
inhibitor (Protease Inhibitor cocktail, Sigma-Aldrich, UK). CD14+ monocytes were suspended 
in DMEM with 10% FCS and 1% Pen/strep at 1 million cells per mL concentration. 5mLs were 
plated in a 6 well plate and left to settle for 1 hour. Cells were stimulated with 20ng/ml IFN-γ 
for two hours, or else left unstimulated. Unstimulated cells were harvested once they had settled 
for one hour. 2.8µL of cyclohexamide was added to the 5ml plate for 5 minutes before 
harvesting to inhibit further translation. Supernatant was then aspirated and stored for later 
protein analysis. Supernatant was replaced with 2 mls of fresh medium and cells were scraped, 
aspirated into a falcon tube and spun at 500g for 10 minutes. Supernatant was completely 
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removed then 250µL of cell lysis buffer was added. The sample was pipetted up and down then 
left on ice for 15minutes. After 15 min the sample was spun in a microcentrifuge at 10,000g for 
15minutes (4 oC). 10µL was aspirated for mRNA quantification. The remaining supernatant was 
pipetted carefully onto the sucrose density gradient and spun in the ultracentrifuge at 150,000g 
for 90 minutes at 4o C with deceleration set to level 9 (0=max deceleration, 10=coasting).  
2.10.4 Sucrose density gradient polysome experiment 
Table 2-3. Equipment used for sucrose density gradient experiment 
Sucrose density gradient equipment   
Brandel Syringe pump USA 
Brandel Tube piercer USA 
Brandel Optical unit with reference flow cell USA 
Dataq Acquisition starter kit UK 
Brandel UV/VIS absorbance detector  USA 
 
Equipment was set up and prepared by running 50mls of 3% hydrogen peroxide on the morning 
of the experiment. This was followed by 100mls of molecular grade water, and then by a 
preparation run of 50% sucrose to establish the baseline settings.  Machine settings were as 
follows: fluid flow speed 0.75 mL/min, paper flow rate 60 cm/hour, sensitivity 0.5 ABS. 
Samples were collected in 1.5ml RNase free ependorfs. Trizol LS was used to extract mRNA.  
2.10.5 Green Fluorescent Protein (GFP) spike 
Following extraction, each sample was ‘spiked’ with a known quantity of GFP mRNA before 
RNA purification, cDNA conversion and RT-PCR analysis. The GFP spike was used to 
normalise values to account for any loss of product during processing. The green fluorescent 
protein (GFP) is a protein composed of 238 amino acid residues (26.9 kDa) that exhibits bright 
green fluorescence when exposed to light in the blue to ultraviolet range and is was first isolated 
from the jellyfish Aequorea Victoria. It has not been conserved in humans. 
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2.10.5.1 Construction of the GFP protein from a Transcription Kit Theory 
DNA from GFP had been inserted into a polylinker site of a transcription vector with a pSPT18. 
The promoters for SP6 and T7 RNA polymerases are located on either side of the polylinker. T7 
RNA polymerases specifically transcribe DNA sequences downstream of the T7 promoters. 
Cloned DNA inserts within the polylinker region can therefore be specifically transcribed. T7 
RNA polymerase uses the cloned DNA as template to synthesize complementary RNA in the 
presence of Mg2+ and ribonucleoside triphosphates. Spermidine stimulates enzyme activity. To 
obtain the DNA, the template DNA must first be linearized with a suitable restriction enzyme 
before the transcription reaction to obtain transcripts of a defined length.   
2.10.5.2 The GFP construct 
GFP had been cloned and stored in the DNA vector. The vector had a SP7/T7 promoter site. 
The vector was first linearized with pBBR1 (a medium copy replicon for Gram-negative 
bacteria) by adding 5µg DNA to 2.5µl buffer; 1µl enzyme and water to a final volume of 25µl 
and incubating for 1-2 hours at 37 oC. Alcohol precipitation of DNA was then undertaken by 
making the digest to 100µl with water and adding 1/10th volume of Na Acetate Ph5.3 and 2.5 
volumes of 100% ethanol and then placing the mixture in a -80oC freezer for 1 hour. Following 
a spin in microcentrifuge for 20minutes at full speed, the digest was then decanted and washed 
with 70% ethanol and spun again for 5 minutes in the microcentrifuge. The pellet was dried 
completely and the concentration was measured. Reverse transcription of DNA to RNA: The 
following was added to a microfuge tube on ice: 1µg DNA; ATP, GTP, CTP, UTP mixture 8µl; 
10xbuffer (vial 8) 2µl; Water to final volume of 18µl and T7 polymerate (vial 12) 2µl. The 
mixture was briefly centrifuged then incubated for 2 hours at 37oC. 2µl DNase 1 and RNase free 
(vial 9) was then added to remove template DNA and the mixture was incubated for a further 15 
minutes at 37 oC. The reaction was then stopped by adding 0.8µL of 0.5M EDTA ph8 and then 
heating to 65 oC for 10 minutes. Alcohol precipitation was undertaken again, followed by 
measurement of the concentration. 40µg was added to each of the sucrose density gradient 
samples.  
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3. Examining the exaggerated cutaneous 
inflammatory response using a skin blister model of 
inflammation 
This chapter describes experiments using two skin blister models of inflammation (suction 
blisters and cantharidin blisters) to investigate the exaggerated cutaneous inflammatory response 
in BS. The pathergy reaction, which forms part of the criteria for the diagnosis of BS [57] is not 
understood. Diagnosis of BS is still entirely clinical. Other than in helping to exclude other 
conditions, existing laboratory tests (e.g. serology) are not particularly useful in diagnosis or 
monitoring disease activity. Acute phase reactants (CRP, ESR) may be normal despite active 
inflammation. There is therefore a clear need for better diagnostic tools for this condition. 
Additionally, increasing our understanding of abnormal cutaneous inflammation may open a 
window into the underlying pathogenesis of this condition. 
3.1.1 Abnormal inflammatory responses in BS 
Pathergy was introduced in Chapter 1 as one of the hallmark characteristic features of BS. It 
manifests as an exaggerated responsiveness to immunologically "non-specific" inflammatory 
stimulation, with patients often reporting exaggerated skin responses to needles, nettles, insect 
bites, plant thorns and other day-to-day trauma. Patients with BS are often given antibiotics 
postoperatively by surgeons concerned by erythema around drip-sites or surgical wounds, and it 
is likely that in many such cases the erythema represents traumatic inflammation rather than 
infection. The "pathergy reaction" refers to the appearance of a papule or pustule 48 hours after 
insertion of a 20g needle into the skin. A positive pathergy reaction provides one of the criteria 
for the International Study Group classification criteria for BS [57]. Although pathergy appears 
to be a common feature of BS in Turkey, it is only demonstrable in ~10% of UK patients [58, 
65, 203, 204]. Furthermore, the test necessitates a visit to clinic on 3 consecutive days, which is 
costly and cumbersome for both the health service provider and the patient. This, along with its 
low sensitivity limits its clinical usefulness.  
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The pathology of pathergy reactions resembles that of other skin lesions in BS, with neutrophils, 
monocytes and lymphocytes present in large numbers, together with increased mRNA 
transcripts for the cytokines IFN-γ, IL-12 p40 and IL-15; the chemokines CCL20 , CXCL10, 
CXCL9, and CXCL11; and adhesion molecules ICAM-1, and VCAM-1 at 48 hours in BS 
versus HC [61, 62]. Whether these abnormalities are due to the occurrence of an inappropriate 
Th1-driven immune response, to dysfunctional NK cells or some other immunological or non-
immunological mechanism is not yet clear. However, importantly, the study of Melikoglu et al 
suggests that the cytokine response to needle injury in the skin in BS is qualitatively different 
from that occurring in healthy individuals [62]. 
3.1.2 Intradermal (id) injection of monosodium urate (MSU) 
crystals 
Intra-dermal (ID) injection of MSU crystals is an alternative way of eliciting inflammation. The 
usual response consists of erythema and induration, which are maximal at ~24 hr. In healthy 
individuals there is an erythematous reaction at 24 hr which has usually largely resolved by 48 
hr. In contrast, BS subjects exhibit a prolonged response [63], with a sensitivity for BS of 78%, 
whereas the classical pathergy test had a sensitivity of 28% [64].  Moreover, the cutaneous 
response to MSU crystals appears to be more reproducible than pathergy (95% concordant 
response after one year, compared to 73% for pathergy) [64]. Our unit have been able to show 
that UK subjects also demonstrate a prolonged inflammatory response to MSU crystals [65]. 
The great advantage of the MSU crystal reaction over the pathergy reaction as an investigational 
approach is that it is a graded rather than a categorical (present/absent) response and can be 
quantified in all individuals. Moreover, the large literature on the inflammatory response to 
MSU crystals in the context of hyperuricaemia and gout provides an excellent mechanistic 
frame-work for exploring how the response is abnormal in BS [66, 67].  
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3.1.3 Immunopathology of  BS  
As discussed in detail in Chapter 1, the immunopathology of BS is not clearly understood. 
There is evidence of involvement of multiple innate and adaptive pathways, resulting in an 
exaggerated or prolonged inflammatory response. There may also be a failure of the anti-
inflammatory mechanisms of the immune system to switch off inflammation. Inflammatory 
tissues in BS typically show a mixed leukocytic infiltrate of neutrophils, macrophages and T 
lymphocytes [205-207].  Immunoglobulin and complement deposition do not appear to be 
marked features, suggesting that cellular immune mechanisms predominate [208].  
There is evidence from analysis of peripheral blood and lesional tissues that the inflammatory 
response is skewed to a Th1 cytokine profile with increased expression of IFN-γ and IL-12, but 
the immunological drivers are still poorly understood [84, 133-135, 209, 210]. This is also 
supported by genetic studies [5, 6, 98, 132, 140]. Raised levels of TNFα are found in the sera of 
BS subjects, as well as IL-6, IL-8 and IL-18 [211-214].   The role of IL-23/IL-17 has also been 
creating interest [143, 215, 216]. Pathways that result in dampening inflammation have also 
featured in genetic studies, with particular interest in a SNP within the IL-10 promoter which 
resulted in less IL-10 protein production in monocytes of subjects with the disease associated 
allele [5, 6]. Other studies have highlighted a polymorphism  within the TGF-beta gene [155]; 
low numbers of regulatory T cells in active BS[156] and a potential involvement of miRNAs 
[157, 158]. 
3.1.4 Inflammatory responses to MSU crystals in vitro  
MSU crystals are thought to stimulate inflammation through activating mast cells, neutrophils 
and monocytes, inducing expression in the latter of pro-inflammatory genes including IL-1, 
TNFα, IL-6, IL-8, and Cox-2 [217-222]. These amplify inflammation through effects on blood 
flow, expression of endothelial cell (EC) adhesion molecules (e.g. E-selectin, ICAM-1, VCAM-
1), chemotaxis of neutrophils and other leukocytes and stimulation of acute phase plasma 
protein generation [223-225]. Our laboratory and others have found that release of IL-1β and 
TNFα fully accounts for the ability of MSU crystal-stimulated monocytes to activate EC 
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adhesion molecule expression in vitro, with IL-1β release preceding and stimulating release of 
TNFα [223, 226]. It has been suggested that MSU crystals stimulate monocytes via a signalling 
mechanism involving CD14 and TLR-2, TLR-4 and MyD88 [227], although the involvement of 
TLRs remains controversial [228, 229].  Importantly, MSU crystals have been shown to 
stimulate IL-1β production by activating the NALP-3 inflammasome [226]. Our laboratory has 
shown that monocyte to macrophage differentiation can lead to reduced expression of pro-
inflammatory factors (e.g. TNFα/IL-1β) in response to MSU crystals and to the acquisition of an 
anti-inflammatory response profile (e.g. TGFβ production)  in vitro. Based upon these 
observations, we have published a series of papers proposing that macrophage differentiation 
contributes to the normal spontaneous down-regulation of MSU-induced inflammation in gout 
[230-232]. Thus, it is possible that the prolonged inflammatory response to MSU crystals in BS 
is related to a failure of macrophage differentiation to this anti-inflammatory phenotype. 
3.1.5 Suction blister model of skin inflammation 
We need to develop clinical research methodology to better understand the abnormal 
inflammatory response to MSU crystals in BS, as (i) there are major differences in the 
metabolism of uric acid between humans and sub-primates so animal models are not ideal, (ii) 
there is no accepted animal model of BS, and (iii) the complexity of the inflammatory response 
cannot be reproduced completely in vitro. Application of a small secure cup to the skin, attached 
to a gentle suction device (150-200mm Hg) leads to the gradual formation of a small blister. 
Suction blister fluid is largely derived from the interstitial fluid [202].  Compared to skin 
biopsies, suction blister fluid is obtained by means of a less invasive sampling technique. This is 
an important consideration in BS, where insults to the skin may lead to an aggressive 
inflammatory response and poor wound healing. Suction blister fluid can be used as body fluid 
to detect soluble mediators of inflammation [233, 234]. For several diseases, including 
epidermal necrolysis [235] and scleroderma [236], suction blister fluid has been used as a 
source to identify/ quantify potential protein biomarkers. Studies have also been published using 
suction blisters to study cellular content, including granulocytes [237]and monocytes [238]. 
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These techniques varied in that blisters were left overnight, and then ‘unroofed’ and stimulated 
with serum before being covered again for 10 hours, following which fluid was collected.  
For our protocol, 2.5 mg MSU crystals were injected intradermally to induce an MSU 
pathergy/inflammatory response. At 24-48 hours suction cups were applied over the 
erythematous area, blisters formed over the following 1-3 hours, following which fluid was 
gently aspirated using a 200μl pipette tip into a siliconized ependorf, and placed on ice. 
3.1.5.1 Cantharidin skin blister model of inflammation 
Our group had previously published studies examining the kinetics of inflammatory responses 
in human skin, using blisters elicited by application of the protein phosphatase inhibitor 
cantharidin [231, 239, 240]. This established the principle that detailed information could be 
obtained on small volumes (~100 μl) of blister fluid using multichannel flow cytometry and 
sensitive immunoassays for cytokines.  We had found that there are marked differences in the 
profile of leukocytes and inflammatory mediators present at 16 and 40 hr after blister 
stimulation by cantharidin in healthy volunteers: (a) blister fluid contains significantly more 
leukocytes at 40 hr than at 16 hr, with Kimura staining showing significantly increased 
proportion of macrophages and reduced proportion of neutrophils; This gave us a model for 
studying early and late phases of the inflammatory response. For this study we used 24 hour 
blisters as an acute inflammation model and 48 hour blisters to reflect resolving inflammation. 
3.1.6 Monocyte and macrophage biology 
Abnormalities of macrophage differentiation could account for the phenomenon of prolonged 
inflammation, or failure to switch off inflammation, which is observed in BS. Furthermore, as 
outlined above, macrophages are central players in augmenting and dampening the 
inflammatory response to MSU crystals. 
Myeloid progenitor cells in bone marrow give rise to monocytes/neutrophils.  Monocytes give 
rise to tissue macrophages, osteoclasts and dendritic cells (although not all of these cells 
differentiate from monocytes) [241].  Monocytes constitute 5-10 % circulating leukocytes.  
They are heterogeneous, with variability in size, granularity and nuclear morphology. Human 
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CD14+ monocytes, which consist of CD16+ and CD16- subsets specialize in phagocytosis, 
production of reactive oxygen species (ROS) and the recognition of ligands for extracellular 
TLRs, in response to which they secrete inflammatory cytokines. Among this subset, CD16 may 
be a marker of activation. Monocytes that lack CD14 (CD14dim) but which express CD16 
monocytes patrol the endothelium of blood vessels in an LFA-1-dependent manner, and respond 
to viruses and nucleic acid-containing immune complexes via a pro-inflammatory TLR7–
TLR8–MyD88–MEK pathway. CD14dim cells may be involved in the innate local surveillance 
of tissues with regard to cell death and viral infection, the scavenging of immune complexes and 
the pathogenesis of autoimmune diseases such as lupus [242-245].  
Macrophages also contain many subgroups. Classically Activated (‘M1’) macrophages are 
responsive to type 1 inflammatory cytokines (e.g. IFN) and microbial products; their function is 
microbicidal and inflammatory; and they have a ‘core response to infection’ with upregulation 
of transcription factors leads to pro-inflammatory cytokine (e.g.IL-1b/TNF/IL-6/IL-12) 
induction and upregulation of cytokine receptors (e.g. IL-7R/IL-15R). They also secrete 
chemokines (e.g. CCL2, CCL5, CXCL8 and CXCL10) and up-regulate the chemokine receptor 
CCR7. Uncontrolled M1 can lead to tissue damage and multiorgan failure [246, 247] . 
M2 polarization is associated with chronic evolution of infectious disease is thought to be 
associated with macrophage reprogramming to M2; Alternatively Activated (’M2a’) 
macrophages are responsive to IL-4 / IL-13; Their role is that of an immunomodulator, leading 
to increased endocytic activity; increased mannose receptor (MR),dectin1 and arginase, 
increased cell growth and increased tissue repair. They are involved in parasite killing. Innate 
activated (‘M2b) macrophages are responsive to immune complexes and TLR agonists/IL1R 
agonists and are also immunomodulators, leading to increased iNOS and ROS and production 
of proinflammatory cytokines. Deactivated (‘M2c’) macrophages are responsive to IL-10; 
glucocorticosteroids; TGFβ; CD200-CD200R and act as an immunomodulator leading to 
increased production of IL-10; TGFβ; PGE2 and reduced expression of MHC2 molecules on the 
cell surface. CCR2, CCR5, and CD163 are cell surface markers for this phenotype [246, 247]. 
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3.1.7 CD163 as a marker of deactivated macrophages  
The development of anti-inflammatory responsiveness to MSU crystals of in vitro differentiated 
macrophages parallels the rise in macrophage expression of CD163 [240].  CD163 is a 
macrophage-specific member of the cysteine-rich superfamily, and functions as a scavenger 
receptor of haptoglobin: haemoglobin complexes [248, 249]. CD163 is known be upregulated 
by incubating monocytes with glucocorticoids or with the predominantly anti-inflammatory 
cytokine IL-10, and, conversely, CD163 expression is suppressed by TNFα, IL-4 or IFN-γ [250, 
251]. On the strength of these observations, CD163 has been proposed as a marker of 
deactivated/anti-inflammatory macrophages involved in resolution [250, 252].  It should be 
noted that CD163 positive deactivated macrophages are not equivalent to the "alternatively 
activated"/M2 macrophage phenotype stimulated by  IL-4/IL-13 [196, 246]. 
3.2 Hypothesis 
We tested the hypothesis that a failure of macrophages to differentiate to the CD163+ 
‘deactivated’ macrophage may contribute to the pathergy response observed in BS. 
3.3 Aims 
The primary aim of this project was to gain an understanding of the abnormal cutaneous 
inflammatory response to stimuli such as MSU in subjects with BS. Our specific question 
related to macrophage differentiation in BS and HC. A secondary aim was to find a useful 
diagnostic tool for this condition. 
3.3.1 Research aims in detail 
1. At the start of this study we aimed to compare the usefulness of two techniques of blister 
formation: (i) using a small suction cup placed over the MSU injection site at 24 or 48 hours, to 
obtain fluid and cells from the MSU lesion, (ii) using the cantharidin model of blister formation.  
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2. Once a skin blister protocol was established, we wished to explore the mechanisms 
underlying the delayed resolution of inflammation in BS, focusing the investigation on the 
following questions: 
(1) Is there a delay in macrophage deactivation in BS and, if so, does this distinguish those with 
BS from healthy individuals 
(2) What is the "bigger picture" of differences in cells and cytokines that distinguishes the                                      
inflammatory response in BS compared to controls? 
(3)  If macrophage parameters do not distinguish BS from controls, what other features of 
inflammation might be responsible? 
(4) Could any of the observations be useful diagnostically? 
3.4 Results 
3.4.1 Assessment of a suction blister model to study cutaneous 
inflammation 
Initially we wished to evaluate the usefulness of suction blisters to study the MSU reaction. For 
the method to be useful it would need to be a reliable way to obtain adequate cells for flow 
cytometry analysis, and fluid for protein analysis. We created two suction blisters over MSU-
injected sites in 6 healthy control subjects. Subjects were injected on the forearm with MSU and 
16 or 40 hours later 5mm suction cups were applied.  We found that following application of a 
suction cup and negative pressure, blisters took between 1 and 2 hours to form.  However, 3 of 
the 12 blisters burst during the suction process, and fluid was lost. In addition to this, a further 5 
of the 12 blisters contained less than 1 x 10 5 cells - too few for flow cytometry analysis.  
Table 3-1. Suction blister volumes and cell counts in 6 healthy controls 
Suction blister volumes and cell counts in 6 HC subjects 
Subject Time point (hr) Blister volume (µl) Total Cell count (x10 5) Comment 
1 16 180 1.5   
  40 0 0 Burst at 80 min 
2 16 0 0 Burst at 15min 
  40 660 68.3   
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3 16 140 135   
  40 160 7.7   
4 16 30 0.8   
  40 30 0.76   
5 16 80 0.2   
  40 70 0.4   
6 16 0 0 Burst at 60 min 
  40 50 0.45   
 
To compensate for the low numbers of cells, we produced suction cups of a larger diameter.  A 
10 mm cup was found not to be effective at creating blisters as the skin was simply pulled to the 
roof of the cup.  Although blisters did form with the 7.5 mm cup, less than 1 x 10 5 cells were 
recovered in both of two volunteers - again too few for multichannel flow cytometry analysis. 
Additionally, the time required for blisters to form increased, and in one of the subjects took 4 
hours. 
In contrast, cantharidin blister techniques were already established in the group and were known 
to be a robust model of skin inflammation, producing reliable quantities of fluid and cells. The 
decision was taken to proceed with this method for the study, but also to perform an MSU 
injection on the other arm to provide a link to a stimulation that had previously been shown to 
differentiate BS from healthy controls. 
3.4.2 Establishment of a 3 day protocol for cantharidin skin 
blisters. 
The final protocol that was used is shown below.  On day one, following informed consent, a 
questionnaire was completed to record subject demographics, history, medications and disease 
activity. A blood sample was taken using an aseptic technique for in vitro experiments. 
Following this, cantharidin was applied to one forearm and an overlying paraffin film and 
bandage applied. MSU was injected into the dermis on the other forearm. On day two, the MSU 
reaction was measured and photographed and the second droplet of cantharidin was applied. On 
day 3, blisters (one being 48 hours old and one being 24 hours old) and the MSU reaction sites 
were measured and digitally photographed and the blister fluid was gently aspirated using a 
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pipette, into a labelled 1ml siliconised ependorf. Samples were kept on ice and brought 
immediately to the laboratory for analysis. 
 
 
 
Figure 3-1. The final protocol to establish 24 hour and 48 hour cantharidin skin blisters, 
and an ID MSU injection test.  
 
 
Figure 3-2. Cantharidin skin blister application.  
Cantharidin solution is applied to a 1cm circular piece of filter paper on the volar aspect of the 
forearm. Parafilm and a bandage are placed over the filter paper. At 24 or 48 hours, the bandage 
is removed and the blister is photographed. Fluid is aspirated and collected for analysis. 
3.4.3 Demographics of the BS and HC cohorts 
We recruited 12 BS and 12 HC subjects. Demographics of the recruits are shown below. Seven 
of the BS were male (58%) versus six of the HC subjects (50%). The median age in the BS 
group was 43years (interquartile range 34.5-46.8) versus 32 years (interquartile range 28.3-36.0) 
in the HC group. Six of the BS group were taking steroids (prednisolone). Of those 6, the 
median dose was 10 mg.  BS subjects were also taking a variety of other disease modifying 
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medications: namely: colchicine (n=3); azathioprine (n=6); an anti-TNF agent (n=5); 
mycophenolate moefetil (n=2) and tacrolimus (n=1). The median disease activity using the 
Leeds questionnaire was 4.1 (scale of 0-12) indicating mild-moderate disease activity. In the HC 
group, all subjects were in good health and taking no regular medications. 
 General Demographics Healthy Controls Behçet  Syndrome 
Cohort size     12   12   
Median age (Interquartile range) 33 (31-38) 43 (37-46) 
Male sex (%)     6 50% 7 58% 
Clinical Characteristics            
Mucocutaneous      0   12 100% 
  Erythema nodosum       3 25% 
  Pathergy or poor wound healing     9 75% 
Musculoskeletal – arthralgias   0   10 83% 
  Arthritis         3 25% 
Cardiovascular     0   3 25% 
  Aneurysm         2 17% 
  Thrombosis       1 8% 
Ocular       0   2 17% 
  Posterior/panuveitis   0   2 17% 
Gastrointestinal inflammation   0   1 8% 
Neurological      0   3 25% 
Disease Activity Score *   0   4   
Current medications           
Colchicine     0   4 33% 
Azathioprine     0   5 42% 
Mycophenolate     0   2 17% 
Anti-TNF therapy     0   4 33% 
Cyclosporine     0   1 8% 
Methotrexate     0   1 8% 
Steroids **     0   6 (10mg) 
* Behçet: Leeds Behçet's disease activity form (2002 version) score of 0-12 (>4 indicates active 
disease). 
** Number of subjects taking steroids, and the median prednisolone dose taken by those subjects 
 
Table 3-2. Demographics of BS and HC subjects recruited for cantharidin skin blister 
study.  
Features listed include general demographics, disease manifestations and medications being 
taken at the time of the study. 
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3.4.4 Monosodium urate injections 
Previous studies, outlined in Chapter one, have shown that ID MSU injections result in 
significantly more erythema in BS than HC at 48 hours. We injected all participants with 2.5mg 
MSU into the volar aspect of the forearm not being used for skin blisters. At 24 and 48 hours 
the maximum diameter of erythema was measured and photographed. We found that BS had 
significantly larger MSU responses at both 24 and 48 hours to the MSU injection than HCs. 
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Figure 3-3. The maximum diameter of erythema in HC and BS subjects 24 and 48 hours 
after the intradermal injection of MSU crystals.  
Kruskal-Wallis non parametric two-tailed testing of analysis of variance between the groups 
P<0.001. Mann Whitney non parametric testing two-tailed testing at 24 and 48 hours showed 
significantly differences between HC and BS (24 hour P=0.0029; 48 hour P=0.004) 
3.4.5 Naked eye assessment of cantharidin skin blisters 
Prior to collecting fluid, cantharidin skin blisters were photographed. Interestingly, many of 
those BS subjects who had a large reaction to the MSU, also developed an erythematous ‘halo’ 
around the MSU blister. We classified MSU responses in all subjects (BS and HC) as ‘strong’ 
or ‘weak’. We found that the presence of the halo around the cantharidin blister strongly 
correlated with having a strong MSU response (Figure 3.5, Figure 3.6). 
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Figure 3-4. The typical appearance of cantharidin skin blisters in HC (left) and BS (right) 
subjects.  
Note the surrounding ‘halo’ of erythema in the BS subject.  
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Figure 3-5. MSU responses classified as ‘strong’ or ‘weak’ depending on the size of 
erythema at 48 hours.  
This grouping was used to correlate with erythema around the cantharidin blisters (see below) 
 
Figure 3-6. The correlation between having a large MSU response and development of 
erythema around the cantharidin skin blister.  
Chi square test 13.2 df 1 P=0.0002 indicating a significant correlation. 
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3.4.6 Cantharidin volume and cell count 
Fluid recovered from the cantharidin skin blister was immediately transferred to a siliconized 
ependorf and placed on ice. The volume was recorded and then 10μl was aspirated and applied 
to a haemocytometer for a total cell count. The remainder was spun in a microcentrifuge at 
300g, following which interstitial fluid was separated, aliquoted and stored in siliconized 
ependorfs at -80oC for future analysis of blister fluid protein content. Cells were resuspended in 
‘FACS buffer’ (phosphate buffered saline (PBS) with 0.5% bovine serum albumin (BSA) 
(Sigma-Aldrich, UK) and 0.05% NaN3 (Sigma-Aldrich, UK)) for immediate characterization by 
flow cytometry. 70µl was set aside for white cell differential slide. 
The median volume of fluid recovered from the HC blisters was 210µL (24hour) and 185µL 
(48hour); and from the BS blisters was 500µL (24 hour) and 180µL (48 hour). Although a trend 
was seen to having less fluid in the 48 hour sample, and more fluid in the BS samples, this did 
not reach significance. 
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Figure 3-7. Cantharidin blister volumes in HC and BS at 24 and 48 hours.  
The line represents the median values for each group. Kruskal-Wallis non parametric two tailed 
analysis of variance did not show significant differences between the groups (P=0.16). 
 
A cell count was undertaken shortly following blister fluid aspiration using a haemocytometer. 
The median cell count (cells x 104 / mL) for HC blisters was 67 and 134, for 24 and 48 hour 
blisters respectively, and that for BS blisters was 110 and 150, for 24 and 48 hour blisters 
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respectively. There was a trend towards a greater density of cells in BS samples, and there 
appeared to be an increased cell number in later samples, but differences between groups did not 
reach significance.  
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Figure 3-8. The cell count (cells x 104 / mL) of 24 and 48 hour blisters in HC and BS.  
There was a trend towards more cells in the BS cohort, and in the later blisters but Kruskal-
Wallis non parametric two tailed analysis of variance showed no difference between the groups 
(P=0.174).  
 
The total cell count obtained was next calculated based on the volume and cell/mL count. The 
median total cell count (x 104) for HC blisters was 16 and 24 for 24 and 48 hour blisters 
respectively, and that for BS blisters was 36 and 25 for 24 and 48 hour blisters respectively. 
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Figure 3-9. Cantharidin blister total cell counts (x104) in HC and BS at 24 and 48 hours. 
The line represents the median values for each group. Kruskal-Wallis non parametric two tailed 
analysis of variance did not show significant differences between the groups (P=0.66). 
 
A slide was prepared and stained for each blister to obtain a white cell differential. The 
differential showed the expected differences between 24 hour and 48 hour blisters. Twenty four 
hour blisters showed a predominantly neutrophilic infiltrate (80% of BS and 86% of HC). Forty 
eight hour blisters show fewer neutrophils (55% in both BS and HC subjects). Macrophages 
were seen with a higher frequency in the 48 hour blisters versus 24 hour blisters as would be 
expected (HC 7.2% increasing to 35% by 48 hours, BS 12% increasing to 29%). Percentages of 
lymphoctyes and other leukocytes were low in all groups with no clear differences observed 
between any of the groups. 
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Figure 3-10. The percentage of neutrophils present in cantharidin skin blisters.  
A higher % of neutrophils were present in the 24 hour sample versus the 48 hour sample in both 
groups (Mann Whitney P=0.0003 HC; P=0.0016 BS). The Kruskal-Wallis non parametric two 
tailed analysis of variance confirmed significant variance between the time points but not 
between the HC and BS groups (P<0.0001). 
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Figure 3-11. The percentage of macrophages present in cantharidin skin blisters.  
A higher % of macrophages were present in the 48 hour sample versus the 24 hour sample in 
both groups (Mann Whitney P=0.0003 HC; P=0.0039 BS). The Kruskal-Wallis non parametric 
two tailed analysis of variance confirmed significant variance between the time points but not 
between the groups ( <0.0001). 
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Figure 3-12. The percentage of lymphocytes; eosinophils and ‘other’ cells present in 
cantharidin skin blisters.  
The Kruskal-Wallis non parametric two tailed analysis of variance found no significant variance 
within any group. 
3.4.7 Flow cytometry 
Flow cytometry is a cellular analysis technology in which a beam of light is directed onto a 
focused stream of fluid passing through the flow cytometer. The scatter of light is analysed to 
reveal characteristics of the cells passing through that stream of buffer. Cells labelled with a 
fluorescent antibody will cause a distinct pattern of light scattering at a specific wavelength 
which can then be detected by the flow cytometer. As outlined in Chapter 2, fluorescence minus 
one (FMO) was the technique applied throughout the following experiments.  
3.4.7.1 Establishment of a flow cytometry protocol 
The final protocol used for multichannel flow cytometry analysis of blister fluid and PBMCs 
from peripheral blood was as follows. Row 1: antibodies for examining monocyte/macrophage 
population. Anti-CD14 antibodies were used to identify the monocyte/macrophage population. 
Use of anti-CD16 (FcγRIII) was intended to separate CD14+ monocytes into 
CD14highCD16low and CD14lowCD16high. CD14+CD163+ cells and CD14+HLA-DR+ 
expression were measured as markers of deactivated or activated populations. (ii) Row 2: 
antibodies for examining T cell subsets. CD3 was used as the marker for all T cells, as it is 
present on cells expressing either αβ or γδ T cell receptors. γδ T cells was measured directly in 
the FL2 channel, whilst the proportion of CD3+ αβ T cells was deduced by subtracting the 
number of CD3+ γδ T cells from the total CD3+ population. (iii) Row 3: antibodies for 
examining NK cells. NK cells express CD56 (a homophilic adhesion molecule of the 
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immunoglobulin superfamily (NCAM)) and CD16. The absence of CD3 but the presence of 
CD56 and CD16 were deemed the most reliable markers for pure NK cells in humans. Two 
functional subsets of NK cells exist: the more mature CD56dim CD16high population is 
potently cytotoxic, whereas the CD56bright CD16low/neg NK cells have low cytotoxicity but 
produce much greater amounts of cytokines. The figure below shows an example of ‘row one’ 
gating of PBMCs.  
 
Figure 3-13. A sample of gating of flow cytometry sample prepared from peripheral blood 
derived mononuclear cells.  
Cells were gated to include monocyte populations. They were then gated for include only 
CD16+ populations. Lastly cells were assessed for CD163 or HLA DR.  
3.4.7.2 Macrophage phenotype: CD163 and HLA DR expression 
The primary research question was to assess whether in HCs there may be an increase in 
CD163high CD14+ cells at 48 hours compared to 24, and whether this increase in 
CD163high CD14+ cells was reduced in BS. Using flow cytometry, we gated cells by 
forward and side scatter and by CD14 positivity to isolate the monocyte/macrophage 
population. These cells were also co-stained with both CD163 and HLA DR antibodies 
and relative fluorescent intensities (RFIs) were calculated. In HCs, CD 163 tended to be 
low in peripheral blood and early blisters, and rose in late blisters. We found that 
CD163 was quite variably expressed in BS subjects. This may have been related to the 
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fact that 50% of our BS subjects taking steroids (a known inducer of CD163 expression 
[248]). We could draw no significant conclusions about differences in expression 
between the two groups. HLA DR expression was low in peripheral blood and increased 
significantly in early blisters in both groups. The late blister showed a continued HLA 
DR expression in both groups. Interestingly, the majority of HC samples were 
stabilising or starting to reduce HLA DR expression at 48 hours – the time point of 48 
hours may have been too early to show advanced resolving inflammation. In contrast, in 
the BS groups, expression in a few individuals continued to increase at 48 hours.  
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Figure 3-14. CD163 expression by flow cytometry of peripheral blood derived monocytes 
(PB), 24 hour blister cells and 48 hour blister cells.  
CD163 is used as a marker of deactivated macrophages. There is a trend in HC for low CD163 
expression in PB monocytes, low expression in 24 hour blisters and higher expression in late 
blisters.  In BS samples there is relatively high CD163 expression in PB, possibly secondary to 
steroid medication. There appears to be less CD163 expression in the BS 48 hour samples 
versus HC. Kruskal-Wallis non parametric two tailed analysis of variance shows no variance 
between groups.  
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Figure 3-15. HLA DR Expression by flow cytometry of peripheral blood derived 
monocytes (PB), 24 hour blister cells and 48 hour blister cells.  
HLA DR is used as a marker of activated macrophages. There is significantly lower HLA DR 
expression in PB monocytes relative to blister samples (Kruskal-Wallis non parametric two 
tailed analysis of variance P<0.001). However no significant differences were observed between 
the blister groups.  
 
3.4.7.3 T cells subsets and NK cells 
In addition to examining macrophage phenotypes we wished to gain a broader picture of 
cells present in early and late blisters. Using multichannel flow cytometry we examined 
T cell subsets and compared these over time between our two groups. Cells were also 
gated by forward and side scatter and CD3 positivity. We found that CD3+CD4+ T cells 
formed approximately 75% of the lymphocyte population in all groups. A higher 
proportion of CD3 T cells were CD4+ in the blister fluid relative to peripheral blood 
samples, indicating CD4+ cells were recruited preferentially. Cells were gated by 
CD56+ and CD3 negativity or positivity to isolate natural killer cells and NK T cells. 
As low levels of these cell types (<1%) were found in all groups, numbers were 
insufficient for further analysis. 
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Figure 3-16. The percentage of CD3+ cells that co-stained for CD4 or CD8.  
No significant differences were observed between the groups. The overall number of CD3+ 
cells was low in blister fluid. 
3.4.8 Blister fluid cytokine and chemokine concentrations 
Blister fluid that had been stored at -80oC  was analysed by multiplex bead analysis on the flow 
cytometer to quantify candidate cytokine and chemokine concentrations in all blisters.  
Cytokines were chosen to assess Th1/Th2/Th9/Th17/Th22 skew by measuring human IFN-γ, 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p70, IL-13, IL-17A, IL-22 and TNF-α in an 
immunoassay analysed on a flow cytometer. 
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Th-1 cytokines include IL-2, IFN-gamma, IL-12 and TNF-beta, while Th-2 cytokines include 
IL-4, IL-5, IL-6, IL-10 and IL-13. Th-17 cytokines include IL-22; IL-6 and IL-17A. Th-9 
cytokines include IL-9 and acute phase cytokines include IL-1β and TNF-α.  
Results of the cytokine analysis are shown below. Disappointingly, results revealed low 
concentrations of many candidate proteins. Before correction for multiple analysis, CXCL10 
levels were significantly different between the two groups, with 24 hour BS blisters having 
significantly lower CXCL10 concentrations than HCs (p=0.014). This was no longer a 
significant difference with multiple analysis corrections (Dunn’s test for multiple analysis). 
Trends of differences were seen in other groups, with trends towards lower IL-10; IL-1β; IL-4; 
IL-13 and IL-17A but none of these results reached statistical significance.  Given that 
concentrations of most cytokines were quite low, and that corrections for multiple analysis was 
undertaken, our study was not powered to find small differences between groups. 
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Figure 3-17. The Th1 skew associated cytokines present in blister fluid at 24 and 48 hours.  
IFN-γ, IL-2 and CXCL10 are associated with a Th1 skew. Very little IFN-γ protein was 
observed in any sample. There was a non-significant trend towards less IL-2 in BS samples. 
There was less CXCL10 protein in 24 hour BS blister samples than in HC samples (Mann-
Whitney test P=0.015), however significance was lost following correction for multiple analysis 
(Dunn’s test for non-parametric analysis).  
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Figure 3-18 The Th2 skew associated cytokines present in blister fluid at 24 and 48 hours. 
 IL-4, IL-5, IL-6, IL-10 and IL-13 are associated with a Th2 skew. Very little protein was 
observed most samples apart from IL-6. There was a non-significant trend towards less IL-4 and 
IL-10 in BS samples. There was also a trend towards more IL-6 in 24 hour BS blister samples 
than in HC samples however no observations were statistically significant.  
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Figure 3-19 The Th17/9 skew associated cytokines in blister fluid at 24 and 48 hours.  
IL-17A, IL-22 and IL-6 are associated with a Th17 skew. IL-9 is associated with a Th9 skew. 
Again, very little of these cytokines was observed in most samples apart from IL-6.  
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Figure 3-20. The acute phase response associated proteins present in the blister fluid at 24 
and 48 hours.  
TNF-α and IL-Iβ are secreted during an acute phase response. There was a non-significant trend 
towards less TNF-α and IL-Iβ protein in BS blister samples. 
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3.5 Discussion 
3.5.1 Skin blister models of inflammation  
Generating suction blisters over inflammatory-responses using the MSU blister model did not 
turn out to be a useful approach for obtaining inflammatory tissue from BS subjects. There was 
a large variation in the quantity of cells and fluid obtained, the procedure was lengthy and the 
incidence of blisters bursting was too high. However, this technique may still have a use for 
protocols requiring fewer cells and offers the benefit of directly sampling cells and fluid from 
the site of the MSU reaction without the need for a biopsy.   
The cantharidin skin blister method was found a useful and robust model of skin inflammation, 
giving reliable volumes of fluid and adequate cell numbers for all analysis. We found it very 
reassuring that a large MSU reaction correlated strongly with the presence of a halo around the 
blister. This implies that the cantharidin model is a valid method of studying the abnormal 
inflammatory response in BS. 
3.5.2 Macrophage activation states  
We found trends but no significant differences between BS and HC with regard to our primary 
aim, assessing markers of macrophage activation/deactivation. In both HC and BS, subjects had 
low percentages of macrophages in early blisters (where neutrophils predominate) which 
increased in late blisters, and there was a non-significant trend towards BS having less 
deactivation in later blisters. However this finding was not statistically significant.  Most 
subjects had low HLA DR in peripheral blood which increased in the early blister and started to 
settle in the late blister. It is possible that with higher numbers of participants, and by excluding 
BS taking corticosteroids we may have found greater differences. 
3.5.3 Other cells and cytokines in early and late blisters  
Both HC and BS had high percentages of neutrophils in early blisters and fewer in late blisters. 
Low levels of lymphocytes and natural killer cells were observed in both groups at all time 
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points which made it difficult to look for differences between the groups with our numbers. We 
were surprised that we found no differences in any cell type or cytokine level between the two 
groups apart from CXCL10 levels which were significantly different but lost that significance 
with multiple testing adjustments. CXCL10 is released by multiple cells (including 
macrophages, endothelial cells and dendritic cells) in response to IFN-γ and this finding is 
explored in detail in Chapter 5. We found no differences in IFN-γ levels between the two 
groups, but cytokine levels in general were very low, making it difficult to find significant 
differences between our groups. 
3.6 Concluding remarks 
The erythema surrounding blisters in BS subjects was a very interesting finding. This correlated 
with the size of erythematous responses to MSU crystals, but was not associated with any 
obvious differences in immune cells or cytokines. CXCL10 was highlighted as a chemokine of 
interest and this chemokine is investigated in detail in Chapter 5. We also reflected on what 
other mechanisms could be resulting in this erythematous response. Neuropeptides came to 
mind for several reasons, as discussed in Chapter 4, as agents that could be playing a role in this 
setting. Chapter 4 investigates a potential role for neuropeptides in BS.  
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4. Investigation of the role of neuropeptides in BS 
4.1 Introduction 
In Chapter 3, we found that BS subjects had a significantly larger reaction to MSU crystals than 
HC at both 24 and 48 hour time points. Subjects with a large MSU reaction also developed a 
ring of erythema around capsaicin blisters. We did not find obvious differences between the two 
groups in cell blister volume, cells or cytokines which led us to consider alternative causes of 
this erythema. In this chapter we explored the possibility that neuropeptides may contribute to 
the abnormal cutaneous inflammatory response seen in subjects with BS. 
4.1.1 The neuro-immune system 
4.1.1.1 Interplay between the nervous system and inflammation 
The intensity and duration of an inﬂammatory process depends on the local balance between 
pro- and anti-inﬂammatory mediators. Peptides of neuronal origin exert speciﬁc effects on 
immune cells and have been shown to regulate inﬂammation. It is logical that the neurological 
system would play a role in controlling the immune system when we consider that it coordinates 
other major physiological responses from heart rate and blood pressure to blood glucose levels. 
Two of the best characterised neuro-immune systems are: (i) the hypothalamic-pituitary-adrenal 
(HPA) axis:  acute physical or psychological stress activates the HPA axis resulting in increased 
plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations. Cortisol is a potent 
anti-inflammatory agent [253, 254]. Interleukin-6 also enhances the HPA axis response to 
inflammation and other stressors [255];  (ii) the cholinergic anti-inflammatory pathway: this is 
an extremely fast, reflex-like anti-inflammatory pathway controlled by brain networks, e.g. 
through the vagus nerve system, designed to control cytokine release and functions [166, 167, 
169, 256, 257].  
The vagus nerve innervates principal organs, including those that contain the reticuloendothelial 
system (liver, lung, spleen, kidneys and gut). Experimental activation of the cholinergic anti-
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inflammatory pathway by direct electrical stimulation of the efferent vagus nerve inhibits the 
synthesis of TNF in liver, spleen and heart, and attenuates serum concentrations of TNF during 
endotoxaemia [258, 259]. Animals subjected to hypophysectomy or adrenalectomy are 
significantly sensitized to the lethal effects of endotoxin [260]. Stimulation of either the right or 
the left cervical vagus nerves protects against the development of hypotension and inhibits 
serum TNF responses to ischaemia reperfusion [259]. In a standardized model of experimental 
murine arthritis induced by the application of carrageenan, vagus nerve stimulation inhibited the 
inflammatory response and suppressed the development of paw swelling, indicating that the 
cholinergic anti-inflammatory pathway can inhibit localized inflammation specifically [164]. 
The molecular dovetail between the cholinergic nervous system and the innate immune system 
is a nicotinic, a-bungarotoxin- sensitive macrophage acetylcholine receptor [258]. Exposure of 
human macrophages, but not peripheral blood monocytes, to nicotine or acetylcholine inhibits 
the release of TNF, IL-1 and IL-18 in response to endotoxin but not anti-inflammatory 
cytokines (such as IL-10) [258]. Acetylcholine inhibits the expression of TNF protein in 
macrophages, but not the induction of TNF messenger RNA levels, indicating that activation of 
the cholinergic receptor transduces intracellular signals that inhibit cytokine synthesis at a post-
transcriptional stage [258].  
4.1.2 Neuropeptides 
Neuropeptides are neuronal signalling peptides, released from nerve endings to perform a 
similar communication/messenger role for nervous tissue that hormones undertake for glandular 
tissue, although usually in a more localized capacity.  
The association between stressful life events and various dermatological diseases is explained 
by the concept of neuro-immuno-cutaneous system involving neuropeptides. It has been shown 
that neuropeptides especially calcitonin gene-related peptide (CGRP), substance P (SP), and 
neurotrophins such as nerve growth factor (NGF) affect the pathogenesis of skin disorders such 
as atopic dermatitis and psoriasis vulgaris [178, 261, 262] .  
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4.1.2.1 Calcitonin-gene-related-peptide (CGRP) 
CGRP is one of the most abundant peptides produced in both peripheral and central neurons 
with receptors found throughout the body including throughout the cardiovascular systems and 
in organs of the immune system [263, 264]. CGRP is a 37-amino acid neuropeptide generated 
by tissue-speciﬁc alternative processing of the calcitonin gene [265, 266]. It is generally co-
expressed with either somatostatin or substance P in sensory neurons [267]. CGRP exists in two 
forms, α-CGRP and β-CGRP. The less-studied β-CGRP differs in three amino acids (in 
humans) and is encoded in a separate gene in the same vicinity (on chromosome 11). CGRP 
mediates its effects though 2 receptors: a heteromeric receptor composed of a G protein-coupled 
receptor called calcitonin receptor-like receptor (CALCRL) and a receptor activity-modifying 
protein (RAMP1). Although part of the calcitonin family, GCRP’s effect on bone is unclear. It 
is known to inhibit osteoclasts in vitro [268].  
CGRP is perhaps best known for its cardiovascular effects. It is the most potent vasodilator of 
the neuropeptides, both of arterial and venous vessels [269, 270]. Additionally, the 
microvasculature is very sensitive to the effects of CGRP, with a potency 10 times greater than 
the prostaglandins [270, 271].  
The interaction of CGRP with the immune system is complex. There is evidence that many 
neuropeptides such as the neurotrophins (e.g. nerve growth factor) and tachykinins (e.g. 
Substance P) play a pro-inflammatory role and CGRP is co-secreted with these peptides. CGRP 
increases vascular permeability leading to increased access of immune cells to sites of 
inflammation. CGRP has also been shown to induce production of IL-8, a well-known 
chemotactic factor for neutrophils [272]. However there is growing evidence for an anti-
inflammatory role for this peptide.  
Speciﬁc receptors for CGRP are present in T and B lymphocytes and in macrophages [273, 
274].  GCRP been shown to promote macrophage IL-10 production, suppress Langerhans cells 
antigen-presenting function, T lymphocyte proliferation and production of IL-2, IL-12 and IFN-
γ [186, 262]. CGRP is also an inhibitor of antigen presentation by macrophages [275]. CGRP 
inhibits LPS induced production of chemokines CXCL8, CXCL1 and CCL2 by human dermal 
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microvascular endothelial cells [276]. It also prevents LPS induced IL-1β, IL-6 and TNF-α 
protein production,   IkBα degradation and NF-κB activation [276-279]. Additionally, systemic 
treatment of mice with CGRP has been found to reduce blood neutrophilia induced by systemic 
administration of LPS and also protected against a lethal dose of LPS [280]. After intradermal 
administration, CGRP inhibited the induction of contact hypersensitivity at the injected site in 
mice [281]. APCs and human monocytes are able to synthesize CGRP, and  CGRP expression is 
enhanced after LPS stimulation. Endogenous CGRP synthesis in monocytes is regulated by 
NGF. Monocytes produce their own NGF and its synthesis is up-regulated on activation and the 
neutralization of endogenous NGF using anti-NGF antibodies markedly reduces the synthesis of 
CGRP induced by LPS [278]. 
4.1.2.2 Tachykinins 
Tachykinins are a group of neuropeptides that include SP. In addition to exciting neurons, in the 
vascular system they increase vascular permeability and are potent vasodilators [282], they 
promote angiogenesis and cell growth [283] and in some situations promote healing [181].  In 
normal human dermal microvascular endothelial cells SP has been shown to induce production 
of IL-8 [272]. SP stimulates hydrogen peroxide production by neutrophils and also stimulates 
pro-inﬂammatory cytokines such as TNF-α, IL-1 and -6, histamine, leukotriene B4 and 
prostaglandin D2, and immunomodulatory cytokines such as IL-2. It induces adhesion 
molecules such as intercellular adhesion molecule (ICAM)-1, vascular cellular adhesion 
molecule (VCAM)-1 and endothelial leucocyte adhesion molecule-1 dermal microvascular 
endothelium, and causes neutrophilic and eosinophilic inﬁltration in cutaneous tissue [272].  
Interestingly SP has been shown to correlate with pro-inflammatory cytokine concentrations in 
synovial fluid in RA subjects, but although CGRP is also present in synovial fluid, there is no 
correlation to cytokine concentrations [284, 285].  
4.1.2.3 BS and neuropeptides 
There is ample clinical evidence suggesting that emotional stress can influence the course and 
disease activity of BS [176, 177], implicating a neuro-immune interaction, similar to that 
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observed in dermatological diseases described above. As neuropeptides such as CGRP and SP 
are potent vasodilators, they could potentially be involved in the erythema observed with during 
the pathergy response, MSU response, or the erythema surrounding the cantharidin skin blisters.  
Recent genome wide association studies in BS identified a SNP with near genome-wide 
significance (rs936551) located at the telomeric end of the short arm of chromosome 4 within 
the promoter region of CPLX1, which encodes the peptide complexin 1 [6]. Complexins play a 
critical role in the control of fast synchronous neurotransmitter release. They operate by binding 
to trimeric SNARE complexes consisting of the vesicle protein synaptobrevin and the plasma 
membrane proteins syntaxin and SNAP-25, which are key executors of membrane fusion 
reactions [183]. SNARE complex binding by complexins is thought to stabilize and clamp the 
SNARE complex in a highly fusogenic state, thereby providing a pool of readily releasable 
synaptic vesicles that can be released quickly and synchronously in response to an action 
potential and the concomitant increase in intra-synaptic calcium levels [184]. It is possible that a 
under or over functioning Complexin-1 in BS may alter the dynamics or quantity of 
neuropeptides with downstream effects on inflammation. 
Complexin I and II knockout mice (KO) have been investigated, primarily with regard to 
neurological function. Complexin I KO mice have seizures from birth, are unable to reproduce 
and are lethal by 2-4 months [286]. Modified KOs display marked deficits in social behaviours, 
ataxia and coordination deficits [287] , and have profound motor and cognitive deficits [286]. 
Nothing is documented in these papers about inflammatory or vascular abnormalities.  
Complexin involvement has been implicated in Alzheimer’s Disease [288], Schizophrenia [289] 
and Hungtington’s Chorea [290].  
Intriguingly, recently a human whole-genome microarray of over 50 thousand genes was used 
to analyse mRNA expression proﬁles of peripheral blood mononuclear cells obtained from four 
BS at baseline and at 22 weeks after initiation of inﬂiximab. Quantitative polymerase chain 
reaction analysis was performed for selected up- or down regulated genes, to conﬁrm the 
microarray results. TNF blockade  resulted in not only reduced expression of many cytokines 
but also reduced expression of complexin II (CPLX2) in all BS subjects [291].  
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In one study of BS volunteers and healthy and psoriasis controls, skin lesion punch biopsies 
revealed strong immunoreactivity for SP in the epidermis, panniculitis lesion and vasculitis 
lesion of BS subjects versus HC. The concentration of SP trended towards more in BS (active 
BS 39.28 pg/ml, inactive BS 33.40 pg/ml) than in normal controls (26.21 pg/ml) but findings 
were not significantly different. The concentration of CGRP in active BS (23.12 pg/ml) and 
inactive BS (19.94 pg/ml) subjects was significantly lower than that of HCs  (67.09  pg/ml) 
[185]. 
A second study of BS and HC showed different findings. They found serum levels of CGRP to 
be higher in BS than HC, and higher in active versus inactive BS. Serum SP values and IL-8 
were also higher in active BS versus inactive and disease controls [292]. Both of these studies 
were small (15 and 30 BS subjects respectively) making it difficult to draw a conclusion. 
4.1.3 Methods of studying neuropeptides 
Several mechanisms exist to study neuropeptides, the most common being to biopsy and study 
samples by immunohistochemistry. Given the poor wound healing experienced by BS subjects, 
a non-invasive mechanism is preferable. 
4.1.3.1 Thermal threshold testing 
Quantitative sensory testing (QST) describes quantitative neurological assessments. 
Proprioception, light touch and vibration sense are conveyed in large, fast –conducting fibres in 
the dorsal columns to the thalamus whereas pain, temperature and pinprick sensation are carried 
by small, slow conducting fibres in the spinothalamic tract (C and Aδ fibres). For the purpose of 
our investigations we were interested in small pain fibres as stimulation of these are understood 
to result in reflex axonal vasodilatation in response to pain. Thermal threshold testing using 
contact heat is a mechanism to assess small fibres without relying upon punch biopsy and has 
been shown to correlate with TRPV1 staining in skin biopsies [293, 294] 
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4.1.3.2 Indirect CGRP measurement using topical capsaicin  
Capsaicin is the naturally occurring pungent compound in hot chilli peppers. It is a highly 
selective and potent exogenous agonist for the TRPV1receptor (transient receptor potential 
cation channel subfamily V member 1, also known as the capsaicin receptor and the vanilloid 
receptor 1) and topical application of capsaicin results in local vasodilation [295-300].  The 
TPRV1 receptor is a non-selective transmembrane cation channel found on small nerve fibre 
terminals [201] . It is activated by a wide variety of exogenous and endogenous physical and 
chemical stimuli.  The best-known activators of TRPV1 are heat greater than 43°C, capsaicin, 
allyl isothiocyanate (the pungent compound in mustard and wasabi).  Activation causes 
neurogenic inflammation and vasodilation the local CGRP release and also by the activation of 
dorsal root reflexes [201].  Capsaicin induced vasodilation can be blocked by CGRP antagonists 
[301]. Upon TRVP1 activation, depolarization results in action potentials, which propagate into 
the spinal cord and brain, and may be experienced as warming, burning, stinging or itching. A 
normal neurotransmitter is broken down or reabsorbed pre-synaptically very quickly. However, 
capsaicin is chemically stable and can generate a biochemical signal with a persistent effect.  
Capsaicin induced increase in dermal blood flow (DBF) assessed by laser Doppler imaging is a 
novel phamacodynamic assay to measure CGPR activity non-invasively. Changes in blood flow 
can be measured by laser imaging following the topical application of capsaicin solution [297, 
301, 302]. 
4.2 Hypothesis and aims 
4.2.1 Rationale for investigating capsaicin induced blood flow in 
BS 
We studied CGRP release indirectly by applying capsaicin topically to the forearm of volunteers 
and measuring the resultant change in blood flow. The primary aim was investigate if 
neuropeptides played an obvious role in the exaggerated cutaneous erythematous response in 
BS. 
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In addition to investigating if neuropeptides play a prominent role in pathergy, capsaicin testing 
offers a non-invasive, well tolerated, rapid assessment tool.  No return visits are required and 
the whole test can be undertaken in under 2 hours. Therefore, the secondary aim of this chapter 
was to evaluate the potential usefulness of capsaicin induced DBF as a diagnostic test. 
4.3 Results 
4.3.1 Pilot study of 5 BS and 5 HC to evaluate the usefulness of 
thermal threshold testing 
Initially 5 BS and 5 HC subjects underwent thermal threshold testing to assess if this may be a 
useful test to study. Following written consent, a full history and examination (including a full 
neurological examination) was undertaken in all participants. No neurological deficits were 
discovered in either group. All participants then underwent thermal threshold testing. A 
thermode was secured to the volar aspect of their arm and subjects were asked to press a on a 
mouse keypad when the thermode felt hot; painfully hot; cold and painfully cold. Subjects 
tended to describe the thermode as hot by 34oC, and as painfully hot by 41oC. Subjects 
experienced the thermode as cold from 28 oC. The groups differed as to their perception of cold 
as painful, with BS finding the thermode painful from 23 oC versus HC who experienced cold 
pain at 14 oC. Given the lack of overall differences, and some logistical difficulties accessing 
this equipment out of hours, thermode temperature testing was not undertaken as part of the 
main experiment. 
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Figure 4-1. The results of thermal threshold testing in 5 BS and 5 HCs.  
Results are expressed as mean with standard deviation. Participants were asked to state when 
they perceived the thermode to be hot, painfully hot (Hot P), cold, painfully cold (Cold P). 
Results were similar between the two groups.  
4.3.2 Establishing a protocol for laser blood flow measurement 
All preliminary capsaicin dose finding experiments were undertaken on the Perimed laser 
doppler machine. The aim was to evaluate if 300µg or 1000µg of capsaicin was a more effective 
and reliable dose to administer. The lower dose was administered to the non-dominant arm and 
1000µg to the dominant arm in 4 BS and HC. Images were taken at 10 minute intervals over the 
next 2 hours to form a picture of the dynamics of the reaction. The total flux and the area under 
the curve were the values calculated. Several subjects produced no response or a minimal 
response with 300µg dose. In contrast the 1000µg dose was found to be a more reliable dose 
and was chosen for future experiments. 
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Figure 4-2. The preliminary dose finding experiment showing doppler flux values in HC 
and BS subjects following the application of either 300µg (top row) or 1000µg (bottom 
row) of capsaicin.  
The higher dose elicited more robust results and was selected for future experiments. 
4.3.3 Perimed Laser Doppler Imager versus Moor Laser Speckle 
Photometry Imager  
During preliminary experiments we noted that the threshold of the Perimed laser doppler had to 
be set at very high setting to exclude background noise (6.4 out of 10) and therefore although 
output values were accurate, images were of low quality. We had the opportunity to use a Moor 
Laser Speckle Photometry scanner (Moor Imager) on loan from Moor Instruments Ltd. which 
produced images of high quality, and therefore the main experiment was undertaken using the 
newer machine. 
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Figure 4-3. A typical image obtained by the Perimed Imager.  
Following application of capsaicin increased blood flow can be seen in the area surrounding the 
rubber O ring over time. The images were deemed of low quality relative to the Moor imager 
(below). 
 
Figure 4-4. A typical image obtained by the Moor Imager.  
This newer machine produced images of impressive quality. This image also highlights 
examples of gating regions of interest (ROIs).  
4.3.4 Establishing a final protocol for the use of capsaicin 
13 HC and BS subjects were recruited for this study. All were asked to abstain from alcohol, 
caffeine and all non-essential medications prior to testing, especially pain killers and 
antihistamines.  
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Following written consent, baseline scanning was performed. Then 20µL of the liquid 
containing 1000µg capsaicin was applied 22cm proximal to the wrist crease on the volar aspect 
of the dominant forearm. The imager recorded at 10 second intervals. Subjects were recorded 
for three 20minute periods with 15 minute breaks in-between. This allowed us to measure the 
initial speed of onset of the flare, the peak of the flare and assess the degree of resolution of the 
response by 90 minutes.  
Output measures were (i) the mean point flux within areas of interest (ROI1 and ROI2), and (ii) 
the pixel count within in the entire image after subtracting pixels with values below a cut-off of 
flux intensity (threshold set at 200 or 500 flux units (PU)). ROI1 was a circular area, which was 
twice the size of the rubber O ring. ROI2 was a circular area 3 times the size of the rubber O 
ring. These AOIs were chosen as the O ring was a fixed value on all images making comparison 
between subjects straight forward. 
4.3.5 Interpretation of results 
Flux (PU) represents blood flow values. The scale is arbitrary because it is impossible to be 
precise about the sample volume. The scale is 0 to 2000 on the Perimed laser doppler and 0-
1000 on the Moor imager.  The scale is linear – so 500PU represents twice the flow of 250PU. 
Data may be presented as total flux or as a % change. A typical image is seen below (Figure 4-
5). We expressed results as the % increase from baseline values. We chose a small ROI (ROI1) 
to evaluate the intensity of the response and a larger ROI (ROI2) to form an impression about 
the lateral spread of the response. 
An alternative method to assess the flare response is to calculate the number of pixels above the 
baseline pixel threshold number (Figure 4-6). By selecting a low threshold (e.g. 200 PU) one 
gets an idea of the lateral spread of the flare response, and by selecting a high threshold (e.g. 
500 PU) one gets an impression of the intensity of the flare response.   
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Figure 4-5. A sample of Moor images following the application of capsaicin into the rubber 
O ring.  
Images are obtained over 90 minutes. The mean flux (PU) within regions of interest are 
calculated for each time point to assess changes in local blood flow over time. This image 
shows the flux values. 
 
Figure 4-6. A sample of Moor images following the application of capsaicin into the rubber 
O ring.  
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Images are obtained over 90 minutes. An arbitrary threshold is set of 500 flux units in these 
images, meaning that areas of low flux are excluded, allowing areas of high flux (and high 
blood flow) to be quantified. The pixels remaining in the image are counted. 
4.3.6 Study cohort 
We recruited 13 HC and 13 BS subjects. Demographics of the recruits are shown below. Six of 
the HC were male (46%) versus 7 of the BS subjects (55%). The median age in the HC group 
was 33 years (interquartile range 27-44) versus 46 years (interquartile range 33-51) in the BS 
group. Nine of the BS group were taking steroids (prednisolone). Of those 9, the median dose 
was 5mg.  BS subjects were also taking a variety of other disease modifying medications. The 
median disease activity using the Leeds questionnaire was 3 (scale of 0-12) indicating mild/low 
disease activity. In the HC group, all subjects were in good health and taking no regular 
medications. 
 General Demographics Healthy Controls Behçet Syndrome 
Cohort size     13   13   
Median age (Interquartile range) 33  (27-44) 46  (33-51) 
Male sex (%) 6 46% 7 54% 
Clinical Characteristics  
Mucocutaneous      0   13 100% 
  Erythema nodosum       8 61% 
  Pathergy/poor wound healing     11 85% 
Musculoskeletal – arthralgias 0   10 77% 
  Arthritis 
 
      5 38% 
Cardiovascular 0   5 38% 
  Aneurysm         1 7% 
  Thrombosis       4 31% 
Ocular 0   5 38% 
  Posterior/panuveitis   0   3 23% 
Gastrointestinal inflammation   0   2 15% 
Neurological      0   4 31% 
Disease Activity Score *   0   3   
Current medications           
Colchicine     0   1 7% 
Azathioprine     0   6 46% 
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Table 4-1. Demographics of BS and HC subjects recruited for capsaicin skin blood flow 
testing. 
 
4.3.7 Change in blood flow within ‘Region of interest 1’ (ROI1) 
In each data set, a region of interest was defined as a circle twice the size of the rubber O ring 
(ROI1). The mean flux within this region was recorded at baseline and over time (0-90 
minutes). Results were expressed as the % increase from baseline flux. Over a 90 minute period 
results increased then returned to near baseline, allowing an area under the curve (AUC) to be 
calculated.  The ROI1 is a small area, and the results reflect the intensity of the flare response 
over time.  
Figure 4-7 shows the mean results of % increase in flux over time (90minutes) for all HC and 
BS subjects. The two graphs show a significant variance (F 2.09, DFn 137, and P < 0.0001). 
Interestingly it was the HC cohort that showed the greater increase in blood flow. We then 
calculated the area under the curve for each individual (Figure 4-8) but this failed to show a 
significant difference between the two cohorts. The trend remained for BS to show a smaller 
increase in blood flow versus HCs. 
Mycophenolate     0   3 23% 
Anti-TNF therapy     0   4 31% 
Cyclosporine     0   0   
Methotrexate     0   2 15% 
Steroids **     0   9 (5mg) 
* Leeds Behçet’s disease activity form (2002 version) score of 0-12 (>4 indicates active disease). 
** Number of  subjects taking steroids, and the median prednisolone dose taken by those subjects 
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Figure 4-7. The mean values of HC and BS for % increase in flux over time within ROI1.  
The HC cohort show a significantly greater % increase versus BS (P<0.0001). 
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Figure 4-8. The percentage increase in mean flux from baseline within ROI1 was 
calculated for each subject at each time point allowing an area under the curve (AUC) 
value to be calculated.  
There was a trend towards a lower change in AOC in BS, indicating   less increase in blood 
flow following capsaicin administration. This finding was not statistically significant (Mann-
Whitney P=0.12). 
4.3.8 Change in blood flow within ‘Region of interest 2’ (ROI2) 
In each data set, a region of interest was next defined as a circle three times the size of the 
rubber O ring (ROI2). The mean flux within this region was recorded at baseline and over time 
(0-90 minutes). Results were expressed as the % increase from baseline flux. Over a 90 minute 
period results increased then returned to near baseline, allowing an area under the curve (AUC) 
to be calculated. The ROI2 is larger than ROI1 and therefore results give an impression of the 
lateral spread of the flare response. 
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Figure 4-9 shows the mean results of % increase in flux over time (90minutes) for all HC and 
BS subjects.  The two graphs show no statistically significant differences. Interestingly again it 
was the HC cohort trended towards showing a greater increase in blood flow. We then 
calculated the area under the curve for each individual (Figure 4-10) but this also failed to show 
a significant difference between the two cohorts. The trend remained for BS to how a smaller 
increase in blood flow versus HCs. 
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Figure 4-9. The mean values of HC and BS for % increase in flux over time within ROI2.  
The two groups show no significant variance although the trend remains for a smaller increase 
in blood flow in the BS cohort. 
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Figure 4-10. The percentage increase in mean flux from baseline within ROI2 was 
calculated for each subject at each time point allowing an area under the curve (AUC) 
value to be calculated.  
There was a trend towards a lower change in AOC in BS, indicating  less increase in blood flow 
following capsaicin administration in BS. This finding was not statistically significant (Mann-
Whitney P=0.34). 
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4.3.9 Flare response assessment using total pixel counts 
An arbitrary threshold may be set which eliminates pixels below a specified flux intensity 
(example shown in Figure 4.6). This allows areas of low flux to be excluded, and areas of high 
flux (and hence high blood flow) to be quantified. The pixels remaining in the image are 
counted. We arbitrarily choose two cut off thresholds of 200 and 500 flux. A threshold of 
200PU does not exclude most areas with high blood flow and therefore allows for an estimation 
of the lateral spread of the flare response. A 500PU threshold excludes all but the most intense 
pixels, and therefore allows for an estimation of the intensity of the blood flow.  
Time
T
o
ta
l 
P
ix
e
ls
 (
2
0
0
 f
lu
x
 t
h
re
s
h
o
ld
)
0
20000
40000
60000
BS
HC
 
Figure 4-11. The mean total pixel counts over time in HC and BS cohorts.  
The BS cohort appear to flare early but the HC reach a greater peak. There was no statistically 
significant variance between the two curves. 
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Figure 4-12. The total pixel counts over time were plotted and an area under the curve 
(AUC) was calculated for each subject.  
There was a trend towards fewer total pixels in the BS cohort following capsaicin 
administration. This finding was not statistically significant (Mann-Whitney P=0.58). 
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Figure 4-13. The mean total pixel counts over time in HC and BS cohorts.  
For this analysis a threshold of 500 flux units was set. The number of pixels above this 
threshold were counted. The HC and BS traces of total pixels over time overlap indicating no 
difference between the groups. As 500 flux units is a high threshold, this result reflects the 
intensity of the flare response. 
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Figure 4-14. The total pixel counts over time were plotted and an area under the curve 
(AUC) was calculated for each subject, using a threshold of 500 flux units.  
There was a trend towards fewer total pixels in the BS cohort following capsaicin 
administration. This finding was not statistically significant (Mann-Whitney P=0.40). 
4.4 Discussion 
In Chapter 3, we found that cantharidin blisters displayed an erythematous halo that was not 
easily explained by any obvious differences in immune cells or cytokines. This led us to 
investigate neuropeptides as a possible contributing agent.  
As BS flare ups may be triggered by stress, it seems plausible that neuro-immune interactions 
may be important in this syndrome. Furthermore, neuropeptides play a role in cutaneous 
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vasodilation and in inflammation. We found previous publications regarding neuropeptide 
levels in BS subjects showed conflicting results, with one paper finding high CGRP in serum 
and the other finding lower concentrations [185, 292]. We decided to study CGRP in this 
chapter as it may be readily investigated non-invasively through the topical application of 
capsaicin and measurement of the subsequent cutaneous vasodilation. We also hoped that the 
capsaicin test may offer a potential diagnostic test for BS. 
4.4.1 BS capsaicin flare responses appeared to be smaller than that 
of HC  
BS subjects who experience pathergy tend to describe an exaggerated response to any stimuli, 
from thorn pricks and nettle stings to surgical cuts and MSU injections. Therefore we were 
surprised when, contrary to our expectations, the BS cohort did not mount an exaggerated flare 
response to capsaicin. In fact the BS cohort displayed a smaller flare response than HCs. This 
experiment therefore did not find evidence of an exaggerated flare in BS subjects and did not 
find the capsaicin skin test to be of any diagnostic use. 
4.4.2 Study limitations 
Possible reasons for the smaller flare response found in the BS cohort are either study limitation 
factors (a false negative) or else that BS subjects do release less CGRP upon stimulation (a true 
positive). Study limitations include (i) the small sample size: however all trends went in the 
same direction of the BS cohort having a smaller flare response; (ii) the BS cohort chosen: 85% 
of the BS cohort reported experiencing symptoms suggestive of the pathergy phenomenon, and 
in this respect were representative for the syndrome; (iii) medications: All of the BS subjects 
were on immunosuppressive medications and 9 were taking prednisolone. However, the median 
dose of prednisolone was only 5mg, and subjects were receiving a wide variety of medications 
making an effect of a particular medication small.  All subjects in both groups were asked to 
abstain from painkillers, caffeine and alcohol prior to the study. These substances are known to 
interfere with neuropeptide release.  
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4.4.3 Reasons why it may be plausible that BS subjects secrete less 
CGRP than HCs 
The findings of this chapter may reflect a true representation of CGRP release in BS. CGRP 
differs from SP in that, in addition to vasodilation, there is evidence of it having anti-
inflammatory properties. As discussed in detail in the introduction to this chapter, CGRP leads 
to less antigen presentation, inflammatory cell recruitment and also directly stimulates IL-10 
release. A SNP in IL-10 which results in less IL-10 protein production in the disease-associated-
allele was discovered in the first two GWAS studies of BS [5, 6].  Less IL-10 may slow down 
the resolution phase of inflammation, and therefore it is possible that if BS subjects secrete less 
GCRP in response to insults such as MSU injections, then this may result in less activation of or 
slower activation of cutaneous anti-inflammatory pathways leading to a prolonged cutaneous 
inflammatory response, as seen following MSU injections. 
4.5 Future work 
Capsaicin is chemically stable and can generate a biochemical signal with a persistent effect. 
The TRPV1 channel is highly calcium permeable which allows significant amounts of calcium 
to flow down its steep electrochemical gradient into nerve fibres.  TRPV1 is also expressed on 
intracellular organelles and prolonged external capsaicin application (e.g. with a capsaicin skin 
patch) results in release of calcium from endoplasmic reticulum and induction of additional 
intracellular calcium release from internal stores via calcium dependent calcium release. 
Sustained high levels of intracellular calcium activate calcium dependent enzymes such as 
proteases and can induce depolymerisation of cytoskeletal components such as microtubules. 
Moreover, osmotic swelling due to the chloride accumulation that accompanies influxes of 
positively charged ions also occurs. An additional effect of high concentrations of capsaicin, is a 
direct inhibition of mitochondrial respiration. Numerous mitochondria are present in peripheral 
terminals of nociceptors and may congregate there in response to nerve growth factor. In this 
setting mitochondria will release pro-apoptotic factors such as cytochrome C. As all of this is 
happening in the nerve cell process rather than in the nucleus, this results in localized 
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degeneration and apoptosis in a nuclear free zone. All of this leads to impaired local nerve 
function for extended periods [297, 303]. Topical low strength capsaicin formulations have been 
widely used for neuropathic [304]and musculoskeletal [305] pain management since the 1980s. 
If CGRP was truly involved in the observed differences in the ID MSU response between HC 
and BS, then it would be expected that the MSU response would be equalized in both groups if 
it was repeated on a skin site that had recently been treated with a prolonged application of 
capsaicin. In this instance neuropeptide release would be abrogated in both groups and it may be 
possible that in this case HCs showed a result similar to their BS counterparts. It was beyond the 
timeframe of this research project to undertake this further experiment. 
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5. Exploring the IFN-γ–Chemokine pathway in BS in 
vitro 
5.1 Context 
In chapter 1 we reviewed inflammation in BS and found among other things, that a Th1 skew 
and IFN-γ signalling had been implicated. In Chapter 3 we used a cantharidin skin blister model 
of inflammation in an attempt to dissect the abnormal cutaneous inflammatory response of BS. 
A chemokine CXCL10 was noted to be potentially interesting because lower levels were noted 
in BS versus HC. While this finding was no longer statistically significant once corrections were 
made for multiple comparisons we felt it was worth investigating given that it is one of the 3 
IFN-γ inducible chemokines. Throughout all in vivo experiments, blood samples were also 
collected for in vitro work. The beginning of this chapter introduces IFN-γ signalling pathways, 
IFN-γ induced chemokines, and provides a brief review of mechanisms of translational control, 
as these are relevant to the results.  
5.2 Background 
5.2.1  Interferons 
Interferons (IFN) are ubiquitous cytokines produced by immune cells in response to infection by 
a DNA or RNA virus. There are three major classes. Type I IFNs in humans consist of 13 IFN-
αs, IFN-β and others. They are encoded by 17 non-allelic genes that lack introns and are located 
on chromosome 9 in humans. These IFNs are glycosylated proteins containing 160-200 amino 
acids and sharing 30% homology. They can usually be produced by all cell types. Stimulation 
via the TLR receptors including TLR 3, 4, 7 and 9, leads to IFN I secretion. IFN binds to 
ubiquitous surface receptors composed of  2 membrane spanning proteins IFNα R1+2 that form 
a ternary complex with the ligand which leads to activation of intracellular signalling involving 
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the Janus kinase 1 (JAK1) and tyrosine kinase (TYK2) pathways and STAT1/STAT2-IRF9 
pathways of intracellular signalling  with the resultant activation of the IFN-stimulated response 
element (ISRE). Type II is IFN-γ, and is mainly produced by NK cells and T cells and is 
discussed in detail below. Type III consists of 3 IFN λ molecules, also known as IL-28A, B and 
IL-29. They are co-produced with IFN-β but act at different receptors, the IFNLR1 and IL-
10R2.  Each type is characterized by a specific receptor and signal transduction pathway and is 
subject to strict regulation. The main role of IFNs is in co-ordinating an anti-viral response, but 
they also play a role in defence against bacterial infections and TB, decreasing tumour growth, 
and angiogenesis. Type I interferons are considered players in innate immunity, and Type II are 
associated with adaptive immunity [306]. They are implicated in several autoimmune diseases 
including SLE, Sjogren’s syndrome, Rheumatoid Arthritis, Polymyositis and Systemic 
Sclerosis[307]; The properties of interferons are used to treat a number of viral infections (e.g., 
hepatitis B and hepatitis C), inflammatory diseases (interferon beta for multiple sclerosis and 
interferon gamma for systemic sclerosis), and malignancies [308].  
5.2.1.1 Type II interferons 
There is only one type II interferon, IFN-γ.  It is produced by dendritic cells during the innate 
immune response, under the influence of IFN Is and IL-12. It is produced by NK cells, NK T 
cells and cytotoxic Th1 cells that are stimulated via their respective activating receptors (e.g. IL-
12R – JAK2/TYK2-STAT4 pathway) [309].  The IFN-γ protein is composed of 140 amino 
acids and shares no homology with type I IFNs.  
5.2.1.2 JAK –STAT signalling  
The IFN-γ receptor is distinct from the type I receptor.  It is a heterodimer of 2 membrane 
spanning proteins, IFN-γ R1+2, of which the first is constitutively expressed on all cell types 
and the second is tightly regulated and expressed on a narrower spectrum of cell types [310].  
Conventional IFN-γ signalling follows the binding of IFN-γ to its cell surface receptors, 
resulting in oligomerization of the receptor. The Janus kinase (JAK) family of kinases JAK1 
and JAK2 are pre-associated with IFNγR1 and IFNγR2 respectively, and receptor 
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oligomerization brings these kinases close together, allowing them to trans-phosphorylate each 
other and the cytoplasmic domains of the receptors. Tyrosine phosphorylation of IFNγR1 (on 
residue 440) provides a docking site for the SH2 domain of the STAT1 transcription factor. 
Docked STAT1 is phosphorylated in the C-terminus (on tyrosine Y701) [311], enabling a 
homodimer of tyrosine phosphorylated STAT1 to form and dissociate from the receptor. A 
second independent C-terminal phosphorylation on the serine residue S727 occurs following 
IFN-γ stimulation [312]. This phosphorylated STAT1 homodimer translocates to the nucleus 
and initiates transcription of genes containing a gamma activated sequence (GAS) [313] in their 
promoter region. STAT1 S727 phosphorylation has no impact on the formation of the STAT1 
homodimer, nuclear translocation and DNA binding [314]. However, S727 phosphorylation is 
important for STAT1 function because STAT1-mediated transcription is markedly attenuated in 
its absence [312]. This serine phosphorylation occurs by a non-JAK mediated mechanism, and 
several kinases have been shown to be involved, such as MAPK, discussed below. 
Further complex inhibition and enhancement of IFN generated signals occurs including through 
the MAPK, PI3Kinase, CaMKII and NF-kB pathways discussed below. Additionally 
perimembranous heparan binding influences the activation and local concentration of IFN-γ. 
5.2.1.3 Non JAK1/2-STAT1 signalling 
Other STATs have been shown to play a lesser role in IFN-γ signalling. STAT3 and STAT5 
have been shown to be activated to some extent by IFN-γ [315, 316]. STAT2 has also been 
found to be very weakly activated by IFN-γ [317]. As mentioned above, STAT1 undergoes 
serine kinase (S727) phosphorylation in addition to the tyrosine kinase phosphorylation [318]. 
This may be mediated by phosphatidylinositol-3’kinase (PI3’K)-AKT [319], Protein kinase 
Cepsilon (PKC) [320] or MAPK [321] pathways. In addition to phosphorylating STAT1 on 
S727, these kinases activate other molecular pathways related to IFN-γ signalling [322].  
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5.2.1.4 The role of phosphatidylinositol (PI) 3’K-AKT-mTOR pathway in 
control of ISGs. 
The PI3’K-AKT-mTOR pathway is an intracellular signalling pathway, typically activated by 
the Insulin-like growth factor – 1 (IGF-1), and has a number of downstream effects which either 
promote protein synthesis or inhibit protein breakdown. Both Type I and II IFNs activate the 
PI3’K-AKT-mTOR pathway [323]. IFN-γ activates PI3-K equally well in cells lacking JAK1 or 
2 [319, 323]. The PI3’K kinase plays an important role in mediating gene transcription in 
response to both Type I and II IFNs and also regulates the translation of ISG15 and CXCL10 
proteins, upon treatment of cells with IFN-α or IFN-γ, respectively [324].  
Although AKT does not appear to play a role in mediating the IFN-dependent activation of 
STAT1, protein expression of CXCL10 by IFN-γ is attenuated in the absence of the Akt1 and 
Akt2 [323]. Both Type I and II IFN-mediated engagement of mTOR leads to 
hyperphosphorylation of translational regulation protein 4E-BP1 [325]. The non-phosphorylated 
form of 4E-BP1 binds to the initiation factor eIF4E and prevents its inclusion in the eIF4F 
initiation complex thereby inhibiting translation imitation. Phosphorylation of 4E-BP1 by 
mTOR prevents the interaction of the protein with eIF4E and thereby enhances mRNA 
translation [326]. 4E-BP1 deficient mouse embryonic fibroblasts have an enhanced protein 
expression of CXCL10 upon treatment with IFN-γ [327].  
In addition to regulation of 4E-BP1 activity, IFN-signalling via mTOR leads to the activation of 
the p70 S6 kinase (S6K) and phosphorylation of the ribosomal protein S6 (RPS6) [326]. RPS6 
may play a role in translation of terminal oligopyrimidine (TOP) mRNAs and may therefore 
play a role in regulating the translation of certain ISGs (TOP mRNAs are transcripts which 
encode for ribosomal proteins and eIF1α and eIF2) [328]. The mTOR/S6K pathway is also 
known to regulate the phosphorylation of the eukaryotic initiation factor 4B (eIF4B) [328] 
which can facilitate translation  [329].  eIF4B is also known to be phosphorylated by the p90 
ribosomal protein S6K (RSK), a downstream effector of the MEK/ERK pathway [322, 330]. 
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5.2.1.5 The role of Mitogen-activated protein kinases (MAPK) in control of 
ISGs. 
MAPK are serine and threonine kinases and are classified into three main categories: the 
extracellular regulated kinases (ERK1-7), the stress activated p38 family (p38a-d) and the c-Jun 
N-terminal kinases (JNK1-3). Type I IFNs and IFN-γ activates p38 MAPK [331, 332]. It is not 
known if engagement of the p38 MAPK pathway plays a role in mRNA translation of ISGs, its 
major role in the induction of IFN-biological responses appears to be related to regulation of 
transcriptional activation [322].  
In addition to the p38 MAPKs, type I IFNs and IFN-γ are also known to activate the ERK1/2 
MAPKs [333]. This pathway is classically activated by epidermal growth factor (EGF) binding 
to the EGF receptor (EGFR) in the cell membrane and the pathway consists of the 
Ras/Raf/MEK/ERK signalling cascade. The role of the MEK/ERK pathway in the regulation of 
the anti-proliferative effects of IFNs is variable in different systems. IFN-mediated activation of 
ERK1/2 plays an essential role in RSK-dependent engagement of the translation initiation factor 
eIF4B. 
Jak1-Jak2
Stat1 Stat1
IFN-γ
Stat1 Stat1
GAS element
MEK1/2
ERK1/2
MNK1         RSK
eIF4E           eIF2B
PI3’K Akt
mTOR
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RPS6 eIF4E
?
AAAA
Translation initiation
Figure 5-1 Proposed model for the control of mechanisms of mRNA translation of ISGs.  
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IFN-γ binds to its receptor leading to the formation of STAT1 dimers that translocate to the 
nucleus and initiate transcription via GAS elements. The expression of ISGs is then regulated at 
the level of mRNA translation. IFNs also activate the PI3’K pathway ultimately leading to the 
phosphorylation of 4E-BP1 and activation of S6K. Phosphorylated 4E-BP1 leads to reduced 
inhibition of translation. Activation of S6K leads to the phosphorylation of eIF4B which also 
positively regulates mRNA translation. IFN mediated engagement of the MEK-ERK pathway 
leads to the activation of Mnk1 and its downstream target eIF4E further promoting the 
translation of ISGs. Depending on the cell type, the MEK-ERK pathway also leads to the 
phosphorylation of eIF4B by RSK, again enhancing the translation of ISGs. 
5.2.1.6 Heparan sulphate binding 
IFN-γ binds directly to glycosaminoglycan heparan sulphate (HS) on cell surfaces. The binding 
of IFN-γ to HS limits the extent of its C-terminal domain degradation which strongly increases 
the cytokine activity, in contrast to free IFN-γ which is rapidly inactivated by extensive C-
terminal processing. This mechanism means that IFN-γ is rapidly captured and activated by HS 
in the vicinity of the secreting cells, ensuring a localized action of the cytokine, while unbound 
IFN-γ is inactivated, thereby preventing unwanted cell stimulation by diffusing cytokines [334].  
5.2.1.7 IFN-γ activates transcription factors other than STAT1 
Although the STAT1 homodimer is the primary and best characterized route to IFN-γ induced 
transcription, IFN-γ additionally activates other transcription factors, that fall into three 
categories: (i) those transcription factors that are activated downstream of STAT1, i.e. they are 
transcriptional targets of STAT1 and therefore represent secondary responses (‘‘STAT1 
dependent’’), e.g. IRF-1; (ii) those transcription factors that form a protein complex with 
STAT1 on gene promoters to augment IFN-γ mediated transcription (‘‘STAT1 co-operative’’), 
e.g. ISGF3, STAT1/IRF9 and STAT1/c-Jun; and (iii) those transcription factors that can be 
activated independently of STAT1 (‘‘STAT1-independent’’), e.g. NF-kB and AP-1[318]. The 
interferon regulatory factor (IRF) family of transcription factors are important IFN-γ factors,  
the most important being IRF-1 and IRF-8 which have the capacity to bind to ISRE and other 
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IFN regulated response elements in the promoter of genes and initiate the transcription of both 
ISGs and the IFNs themselves[335]. 
5.2.1.8 Inducers of IFN production 
Viruses, some bacterial, bacterial lipopolysaccharide (LPS) (TLR4) can induce type I IFNs. The 
production of IFN-γ is stimulated by several lectins that are mitogenic for T cells, such as 
phytohemagglutinin (PHA), double stranded RNA (TLR3), single stranded viral RNA (TLR 
7,9) and hypomethylated bacterial or viral DNA via TLR9. Other receptors that respond include 
helicases containing a caspase recruitment domain (CARD) and known as RIG-1 and MDA5 
[336].  Transduction from the TLRs require either junction proteins such as MyD88 and TRAF6 
or TRIF and transcription factors belonging to the IFN regulatory factor (IRF) family such as 
ITFR3 for TLR3/4 . Several studies point to involvement of specific allelic IRF5 variants in 
SLE where IFN-α has been implicated [337]. 
5.2.1.9 Immunological effects of IFNs 
IFN signatures include genes encoding cytokines and chemokines, membrane receptors, signal 
transduction proteins, growth factors or apoptosis factors, antimicrobial proteins, adhesion 
molecules [338]. Th1 cell maturation is influenced by IFN-γ via the T-box transcription factor 
for TBX21 (T-Bet) [339], and this in turn increases IFN-γ by activating STAT4. IFN-γ increases 
the expression of Class II HLA molecules and promotes ThCD4+ response. It also increases the 
expression of Class I HLA molecules, antigen priming and antigen presentation. Other effects 
include effector cell recruitment to sites of inflammation via the production of chemokines and 
chemokine receptors, stimulation of the macrophage oxidative burst via enhanced expression of 
iNOS and NADPH oxidase [340, 341]. 
5.2.2 Chemokines 
Chemokines are low molecular weight cytokines whose major biological activity is that of 
chemotaxis of both specific and overlapping subsets of leukocytes. They play a critical role in 
the directed movement of leukocytes from the bloodstream into tissue. They are almost 
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exclusively secreted and act as extracellular messengers for the immune system. However, 
emerging data also show that various members of the chemokine gene superfamily exert other 
biological effects outside the immune system [342].  
CX3CL chemokines are subdivided into two categories, those with a motif of glutamic acid-
leucine-arginine (ELR motif) immediately before the first cysteine of the CXC motit, and those 
without. ELR-positive CXC chemokines specifically induce the migration of neutrophils, and 
interact with chemokine receptors CXCR1 and CXCR2. They are pro-angiogenic. An example 
of an ELR-positive CXC chemokine is interleukin-8 (IL-8).  CXC chemokines that lack the 
ELR motif include those induced by IFN-γ CXCL9, CXCL10 and CXCL11 tend to be 
chemoattractant for lymphocytes and are anti-angiogenic [343-345]. 
Members of the chemokine gene superfamily can be roughly divided into two main categories 
based on functional expression—the inducible and the constitutive chemokines. The inducible 
chemokines participate primarily in inflammation responses and are the bulk of the members of 
the supergene family. The constitutive chemokines are expressed primarily in secondary 
lymphoid organs and appear to play a major role in lymphocyte homing.  All chemokines exert 
their effects via ligation of cell surface receptors, which are G protein-coupled seven 
transmembrane domain receptors. Few receptors that bind only one ligand have been identified. 
However, chemokine subfamily integrity is maintained, in that binding to receptors generally 
occurs for chemokines within one subfamily.  An exception to this rule is the Duffy antigen 
receptor for chemokines (DARC), a receptor expressed on erythrocytes and endothelial cells 
that binds chemokines from both the CXC and the CC subfamilies and is also used as a binding 
site for the malarial parasite Plasmodium vivax [346]. Ligation of chemokines to their receptors 
leads to the generation of second messengers and activation of effector enzymes [342]. 
C
C
C
C
C
C
C
C
C
C
X
C                                                    CC CXC                                                CX3C
MD-HD
C
CC
C
XXX
 
Figure 5-2. Members of the chemokine superfamily.  
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Schematic representation of the cysteine signature motifs with disulphide bonds. The X 
represents an amino acid separating the cysteine residues. The CX3C chemokine also contains a 
mucin domain (MD) and a hydrophobic domain (HD). 
 
CXCR3 is activated by the three IFN-γ inducible ligands CXCL9, CXCL10 and CXCL11 [347]. 
CXCR3 is rapidly induced on naıve T cells following activation, and preferentially remains 
highly expressed on Th1 CD4+ T cells, effector CD8+ T cells and innate-type lymphocytes, 
such as NK and NKT cells. Some studies have revealed that these ligands have redundant 
functions in vivo, other studies have demonstrated that the three CXCR3 ligands can also 
collaborate and even compete with each other. Differential regulation of the three ligands at 
specific times in defined anatomically restricted locations in vivo likely participates in the fine 
control of T-cell trafficking over the course of an immune response [348]. Unique promoters 
control the distinct pattern of expression of each CXCR3 ligand. The CXCL10 and CXCL11 
promoters contain a functional IRSE and nuclear factor kappa B1 (NF-kB1) element, whereas 
the CXCL9 promoter contains an IRE-1 element and a weak NF-kB2 element [342].  For 
CXCL11 expression, a STAT3–STAT1 heterodimer, rather than the STAT1–STAT2 
heterodimer, binds to the CXCL11 promoter following IFN stimulation. In addition, the NF-kB 
p65 and IRF-1 also bind to the CXCL11 promoter. As such, the CXCR3 ligands are 
differentially regulated. CXCL10 is strongly induced by IFN-γ as well as by the Type I 
interferons IFN, and weakly induced tumour necrosis factor, although tumour necrosis factor 
synergizes strongly with the IFNs for CXCL10 induction. 
Chemokine Stimulus Promoter 
CXCL9 IFN>>>>TNF γ-IRE-1, NF-kB2 
CXCL10 IFN-γ>IFN-α/β>TNF IRSE, NF-kB1 
CXCL11 IFN-γ=IFN-β>IFN-α>TNF STAT3, NF-kB2 
Table 5-1 CXCL9, CXCL10 and CXCL11 stimulus preference and promoter 
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5.2.3 BS and IFN-γ pathways 
As mentioned in Chapter 1, STAT4 polymorphisms have been found to be associated with BS 
in the Turkish, Japanese, Han Chinese and Korean populations [98, 131, 132]. Furthermore the 
IL23R-IL12RB2 is a common variant SNP that was identified in the first two GWAS studies 
published in 2010 [6, 116]. In clinical studies, IL-12 was found to be elevated in peripheral 
blood of BS subjects and correlated with disease activity [133]. High levels IFN-γ were found in 
BS aqueous fluid versus other causes of uveitis [84].  High levels of CXCL9, 10 and 11 have 
been observed in BS associated uveitis versus other forms of uveitis, and high CXCL10 was 
found in CSF fluid of BS subjects [134, 135]. CCR5 and CXCR3 receptors have been shown to 
be highly expressed in BS biopsies from oral ulcers [154]. The pathology of pathergy reactions 
shows increased mRNA transcripts for the chemokines CCL20, CXCL10, CXCR3, and 
CXCL11 [61, 62].  
5.2.4 mRNA Translation: from gene to protein 
Translation initiation is the process of assembly of elongation-competent 80S ribosomes, in 
which the initiation codon is base-paired with the anticodon loop of initiator tRNA (Met-
tRNAMeti) in the ribosomal P-site. It requires several eukaryotic initiation factors (eIFs) and 
comprises several steps which first lead to the formation of 48S initiation complex and then the 
joining of 48S complex with 60S subunit. On most mRNAs, 48S complexes form by a 
'scanning' mechanism, whereby a 43S preinitiation complex (containing the eIF2–GTP–Met-
tRNAMeti ternary complex) attaches to the capped 5′ proximal region of mRNAs in a step that 
involves the unwinding of the mRNA's 5′ terminal secondary structure by eIF4A, eIF4B and 
eIF4F. The 43S complex then scans the 5′ untranslated region (5′ UTR) in the 5′ to 3′ direction 
until it reaches the initiation codon. After initiation codon recognition and 48S complex 
formation, eIF5 and eIF5B promote the hydrolysis of eIF2-bound GTP, the displacement of eIFs 
and the joining of a 60S subunit. Although most mRNAs use the scanning mechanism, initiation 
on a few mRNAs is mediated by internal ribosome entry sites [349]. 
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There is another protein associated with the eIF4F complex called the Poly(A)-binding protein 
(PABP), which binds the poly-A tail of most eukaryotic mRNA molecules. This protein has 
been implicated in playing a role in circularization of the mRNA during translation.[350] 
 
Figure 5-3. Eukaryotic translation. Reproduced from [349].  
The pathway of eukaryotic translation initiation is divided into eight stages (2–9). These stages 
follow the recycling of post-termination complexes to yield separated 40S and 60S ribosomal 
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subunits, and result in the formation of an 80S ribosomal initiation complex, in which Met-
tRNAMeti is base paired with the initiation codon in the ribosomal P-site and which is 
competent to start the translation elongation stage. These stages are: eukaryotic initiation factor 
2 (eIF2)–GTP–Met-tRNAMeti ternary complex formation (2); formation of a 43S preinitiation 
complex comprising a 40S subunit, eIF1, eIF1A, eIF3, eIF2–GTP–Met-tRNAMeti and probably 
eIF5 (3); mRNA activation, during which the mRNA cap-proximal region is unwound in an 
ATP-dependent manner by eIF4F with eIF4B (4); attachment of the 43S complex to this mRNA 
region (5); scanning of the 5′ UTR in a 5′ to 3′ direction by 43S complexes (6); recognition of 
the initiation codon and 48S initiation complex formation, which switches the scanning complex 
to a 'closed' conformation and leads to displacement of eIF1 to allow eIF5-mediated hydrolysis 
of eIF2-bound GTP and Pi release (7); joining of 60S subunits to 48S complexes and 
concomitant displacement of eIF2–GDP and other factors (eIF1, eIF3, eIF4B, eIF4F and eIF5) 
mediated by eIF5B (8); and GTP hydrolysis by eIF5B and release of eIF1A and GDP-bound 
eIF5B from assembled elongation-competent 80S ribosomes (9). Translation is a cyclical 
process, in which termination follows elongation and leads to recycling (1), which generates 
separated ribosomal subunits. 
5.2.4.1 Control of translation 
Regulating protein production by control of mRNA translation offers advantages over 
transcriptional regulation. It provides a rapid on/off mechanism. Cytokines can be translated 
from RNA molecules stored in cytoplasmic granules more rapidly than from newly synthesized 
transcripts. Storage of mRNA also allows cells to be ‘primed’ by an initial stimulus, which 
allows a rapid response to a subsequent stimulus. Translational repression allows the rapid 
turning off of cytokine production.   
Posttranscriptional control of cytokine production is achieved by the regulation of nuclear 
export, cytoplasmic localization, translation initiation and mRNA decay.  Two general modes of 
control can be envisaged (1) global control, in which the translation of most mRNAs in the cell 
is regulated, for example in response to stress or infection; (2) and mRNA-specific control, 
whereby the translation of a defined group of mRNAs is modulated without affecting general 
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protein biosynthesis or the translational status of the cellular transcriptome as a whole. Global 
regulation mainly occurs by the modification of translation-initiation factors, whereas mRNA 
specific regulation may also occur through translation initiation factors or may occur by 
regulatory protein complexes that recognize particular elements that are usually present in the 5′ 
and/or 3′ untranslated regions (UTRs) of the target mRNA. 
5.2.4.2 Regulation of initiation: Global control: eIF4E–4E-BPs and eIF2α 
kinases  
Global control of protein synthesis is generally achieved by reversible changes in the 
phosphorylation state of initiation factors or the regulators that interact with them, or sometimes 
irreversible proteolysis of these factors. Two well-characterized examples are the eIF2α kinases 
and the eIF4E–4E-BPs.  
5.2.4.3 eIF2α kinases 
eIF2 is part of the complex that associates with the 40S ribosomal subunit in its GTP-bound 
form. This GTP is hydrolysed when the initiator AUG is recognized during translation 
initiation, producing eIF2 in the GDP-bound state. Exchange of GDP for GTP again on the eIF2 
is catalysed by eIF2B. eIF2 is made of three subunits ( α, β and γ) and phosphorylation of the α 
subunit at residue Ser51 blocks the GTP-exchange reaction by reducing the dissociation rate of 
eIF2 from eIF2B [351]. In effect, this sequesters eIF2B and, as a consequence, GDP–GTP 
exchange no longer occurs and global mRNA translation is inhibited.  
A number of kinases can phosphorylate eIF2α at Ser51 including the haem-regulated inhibitor 
which is stimulated by haem depletion; the general control non-repressed 2 (GCN2) which is 
activated by amino-acid starvation; Protein kinase R (PKR) which is stimulated by viral 
infection  and protein kinase RNA-like endoplasmic reticulum kinase (PERK) which is 
activated under circumstances of endoplasmic reticulum (ER) stress [352, 353]. Although 
phosphorylation of eIF2α by these kinases decreases global translation, this modification can 
also result in the translational activation of specific mRNAs.  
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5.2.4.4 eIF4E 
The availability of the cap-binding protein eIF4E also regulates general translation rates. eIF4E 
interacts with the scaffold protein eIF4G to recruit the 43S ribosomal complex to the mRNA 
during translation initiation. Association between eIF4E and eIF4G requires a small domain in 
eIF4G that is shared by proteins that are known as the 4E-binding proteins (4E-BPs). 
Hypophosphorylated 4E-BPs bind to eIF4E and competitively displace eIF4G, resulting in the 
inhibition of the association of the 43S complex with the mRNA and hence, translational 
repression[354]. In addition to the phosphorylation-mediated reversible global regulation, 
proteolytic cleavage of translation factors can inhibit cellular protein synthesis. For example, the 
apoptotic protein caspase-3 cleaves eIF4G and  Poly-A binding protein (PABP) [354] 
5.2.4.5 Specific translation regulation 
Specific regulation occurs by many mechanisms. Translation inhibition by message-specific 4E-
BPs target steps of the translation-initiation pathway. Canonical end modifications of mRNA 
molecules may occur and the cap structure and the poly(a) tail are strong promoters of 
translation initiation; internal ribosome-entry sequences (IRESs) mediate cap-independent 
translation initiation; upstream open reading frames (uORFs) which normally reduce translation 
from the main ORF; secondary or tertiary RNA structures play important roles for example 
hairpins and pseudoknots which may block initiation, but can also be part of IRES elements and 
therefore promote cap-independent translation; and, specific binding sites for regulatory 
complexes, are all crucial determinants of mRNA translation [354]. 
5.2.4.6 Regulation of elongation or termination 
Translation can also be controlled at late-initiation and post-initiation steps. For example, the 
RNA-binding proteins heterogeneous nuclear ribonucleoprotein (hnRNP) K and E1 inhibit the 
translation of 15-lipoxygenase (LOX) mRNA during early erythroid differentiation. They bind 
to a repeated CU-rich element, which is known as the differentiation-control element (DICE) 
that is located in the LOX 3′ UTR. Translational repression of LOX is occurs at a late step in 
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initiation [355]. Sucrose-gradient analysis showed that 48S-complex formation occurred, but 
formation of the 80S ribosome was inhibited by the hnRNP-K–hnRNP-E1 complex [356]. 
5.2.4.7 mRNA stability or decay: ARE binding motifs   
Adenine and uridine–rich elements (AREs) are found in the 3′ untranslated regions (UTRs) of 
newly cloned mRNA molecules. The ARE recruit several different ARE-binding proteins 
(ARE-BPs) that can positively or negatively regulate mRNA stability and or translation. ARE-
BPs shuttle between the nucleus and the cytoplasm so binding to specific mRNA molecules 
may occur in either compartment. Several protein domains specifically bind AREs, including 
the RNA recognition motif (e.g. HuR), the zinc-finger domain (e.g.  TTP) and the K-homology 
domain (e.g. KSRP). These domains may also bind to stemloop–containing elements. Each of 
these proteins can individually affect the translation and/or decay of ARE-containing mRNA 
molecules: Usually TTP promotes decay[357] whereas  HuR inhibits decay [358]. IFN-γ mRNA 
contains an ARE that HuR may act on leading to mRNA stability. Once HuR stabilises, it may 
either promotes or inhibits translation depending on the context [359].  p38–MAPK-activated 
kinase 2 pathway can lessen ARE-dependent destabilization and translational silencing leading 
to more stable mRNA and promoting translation [359]. 
In T cells, costimulatory molecules such as CD28 and the integrin LFA-1 can influence the 
stabilization of mRNA molecules encoding cytokines [356]. Ligation of CD28 stabilizes IL-2 
transcripts, suggesting that CD28 engages an unidentified general signalling pathway to 
stabilize mRNA [360]. 
5.2.4.8 mRNA decay initiation 
In eukaryotes, degradation of mRNA is usually initiated by shortening of the 3’ polyA tail 
(deadenylation) which generally leads to the removal of the 5’cap structure by Dcp1/Dcp2 
decapping enzyme followed by 5’-3’ exonucleolytic digestion by Xrn1. The competition 
between mRNPs engaged in translation and those assembled with the decapping machinery 
correlates with the location of the mRNA. Translating mRNAs are distributed throughout the 
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cytosol but mRNAs complexed with the decapping machinery can concentrate in P bodies 
(regulation by sequestration). 
5.2.4.9 Regulation by sequestration  
As mRNA exists the nucleus, the cap binding protein 20 (CBP20)-CBP80 complex initiates a 
round of translation that strips off exon-junction complexes (multiprotein complexes that are 
deposited at exon exon junctions during splicing) and the CBP20-CPB80 is replaced by the 
cytoplasmic cap binding protein eukaryotic translation initiation factor 4E (eIF4E), which 
recruits the translation initiation complex as described above [361]. Recruitment of this 
initiation complex leads towards translation, whereas recruitment of the CCR5-NOT complex 
promotes deadenylation and eventually mRNA decay [362].   In many cases, newly formed 
transcripts are packaged into distinct classes of RNA granules that help control translation and 
decay. Disassembly of translating polysomes can drive the assembly of either processing bodies 
(P bodies) [363] or stress granules (SGs) [364]. SGs contain components of the translation 
initiation machinery whereas PBs contain components of the mRNA decay machinery [365]. 
Both SGs and PBs contain Argonaute proteins and associated miRNAs [365]. The components 
of most RNA granules appear to be in dynamic equilibrium with the actively translating pool 
allowing rapid shifts between translation storage and decay [365]. 
5.2.4.10 Regulation by microRNAs 
MicroRNAs (miRNAs) are being increasingly recognised as important players in translational 
control. miRNAs are transcribed as primary transcripts that are processed in the nucleus by 
Drosha, a member of the RNase III superfamily to yield precursors of ~70 nucleotides (pre-
miRNAs) that have the capacity to form stem–loop structures. The pre-miRNAs are further 
processed into mature miRNAs in the cytoplasm by another RNase-III-like enzyme that is 
known as Dicer.  miRNAs hybridize by incomplete base-pairing, usually to several sites in the 
3′ UTR of target mRNAs. Because the target mRNA remains intact after miRNA binding, the 
miRNAs are believed to repress translation, rather than prevent translation by degrading the 
mRNA. miRNA is biochemically indistinguishable from another small RNA species that is 
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known as small interfering RNA (siRNA). siRNAs are double-stranded RNA molecules of 21–
23 nucleotides in length, and they mediate the degradation of mRNAs that show perfect 
complementarity to either of the siRNA strands [366].  
The miRNA are associated with multiple proteins to form micro ribonuclear proteins (miRNPs) 
and these proteins include the Argonaute (AGO) family [354, 367]. AGOs are intimately 
associated with the paired miRNA–mRNA interaction, and many other proteins are present 
more peripherally. miRNAs appear to  act as adaptors that confer sequence-specific mRNA 
binding on AGO [349]. Repression seems to have end results: repression of mRNA translation, 
and an accelerated rate of mRNA degradation through the normal deadenylation-dependent 
pathways. The relative importance of these two components seems to vary between different 
miRNA–mRNA pairs [349, 368]. 
The mechanism of translational repression by miRNAs is largely unknown. Some investigators 
find the repressed mRNA is displaced from large polysomes into small polysomes or sub-
polysomal particles, which is indicative of inhibited initiation. Others find the repressed mRNA 
in polysomes that are a similar size to those present when the reporter mRNA is not repressed, 
implying inhibition at a post-initiation stage. For example, translational repression of lin-14 
mRNA by lin-4 miRNA has been shown not to alter its association with polysomes [354, 369]. 
It has been suggested in the later model, where polysomes continue to be associated with the 
mRNA that specific co-translational degradation of the nascent protein is the mechanism of 
control [370]. Two opposing theories are of  premature ribosome drop-off (which would have to 
be infrequent to maintain polysome size) and a reduced rate of elongation (which would cause 
polysome size to increase unless it was coupled with a quantitatively similar reduction in 
initiation frequency) [349].  Those who do not find polysome association, feel that the 
mechanism of inhibition  is that of  inhibition of initiation but more exact theories remain 
controversial [371]. Those who observe inhibition of initiation are generally agreed that strong 
repression is only seen if the mRNA has the normal  Gppp cap, and not if this is replaced by 
Appp, nor if the mRNA has a viral IRES, suggesting that it may be the cap–eIF4F interaction 
that is the proximal target of the repression mechanism [349, 372]. 
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5.2.4.11 IFN-γ mediated translational control 
IFN-γ mediated translational control is incompletely understood.  One well described example 
is that of IFN-γ mediated translational control involving the large ribosomal subunit protein 
L13A. Ceruloplasmin synthesis is inhibited 24 hours after treatment with interferon-γ by the 
action of the ribosomal cellular factor L13a,  that binds to a stem–loop structure in the 3′ UTR 
of the mRNA [373-375]. Phosphorylation of L13a after interferon-γ treatment causes its release 
from the 60S ribosomal subunit and promotes binding to the 3′ UTR the mRNA [375]  
5.2.5 miRNAs with IFN-γ and CXCL10 
Recent evidence suggests that miRNAs may play an important role in IFN-signaling. Using a 
microarray based approach, a study by Pedersen et al. demonstrated that both Type I and II IFNs 
can up regulate or decrease the expression of several cellular miRNAs [376] . Also, it was 
recently shown that IFN-γ induced ICAM-1 mRNA translation is mediated by IFN-γ dependent 
suppression of miRNA-221 in a STAT1 dependent manner in cholangiocytes [322, 377]. 
5.2.6 Polysome analysis 
Polysome analysis is a technique used to investigate differential translation 
regulation[378]. RNA from cells is layered on top of a tube containing a sucrose density 
gradient (sucrose 50% at the bottom to 20% at the top of the tube). It is then spun at 
very high speeds which results in ‘heavy’ polysomes travelling further down the tube 
then 80S or 40S subunits. Free RNA will travel the least far. A needle pierces the 
bottom of the tube and very even denser sucrose is introduced slowly (60%) to push the 
contents of the tube into a collecting tube and past a laser (which feeds to a graph tracer 
giving an image of passing fluid contents), and finally the sucrose is fed into collecting 
ependorfs, which allows the sample to be collected in fractions and analysed.  Usually 
polysomal fractions reflect actively translating mRNA and free RNA fractions reflect 
untranscribing mRNA. The main exception to this is that mRNA may be arrested in 
both free and polysomal states by miRNAs [369, 370]. 
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5.2.7 BS and miRNA work to date 
Work has been undertaken by a Chinese group studying miRNAs in BS. They genotyped over 
800 BS as well as HC and disease controls,  for specific miRNA-146 polymorphisms and found 
they were associated with ocular BS and Vogt-Koyanagi-Harada syndrome (VKH). miRNA-
146a has been identified as a negative feedback regulator in TLR signalling by targeting TRAF6 
and IRAK. Carriers of the disease associated SNP (GG) was associated with higher TNF-α, IL1-
β and IL-17 production. They did not assess CXCL10 or IFN-γ but STAT1 has been shown to 
be a target for this miRNA [158]. A second study examined miRNA-155 and found decreased 
expression in ocular BS. Overexpression of this miRNA has been shown to inhibit IL-6 and Il-
1β and to promote IL-10.This experiment used miRNA-155 mimics and inhibitors (single 
stranded chemically modified oligonucleotides) [157]. A third study using genotyping, found a 
functional variant of pre-miRNA-196a2 confers risk for BS but not VKH, specifically the 
arthritis phenotype. PBMCs from subjects with the disease associated genotype produced more 
IL-1β and MCP-1 protein following LPS stimulation, but not more IFN-γ  [379]. Published 
miRNA work to date in BS has been undertaken in a Chinese cohort.   
5.2.8 The  choice of SLE as a disease control 
Type I interferons have been thought of as central players in SLE for many years, and  IFN-γ 
has also been implicated [380]. A study examining the IFN-γ signalling pathway in peripheral 
blood mononuclear cells and purified monocytes in SLE found an increased expression of 
STAT1, and also increased expression of CXCL9 and CXCL10 mRNA at 6 hours (cells had 
been previously primed with IFN-α/γ two days prior to the start of the experiment)  [381].  
5.2.9 The choice of RA as a disease control 
We chose RA as a disease control for our experiments as it is a disease that this pathway has 
been studied in detail. CXCL10 have been found to be upregulated in RA Synovial fluid (SF) 
compared with osteoarthritis(OA) SF [382]. CXCL10 serum levels in rheumatoid factor (RF)–
positive individuals have been found to be higher than those in control (OA or trauma) subjects  
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[382]. Serum CXCL10 levels were reported as being similar to normal in one study (40) but 
increased in another study [382]. RA synovial tissue (ST) was found to express greater amounts 
of CXCL10 messenger RNA (mRNA) than OA ST [383]. Overall, CXCL10 is felt to be a key 
player in recruitment of Th1 cells into RA ST [384, 385]. An in vitro study of PBMCs and 
CD14+ monocytes stimulated with IFN-γ for 48 hours, in RA and HC, found higher STAT1 
mRNA expression in RA versus HCs, There was also increased CXCL10 in the RA group at 
this time point, although mRNA levels did not show a significant difference between the 
groups. MDX-1100, a fully human anti-CXCL10 monoclonal antibody (Bristol Myers Squibb) 
bind to CXCL10 with high affinity. A randomized, double blind, placebo controlled phase II 
proof of concept study was undertaken in RA to determine the clinical efficacy and safety of 
this therapy. Although most subjects improved by 20% (ACR20), almost none (2.9%) improved 
by 70% (ACR70). 
5.3 Hypothesis 
That the IFN-γ inducible chemokine CXCL10 may be an important player in the abnormal 
inflammatory response observed in BS. 
5.4 Aims of in vitro work 
1. To compare the CXCL10 chemokine response in CD14+ monocytes following stimulation 
with IFN-γ in BS and HCs, at a protein and mRNA level. 
2. To assess specificity of any of observed differences. Specificity has three main prongs: (i) 
IFN-γ chemokine specificity; (ii) Stimulus specificity (e.g. observing if any differences are 
global observations that may also be observed following stimulation with other cytokines and 
(iii) disease specificity (we recruited Rheumatoid Arthritis (RA) and Systemic Lupus 
Erythematosus (SLE) as disease control groups). 
3. To assess if any significant in vitro observations correlated clinical findings such as: (i) 
having a large MSU skin response; (ii) the disease activity score of BS subjects; (iii) 
medications that BS subjects were taking. 
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4. To dissect any significant observations to try and understand underlying mechanistic 
processes.  
5.5 Methods 
Chapter 2 provides a detailed description of in vitro tissue culture methods. Peripheral blood 
derived CD14+ monocyte cultures were used for all experiments. Cells were allowed rest for 
one hour after isolation, following which they were stimulated with IFN-γ or other stimuli.  
5.6 Results 
5.6.1 Demographics  
In total, 27 BS subjects, 25 HC, 15 RA and 15 SLE subjects donated samples for in vitro 
work, following written consent. There were three rounds of subject recruitment over an 
18 month period to answer consecutive questions relating to the aims of this chapter. 
The demographic data and clinical characteristics (including medication use) of these 3 
cohorts of subjects is listed in Tables 1-4. Many subjects donated samples during each 
round of recruitment, and where results are pooled, the first sample received from a 
subject is the one that was included. In addition, we also had serum samples stored at 
minus 80 degrees Celsius on numerous HC, BS and SLE subjects who had previously 
participated in research at Hammersmith Hospital. These samples were used to gather 
preliminary data and ELISA results are included in the first results section. 
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Cohort 1 Demographics Healthy Controls Behçet Syndrome 
Cohort size     9   9   
Median age (Interquartile range) 34 (32-36) 35 (26-53) 
Male sex (%)     6 66.7% 5 55.6% 
Clinical Characteristics            
Mucocutaneous      0   9 100% 
  Erythema nodosum       5 56% 
  Pathergy or poor wound healing     6 67% 
Musculoskeletal - arthralgias   0   8 89% 
  Arthritis         1 11% 
Cardiovascular     0   3 33% 
  Aneurysm         2 22% 
  Thrombosis       2 22% 
Ocular       0   3 33% 
  Posterior/panuveitis   
 
  2 22% 
Gastrointestinal inflammation   0   1 11% 
Neurological      0   2 22% 
Disease Activity Score *   0   3   
Current medications           
Colchicine     0   2 22% 
Azathioprine     0   1 11% 
Mycophenolate     0   1 11% 
Anti-TNF therapy     0   5 56% 
Cyclosporine     0   0   
Methotrexate     0   2 22% 
Steroids **     0   2 (5.5mg) 
* Behçet: Leeds Behçet’s disease activity form (2002 version) score of 0-12 (>4 indicates active disease). 
** Number of subjects taking steroids, and the median prednisolone dose taken by those subjects 
Table 5-2. Demographics of cohort 1 HC and BS subjects recruited for in vitro 
experiments.  
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Cohort 2 Demographics Healthy Controls Behçet Syndrome 
Cohort size     13   13   
Median age (Interquartile range) 34 (24-39) 46 (27-58) 
Male sex (%)     7 53.8% 5 38.5% 
Clinical Characteristics            
Mucocutaneous      0   13 100% 
  Erythema nodosum       6 46% 
  Pathergy or poor wound healing     10 77% 
Musculoskeletal - arthralgias   0   13 100% 
  Arthritis         9 69% 
Cardiovascular     0   1 8% 
  Aneurysm             
  Thrombosis       1 8% 
Ocular       0   9 69% 
  Posterior/panuveitis   
 
  5 38% 
Gastrointestinal inflammation   0   3 23% 
Neurological      0   2 15% 
Disease Activity Score *   0   3   
Current medications           
Colchicine     0   1 8% 
Azathioprine     0   4 31% 
Mycophenolate     0   0   
Anti-TNF therapy     0   4 31% 
Cyclosporine     0   0   
Methotrexate     0   0   
Steroids **     0   7 (6mg) 
* Behçet: Leeds Behçet’s disease activity form (2002 version) score of 0-12 (>4 indicates active 
disease). 
** Number of subjects taking steroids, and the median prednisolone dose taken by those subjects 
Table 5-3. Demographics of cohort 2 HC and BS subjects recruited for in vitro 
experiments. 
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Cohort 3 demographics HC BS RA SLE 
Cohort size 15   16   15   15   
Median age  (IQR) 37 (35-42) 46 (37-64) 59 (52-67) 52 (36-53) 
Male sex (%)  8 53.3% 6 37.5% 2 13.3% 3 20.0% 
Clinical Characteristics                   
Mucocutaneous  0   16 100% 0   7 47% 
Erythema nodosum     7 44% 0   0   
Pathergy     14 88% 0   0   
Arthralgias 0   14 88% 15 100% 14 93% 
Arthritis     7 44% 15 100% 4 27% 
Cardiovascular  0   3 19% 0   3 20% 
Aneurysm     2 13% 0   0   
Thrombosis     1 6% 0   3 20% 
Ocular 0   8 50% 0   1 7% 
Posterior/panuveitis 
 
  5 31% 0   0   
Gastrointestinal  0   4 25% 0   1 7% 
Neurological   0   3 19% 0   2 13% 
Renal  0   0   0   11 73% 
Median DAS * 0   2.6   4.3   5.2 
 
Current medications                 
Colchicine     0   3 19% 0   0   
Azathioprine     0   1 6% 0   1 7% 
Mycophenolate 0   5 31% 0   9 60% 
Anti-TNF therapy 0   5 31% 3 20% 0   
Cyclosporine     0   1 6% 0   0   
Methotrexate     0   2 13% 11 73% 0   
Tacolimus     0   0   0   3 20% 
Plaquenil     0   0   4 27% 9 60% 
Toculizumab     0   0   1 7% 0   
Rituximab     0   0   0   1 7% 
Steroids **     0   8 (10mg) 6 (5mg) 6 (5mg) 
*Behçet: Leeds Behçet's disease activity form (2002 version) score of 0-12 (>4 indicates active disease).    
SLE: Sledai score 0-105 (>6 indicates active disease).   RA: Disease Activity Score 1-10 (>5.1 indicates active 
disease).  IQR=interquartile range. 
** Number of subjects taking steroids, and the median prednisolone dose taken by those subjects 
Table 5-4. Demographics of cohort 3 HC, BS, RA and SLE subjects recruited for in vitro 
experiments.  
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General Demographics Healthy Controls Behçet Syndrome 
Cohort size     25   27   
Median age (Interquartile range) 35 (30-38) 45 (33-51) 
Male sex (%)     13 52.0% 12 44.4% 
Clinical Characteristics            
Mucocutaneous      0   27 100% 
  Erythema nodosum       12 44% 
  Pathergy or poor wound healing     19 70% 
Musculoskeletal - arthralgias   0   24 89% 
  Arthritis         13 48% 
Cardiovascular     0   6 22% 
  Aneurysm         3 11% 
  Thrombosis       4 15% 
Ocular       0   13 48% 
  Posterior/panuveitis   0   9 33% 
Gastrointestinal inflammation   0   6 22% 
Neurological      0   9 33% 
Disease Activity Score *   0   3   
Current medications           
Colchicine     0   3 11% 
Azathioprine     0   6 22% 
Mycophenolate     0   5 19% 
Anti-TNF therapy     0   10 37% 
Cyclosporine     0   1 4% 
Methotrexate     0   4 15% 
Steroids **     0   15 (9mg) 
* Behçet: Leeds Behçet’s disease activity form (2002 version) score of 0-12 (>4 indicates active disease). 
** Number of subjects taking steroids, and the median prednisolone dose taken by those subjects 
Table 5-5. Demographics of pooled cohort of HC and BS subjects recruited for in vitro 
experiments. 
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5.6.2 Pilot data 
5.6.2.1 Assessment of cytokines in serum from HC, BS and SLE subjects 
We had noted that there was a difference in CXCL10 concentrations in blister fluid of BS 
versus HC in Chapter 1. We had serum stored from 69 HCs, 72 BS and 65 SLE subjects from 
previous work undertaken in our laboratory. We decided to undertake ELISAs to look at 
random serum IFN-γ and CXCL10 protein concentrations in these samples. We did not have 
clinical details on this cohort and therefore the aim of this experiment was simply to gather 
preliminary data and to help form a hypothesis for in vitro work. We found that serum from 
SLE subjects contained significantly more IFN-γ protein than serum from BS or from HC. 
Serum from SLE and BS subjects contained significantly more CXCL10 protein than serum 
from HC.   
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Figure 5-4. Serum protein levels of IFN-γ and CXCL10 in samples from HC (n=69), BS 
(n= 72) and SLE (n=65).  
(a).There was significant variance between the three groups (P=0.03) with more IFN-γ protein 
in SLE samples than in either HC or BS samples. Dunn’s Multiple comparison test revealed a 
significant difference between the BS and SLE groups (P<0.05).  There was no significant 
difference in IFN-γ protein concentrations between BS and HC (b). Despite no significant 
difference between HC and BS in IFN-γ concentrations, significantly more CXCL10 protein 
was observed in BS samples versus HC (Dunn’s multiple comparison testing p<0.05). There 
was also a marked increase in CXCL10 protein in SLE samples versus HC (Dunn’s multiple 
comparison testing p<0.05). ANOVA Kruskal Wallis test showed an overall significant variance 
between groups (P=0.0001). Analysis: ANOVA Kruskal Wallis test with Dunn’s multiple 
comparison testing.  
This preliminary data suggested that there may be a difference in the IFN-γ –CXCL10 pathway 
in BS versus either HC or BS.  This was preliminary data and clinical correlation relating to 
disease activity or medications was not available. However, the data was interesting in that it 
suggested that the IFN-γ - CXCL10 pathway may be worth formally investigating in vitro. BS 
subjects had more CXCL10 protein than HCs but only a moderate (non-significant) increase in 
IFN-γ concentration. In contrast, in the SLE samples there was a straightforward increase in 
both IFN-γ and CXCL10. Possibilities for the observation in BS were numerous but included 
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that other cytokines such as TNF-α may be stimulating the CXCL10 pathway or that BS may 
have and increased transcriptional or translational response to modest levels of IFN-γ.  
5.6.3 Comparison of  CXCL10 protein response in BS and HCs 
In order to evaluate the IFN-γ –CXCL10 pathway formally, we recruited 9 HC and BS subjects 
(Table 5-2.) They were similar in age (median 34 yr in HC, 35 yr in BS), 6 of the HC were male 
versus 5 of the BS subjects. The BS subjects were on a range of medications, and 5 were 
receiving anti-TNF therapy. Only 2 were taking prednisolone (median dose 5.5mg daily). 
CD14+ monocytes were isolated from peripheral blood and plated. Cells were allowed to rest 
for an hour, following which, they were stimulated with IFN-γ, or left unstimulated. At 2 or 4 
hours, supernatants were aspirated for ELISA of CXCL10 protein levels and cells were scraped 
and stored for later mRNA extraction.   
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Figure 5-5.  CXCL10 protein concentration. CD14+ monocytes from HC and BS subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for either 2 or 4 hours, or else were left 
unstimulated. Supernatants from unstimulated cells contained low concentrations of CXCL10 in 
both HC and BS, with no difference between the two groups. In contrast, supernatants from BS 
samples had a significantly higher concentration of CXCL10 protein at both 2 hours (P=0.005) 
and 4 hours (P<0.001) despite being stimulated with the same concentration of IFN-γ. Analysis: 
Two tailed Mann Whitney test. Line represents median values. Subject cohort 1. 
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We found that at both the 2 and 4 hour time point more CXCL10 protein was present in the BS 
samples. There was very little CXCL10 in unstimulated samples from either group. In order to 
evaluate if there was a pool of preformed protein in monocytes from BS accounting for the 
observation, the experiment was repeated, this time samples were collected every 30 minutes 
from time 0 to 2 hours. For this experiment 13 HC and 13 BS subjects were recruited. Again, 
the groups were well matched for age and sex (Table 5-3). Seven of the 13 BS subjects were 
receiving prednisolone (median 6mg), and 4 were on anti-TNF therapy. We found that CD14+ 
monocytes from BS subjects began to produce more CXCL10 protein than those from HC from 
2 hours 
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Figure 5-6. CXCL10 protein concentration. CD14+ monocytes from HC and BS subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for periods from 30 minutes to 2 hours, or else 
were left unstimulated. Supernatants from unstimulated cells contained low concentrations of 
CXCL10 in both HC and BS, with no difference between the two groups. Supernatants from BS 
samples had a significantly higher concentration of CXCL10 protein from 2 hours (P=0.027). 
Analysis: Two tailed Mann Whitney test. Line represents median values. Subject cohort 2. 
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These results inferred that our observations were not due to the release of preformed protein. 
The two hour time point was used for all further experiments, as this was the earliest time that a 
significant difference in protein production was observed between BS and HC.  
5.6.3.1 Evaluation of CXCL10 mRNA in response to IFN-γ 
During the experiments detailed above, cells had been scraped and stored allowing later mRNA 
extraction. mRNA was extracted from the samples from the above 2 experiments (cohort 1 and 
2, Tables 5-2 and 5-3), and RT PCR was undertaken to assess the relationship between CXCL10 
mRNA and protein levels in monocytes following IFN-γ stimulation. 
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Figure 5-7. CXCL10 mRNA expression.  CD14+ monocytes from HC and BS subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for periods from 30 minutes to 4 hours, or else 
were left unstimulated. mRNA was semi-quantitatively investigated by Reverse Transcriptase 
Real Time Polymerase Chain Reaction and results expressed relative to the expression of the 
house keeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT). mRNA 
expression of CXCL10 in both HC and BS showed no significant differences at any time point. 
Indeed, contrary to expectations, there tended to be lower values of mRNA expression in the BS 
samples although these differences were not statistically significant. Analysis: Mann Whitney t 
test at each time point. Line represents median values. Subject cohort 1 and 2 pooled. 
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During preliminary experiments other housekeeping genes (Actin and GAPDH) had also been 
assessed, but results indicated that HPRT remained the most reliably constant following IFN-γ 
stimulation (results not shown).  
These results indicated that although there was no difference in the mRNA expression (or if 
anything, there was lower mRNA expression of CXCL10 in the BS cohort), there was an 
increased protein concentration in BS samples following IFN-γ stimulation. This protein was 
likely to be newly formed as results were only apparent from 2 hours. This indicated an 
uncoupling between transcription and translation. We expressed this by plotting CXCL10 
protein against mRNA (below), and by dividing protein by mRNA to establish the ratio, and this 
confirmed the observation of an uncoupling between the two processes. 
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Figure 5-8. The relationship of CXCL10 protein to mRNA. CD14+ monocytes from HC 
and BS subjects.  
Protein values (y axis) were plotted against mRNA expression (relative to HPRT) (x axis) from 
monocytes stimulated with IFN-γ (20nL/mL) at the 2 hour time point.  It was found that BS (▲) 
values clustered along the y axis and HC (●) clustered along the x axis, suggesting more 
efficient translation in the BS samples. Linear regression of the groups showed that the slopes 
were significantly different (F = 6.55706.  DFn=1, DFd=34, P=0.015). Subject cohort 1 and 2 
pooled. 
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Figure 5-9. CXCL10 protein:mRNA ratio. CD14+ monocytes from HC and BS subjects.  
Monocytes were stimulated with IFN-γ (20nL/mL) for 2 hours. The ratio of protein production 
to mRNA expression at 2 hour time point was calculated. BS were found to have a significantly 
increased ratio of protein: mRNA production versus HC, again indicating more efficient 
translation. For this analysis results pooled from subject cohort 1, 2 and 3 are shown. P= 0.01. 
Analysis: Two tailed Mann Whitney test. Line represents median values. Results were also 
statistically significant when cohorts were analysed individually. 
5.6.4 Assessing the specificity of observed differences in CXCL10 
protein and mRNA  
We wished to evaluate if this was a specific observation for just this one cytokine/chemokine 
pathway, just in this one inflammatory condition, or whether it was a response that would be 
seen in BS in response to any stimulus, or indeed one that would be observed in other 
inflammatory conditions. As discussed in the introduction, we choose RA and SLE as suitable 
disease controls (DC). For this experiment 15 HC, 16 BS, 15 RA and 15 SLE subjects were 
recruited. The RA and SLE subjects were slightly older and had a higher proportion of females. 
We felt we may have recruited a rather atypical cohort of SLE /RA subjects and we matched 
exactly for sex. Most BS, RA and SLE subjects were taking disease modifying anti-rheumatic 
drugs (DMARDs), with SLE subjects more likely to be taking hydroxychloroquine (plaquenil), 
RA more likely to be taking methotrexate, and slightly more BS subjects taking azathioprine or 
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anti-TNF therapy. The BS group were taking slightly more prednisolone. The disease activity 
score for all groups showed mild to moderately active disease (Cohort 3, table 5-4).  
We divided specificity questions into three main prongs: (i) IFN-γ chemokine specificity; (ii) 
Stimulus specificity (iii) BS specificity. For IFN-γ chemokine specificity we analysed samples 
from all BS and HCs (Cohorts 1-3). 
In order to assess the first prong of the specificity question, we decided to look at CD14+ 
monocytes production of other chemokines following IFN-γ stimulation. We choose to study 
CXCL9, CXCL11 (both are documented to be IFN-γ inducible) and CCL2. To this end we 
evaluated these chemokine protein concentrations in samples from Cohorts 1-3 of HC and BS 
subjects. Results showed that CXCL9 protein was significantly higher in BS versus HC. There 
was a trend towards higher CCL2 but this was not significant. Very little CXCL11 was present 
in any samples.   
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Figure 5-10. CXCL9, CXCL11 and CCL2 protein concentration. CD14+ monocytes from 
HC and BS subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for 2 hours. Supernatants from BS cells 
contained significantly more CXCL9 protein than HC (P=0.001), similar concentrations of 
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CCL2 (P=0.34) and very low concentrations of CXCL11.  Analysis: Two tailed Mann Whitney 
test. Line represents median values. Subject cohort 1-3. 
As CXCL9 protein was found to be significantly higher in the BS group compared to HC, we 
next assessed the CXCL9 mRNA expression and calculated the ratio of CXCL9 protein:mRNA. 
In contrast to the CXCL10 mRNA, there was a trend towards the BS cohort having more rather 
than less CXCL9 mRNA expression, and there was no significant difference between the groups 
when the ratio of protein:mRNA expression was calculated. This indicated that for CXCL9 
there was a more direct relationship between transcription and translation. 
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Figure 5-11. CXCL9 mRNA and protein:mRNA ratio. CD14+ monocytes from HC and BS 
subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for 2 hours. CXCL9 mRNA was semi-
quantitatively investigated by Reverse Transcriptase Real Time Polymerase Chain Reaction and 
results expressed relative to the expression of the house keeping gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). mRNA expression of CXCL9 showed the opposite pattern 
to that of CXCL10, with a non-significant trend towards the BS cohort having a higher CXCL9 
mRNA expression. The protein to mRNA ratio showed no statistically significant difference 
between HCs and BS.  Analysis: Two tailed Mann Whitney test. Line represents median values. 
Subject cohort 1-3. 
5.6.4.1 Assessing CXCL10 protein and mRNA in disease controls 
We next wished to assess if this observation would be found in other inflammatory conditions. 
We therefore isolated CD14+ monocytes from HC, BS and disease controls (RA and SLE) 
(cohort 3, Table 5-4). As before, cells were isolated, plated, rested then stimulated with IFN-γ 
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for 2 hours, following which supernatants were collected for ELISA protein measurement, and 
cells were scraped and stored for mRNA extraction.   
 
(a).
C
X
C
L
1
0
 p
ro
te
in
 (
p
g
/m
L
)
HC BS RA SLE
0
500
1000
1500
2000 *
**
 
 
(b).
C
X
C
L
1
0
 m
R
N
A
 e
x
p
re
s
s
io
n
HC BS RA SLE
0
500
1000
*
*
 
 
 156 
 
(c).
C
X
C
L
1
0
 p
ro
te
in
:m
R
N
A
HC BS RA SLE
0
10
20
220 *
*
 
Figure 5-12. CXCL10 evaluation in Disease controls. CD14+ monocytes from HC, BS, RA 
and SLE subjects.  
Monocytes were stimulated with 20ng/mL IFN-γ for 2 hours. (a). CXCL10 protein 
concentration was higher in the supernatant of samples from BS than those of RA (P<0.05) or 
SLE (P<0.05) subjects. Analysis of variance between the groups was highly significant 
(P=0.0024). While this cohort did not show a statistically significant difference in protein 
concentrations between HC and BS (p=0.17), pooled results from all cohorts (not shown) 
continued to show a significant difference. (b). CXCL10 mRNA was semi-quantitatively 
investigated by Reverse Transcriptase Real Time Polymerase Chain Reaction and results 
expressed relative to the expression of the house keeping gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). There was a significant difference between groups 
(P=0.02), with significantly greater mRNA expression in HCs compared to BS or RA subjects 
(P<0.05). (c). The protein to mRNA expression of CXCL10 was highest in the BS cohort. 
Analysis of variance showed significant variance between the groups (P=0.008) with a 
significant difference between the BS and HC and SLE subjects (P<0.05) implying that post-
transcriptional regulation may be more important in BS than in the other groups. Analysis: 
ANOVA to look for variance between all groups and Dunn’s multiple correction. Line 
represents median values. Subject cohort 3. 
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These results showed that the protein:mRNA pattern observed in the BS cohort was not 
observed for CXCL10 in the disease control cohorts, indicating that this observation is specific 
for BS. 
We wished to evaluate stimulus specificity for our observation, to decide if this was specific to 
the IFN-γ pathway. Monocytes from subjects in Cohort 3 were stimulated with LPS, and the 
TNF-α protein and mRNA response was evaluated. In the interest of consistency, the 2 hour 
time point continued to be used. We found that at 2 hours all groups produced a robust TNF-α 
response to LPS stimulation. Again we found a trend towards an increased protein:mRNA ratio 
in BS versus HC (non-significant), but the same trend was also observed in both the RA and 
SLE cohort, indeed the SLE group had the highest ratio. Therefore we concluded that there was 
no BS specific response regarding protein or mRNA for TNF-α following 20ng/mL LPS 
stimulation 
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Figure 5-13. LPS response in BS, HC and Disease Controls. CD14+ monocytes.  
Monocytes were stimulated with 20ng/mL LPS for 2 hours. (a). All groups displayed a robust 
response with induction of TNF-α protein. There were no statistically significant differences 
between the groups. (b). TNF-α mRNA was semi-quantitatively investigated by Reverse 
Transcriptase Real Time Polymerase Chain Reaction and results expressed relative to the 
expression of the house keeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT). 
There were no significant differences between any of the groups, although there was a trend 
toward HC subjects having higher mRNA expression than other groups, which had also been 
seen with IFN-γ stimulation. (c). The protein to mRNA expression of TNF-α was no longer 
highest in the BS cohort, and there were no significant differences in protein:mRNA ratios 
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between any group.  Analysis: ANOVA to look for variance between all groups Dunn’s 
multiple testing. Line represents median values. Subject cohort 3. 
5.6.5 Correlation of observations to clinical features such as MSU 
response, disease activity and medications 
We wished to investigate if the IFN-γ - CXCL10 observation would correlate with clinical 
features such as the MSU skin response, BS disease activity, BS subtype or medication use. We 
first evaluated the MSU response. A subgroup of in vitro volunteers had also volunteered for the 
skin blister experiment (Chapter 3), where a MSU skin prick had been undertaken and the size 
of the response had been recorded. We divided subjects either into HC and BS, or into ‘weak’ or 
‘strong’ responders to the MSU injection regardless of their diagnosis, and then compared 
CXCL10 protein and mRNA results. We found no correlation between the in vitro IFN-γ-
CXCL10 results and the MSU skin prick response, in the subgroup of subjects involved in both 
experiments.  
We found it interesting that most of the subjects who had volunteered for the skin blister 
experiment had quite low concentrations of CXCL10 protein relative to the entire BS cohort and 
this suggests that this subgroup may have had a milder disease phenotype (which perhaps 
explains the lack of positive results in Chapter 3). 
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Figure 5-14. Comparison of in vitro IFN-γ – CXCL10 response with the in vivo MSU 
response.  
A subgroup of the in vitro volunteers had previously volunteered to have an MSU skin prick test 
as part of the cantharidin skin blister test. These figures pick out the subgroups either by their 
diagnosis (MSU HC and BS) or by the size of their MSU response regardless of underlying 
diagnosis (MSU Weak and Strong) and  the CXCL10 (a) protein (b) mRNA and (c) 
protein:mRNA ratio in these subjects are shown. There does not appear to be a strong 
relationship between the skin response and the in vitro results, although numbers are small. 
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Another interpretation is that subjects chosen for the cantharidin skin blister test perhaps had 
milder disease phenotype than subjects later recruited for in vitro experiments, and this may 
possibly partially account for the disappointing lack of significant findings in the skin blister 
chapter. 
We next wished to have a look for correlations between medication use and CXCL10 levels. 
While we were not sufficiently powered to out rule a correlation, we felt that if there were any 
very strong correlations, this may be a useful evaluation. We found no correlation between 
medications and CXCL10 levels in BS subjects. 
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Figure 5-15. Comparison of CXCL10 (a) protein and (b) mRNA levels to medications that 
BS subjects were concurrently taking.  
No significant differences were observed between the groups. The number of subjects recruited 
was not large enough for the influence of medications to be completely ruled out as partially 
responsible for our findings. 
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We next evaluated if CXCL10 protein and protein:mRNA would correlate with disease activity, 
and we found a positive correlation. We divided the BS cohort into those subjects that had a low 
or a high disease activity. While both these groups showed a significant difference from HCs at 
the protein level, when we evaluated the protein:mRNA ratio we found that only the high DAS 
groups results remained significant. This indicated a correlation in our observation with disease 
activity. 
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Figure 5-16. Correlation of CXCL10 (a) protein and (b) protein:mRNA with BS disease 
activity (DAS).  
Disease activity was calculated using the Leeds Behçet’s disease activity form (2002 version). 
The score ranges from 0-12 with values of 4 or greater indicating active disease (high DAS). (a) 
Analysis of variance of CXCL10 protein concentration showed a significant variance between 
the groups (Kruskal Wallis test of non-parametric analysis of variance P=0.005). Dunn’s 
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multiple comparison test showed a significant difference between HC and low DAS (P<0.05) 
and also HC and High DAS (P<0.05). (b) Analysis of variance of CXCL10 protein:mRNA ratio 
also showed a significant variance between groups (Kruskal Wallis test of non-parametric 
analysis of variance P=0.02). Dunn’s multiple comparison test showed a significant difference 
between the HC group and the high DAS group P<0.05, but no significant difference between 
HC and the low DAS group. 
Lastly, we looked for correlations between clinical disease manifestations and CXCL10 protein 
and protein:mRNA levels. We divided the BS cohort into subgroups depending on clinical 
manifestations. Those in the mucocutaneous group (MC) had limited mucocutaneous disease 
with no cardiovascular (CV), ocular (OC) or neurological (NEU) involvement. We found no 
difference between the limited MC BS subjects and HCs regarding CXCL10 protein, or the 
protein:mRNA ratio. There was a significant difference in the ocular and neurological groups 
relative to HC at the protein level, but significance was lost in the protein:mRNA evaluation, 
once corrections had been made for multiple comparisons. These results indicate that, in 
particular, neurological and ocular BS show a stronger correlation to the CXCL10 observations 
than limited mucocutaneous subjects.   
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Figure 5-17. Comparison of CXCL10 (a) protein and (b) protein:mRNA with clinical 
subgroups of BS subjects.  
MC= subjects with limited mucocutaneous manifestations; CV= subjects with a history of 
cardiovascular or thrombotic manifestations; OC = subjects with a history of ocular 
inflammation; NEU = subjects with a history of neurological involvement. (a) Analysis of 
variance of CXCL10 protein concentration showed a significant variance between the groups 
(Kruskal Wallis test of non-parametric analysis of variance P=0.0006). Dunn’s multiple 
comparison test showed a significant difference between HC and ‘ocular’ subjects (P<0.05) and 
also HC and ‘neurological’ subjects (P<0.05). (b) Analysis of variance of CXCL10 
protein:mRNA ratio also showed a significant variance between groups (Kruskal Wallis test of 
non-parametric analysis of variance P=0.03). Dunn’s multiple comparison test showed no 
significant difference between the HC group and of the BS subgroups. Although differences 
were not statistically significant with multiple testing corrections, there is a trend towards 
having a higher protein:mRNA ratio with the ocular and neurological groups, and in contrast the 
HC and the limited mucocutaneous groups closely resemble each other. 
5.6.6 Polysome profiling to assess post-transcriptional regulation 
of IFN-γ - CXCL-10 
Results to this point indicated that BS subjects may translate CXCL10 protein more 
efficiently than HC or disease controls. To further investigate translational efficiency in 
BS and HC, sucrose density gradient analysis was undertaken. Sucrose density analysis 
or polysome analysis is a technique used to investigate differential translation 
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regulation. RNA from cells is layered on top of a tube containing a sucrose density 
gradient (sucrose 50% at the bottom to 20% at the top of the tube). It is then spun at 
high speeds resulting in ‘heavy’ polysomes travelling further down the tube then 80S or 
40S subunits. Free RNA will travel the least far. Following high speed centrifugation, 
the tube is transferred to the analyser, where a needle pierces the bottom of the tube and 
60 % sucrose is introduced slowly to push the contents of the tube into a collecting tube 
and past a laser (which feeds to a graph tracer giving an image of passing fluid 
contents), and finally the sucrose is fed into collecting ependorfs, allowing the sample to 
be collected in fractions and analysed. Usually polysomal fractions reflect actively 
translating mRNA and free RNA fractions reflect un-transcribing mRNA. The main 
exception to this is that mRNA may be arrested in both free and polysomal states by 
miRNAs. 
As the sample flows past the laser, a graph voltage tracer produces an image of passing 
contents.  
 
Figure 5-18. A representative voltage tracing of polysome factions within a sucrose 
density gradient passing though under laser over time.  
The far left of the trace represented free RNA contained within the least dense upper faction of 
the gradient. The middle and later segments representws RNA associated with ribosomal 
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subunits and polysomes. Samples were collected and mRNA is extracted. A known quantity of 
GFP was spiked into each sample prior to processing. CXCL10 and GFP mRNA was then 
measured in each sample, and CXCL10 mRNA expressed relative to the GFP, thereby 
normalizing for any loss of mRNA that had occurred through the processing. Sample values 
were expressed as a percentage of the entire CXCL10 mRNA quantity (% occupancy).  
For this experiment, we identified the 3 BS subjects with the highest CXCL10 protein:mRNA 
ratio and the 3 HCs with the lowest CXCL10 protein:mRNA ratio and asked them to attend to 
donate a further 100ml sample of blood. 
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Figure 5-19. The percentage occupancy of CXCL10 mRNA.  
CD14+ monocytes from BS (n=3) and HC (n=3) stimulated for 2 hours with IFN-γ (20μL/mL). 
The quantity of CXCL10 mRNA from each fraction collected (n=22) was expressed as a 
fraction of the entire CXCL10 mRNA from all the samples. Samples 1 and 2 represent free 
RNA. Samples from 3 onwards represent ribosomal and polysomal RNA. Samples to the far 
right represent heavier polysomes that had more ribosomes associated. We found high quantities 
of mRNA in both HC and BS. Collected samples had a known quantity of GFP RNA added 
before RNA extraction and RT PCR to normalise values. Values were expressed as mean and 
standard deviation. There was no statistically significant difference between HC and BS, 
suggesting that despite different quantities of protein being produced by the two groups, there 
was no change in polysomal association between the groups.  
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The laser trace indicated that the samples contained a large quantity of free RNA. However, the 
RT PCR CXCL10 values of samples collected showed very little of the CXCL10 mRNA 
existed in this unbound fraction. Most CXCL10 mRNA was found to be associated with 
polysomes in both BS and HC samples. Unstimulated samples had very low quantities of 
CXCL10mRNA, and this was true for both BS and HCs, but even in these unstimulated 
samples, the small quantity of mRNA present tended to be associated with polysomes. 
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Figure 5-20. The proportion of the mRNA present within the free RNA portion or 
the polysomal portion of each sample (represented as a percentage of the whole). 
CD14+ monocytes from BS (n=3) and HC (n=3) (a) unstimulated or (b) stimulated for 2 hours 
with IFN-γ (20μL/mL).  In unstimulated samples overall quantities of CXCL10 were very low, 
but appeared to be associated with polysomes (although not translating). In stimulated samples 
we found high quantities of CXCL10 mRNA in both HC and BS which was largely found to be 
associated with the polysomes. Collected samples had a known quantity of GFP RNA added 
before RNA extraction and RT PCR in order to normalise values for any loss of RNA during 
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processing. Values were expressed as mean and standard deviation. There was no statistically 
significant difference between HC and BS, supporting the finding that despite different 
quantities of protein being produced by the two groups, there was no change in polysomal 
association between the groups.  
These findings indicate that the explanation for observed differences in protein expression are 
not related to production of more mRNA, but are more likely to be related to mechanisms 
involved in control of translation, for example miRNAs.  
5.7 Discussion 
The IFN-γ – CXCL10 pathway was of interest to us as IFN-γ appears to be an important 
cytokine in BS and CXCL10 has been found in excess in histological samples in BS subjects, as 
reviewed in Chapter 1. We observed that serum from BS did not have significantly more IFN-γ 
protein than HCs, in contrast to SLE samples. Despite this serum from BS subjects had greater 
quantities of CXCL10 protein.  This chapter explored this observation in detail in vitro. 
We initially stimulated peripheral blood derived CD14+ monocytes from HC and BS with IFN-
γ and found that more CXCL10 protein was present in supernatants from the BS cohort at 2 and 
4 hours. To assess if this was pre-formed protein, we brought the time point back to zero and 
found that the significant difference was only observed from 2 hours, indicating this was new 
protein being translated. Additionally others have shown that CXCL10 is not stored 
intracellularly, but rather, it is released on production [386].  
When we evaluated the mRNA expression of CXCL10 relative to the housekeeping gene HPRT 
we found no difference between the groups, indeed there was a trend towards less CXCL10 
mRNA in the BS cohort. This made transcriptional signalling less likely to account for our 
observations, and more likely that this as a post transcriptional process. When we plotted the 
CXCL10 protein to mRNA we found a significantly higher ratio in BS versus HCs, again 
suggesting post-transcriptional processes. 
We next investigated the specificity of this observation. We found no significant difference 
between CCL2 protein in HC and BS following IFN-γ stimulation, and no significant induction 
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in either group of CXCL11. While we did find significantly more CXCL9 protein in the BS 
cohort, when we assessed the CXCL9 mRNA we found no significant differences between 
mRNA expression in HC and BS, and that the trend was in the opposite direction to CXCL10, 
with a trend towards more CXCL9 mRNA expression in the BS cohort, indicating that this 
control was likely to involve transcriptional +/- post transcriptional regulation. The 
protein:mRNA ratio was still marginally in favour of the BS cohort but differences were not 
significant, and we concluded that the observation of post-transcriptional regulation of the IFN-
γ chemokine pathway in BS that we had observed was relatively specific for CXCL10. 
We next wished to investigate if this observation was specific to BS or was observed in other 
inflammatory conditions. We chose RA and SLE as disease controls because the IFN-γ 
CXCL10 pathway has been implicated in these diseases. We found that at the 2 hour time point 
we did not observe an excess of CXCL10 production in these disease controls. We were 
surprised that these subjects did not produce more protein than HCs, and it is possible that 
medications played a role, or that the time point was too early. These experiments were also 
undertaken during winter and possibly our ‘HC’s had been exposed to more environmental 
viruses than the disease cohorts. When we assessed the mRNA expression and the CXCL10 
protein:mRNA ratio, the RA and SLE cohorts did not show the same pattern of expression or 
the same elevated protein:mRNA ratio that had been found in the BS cohort. 
We were interested in assessing if other stimuli would also induce an exaggerated response in 
BS. In order to address this, we stimulated CD14+ monocytes with LPS and assessed TNF-α 
protein production. All groups produced a robust response to LPS stimulation. Again HCs had 
the highest expression of TNF-α mRNA and it appeared that all the inflammatory cohorts had 
more efficient translation as compared to the HCs when the protein:mRNA ratio was assessed. 
However, these results were not statistically significant. Interestingly, for this pathway, it was 
the SLE cohort that had the highest protein:mRNA ratio.  
We concluded from these experiments that only the IFN-γ– CXCL10 pathway showed 
differential translational control specific to BS.  
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The possible explanations for this observation include differential post-transcriptional regulation 
through specific regulation of initiation factors, mRNA stability (although mRNA was if 
anything reduced in BS, not supporting the notion of increased mRNA stability in BS), 
differential sequestration of mRNA into processing bodies, miRNAs being more highly (if pro-
translational) or less expressed (if inhibitory) in BS, less protein being immediately degraded in 
BS, less protein being stored in BS (although CXC10 does not appear to be stored), or less 
degradation of secreted protein in BS. Transcriptional factors may also influence translation, in 
part by activating miRNA genes, and their role was not clear. 
We undertook a sucrose density gradient experiment to assess if there was a difference in 
polysomal association between HCs and BS. We undertook these experiment in the 3 most 
‘extreme’ responders in the HCs and BS, i.e. those BS subjects with the highest protein:mRNA 
ratio, and those HCs with the lowest. If differences were at the level of differential regulation of 
translational initiation we would have expected more polysomal association in the BS cohort 
than the HCs. If the difference was post-initiation we would not expect to find differences 
between the two groups. The sucrose density gradient experiments showed similar findings in 
both groups. Although the majority of the total mRNA in the samples was free mRNA (figure 
22 shows the main peak in the free mRNA fraction), very little CXCL10 mRNA was free in 
either HCs or BS. Levels of CXCL10 mRNA expression were very low in the unstimulated 
samples, but even in these samples, most of that small amount of mRNA was associated with 
polysomes. It may be that there is a basal level of CXCL10 mRNA sequestered in association 
with polysomes and miRNAs, which upon stimulation may dissociate from miRNAs and 
translation may occur. The results of these experiments lead us to hypothesise that miRNAs 
may be responsible for the differential CXCL10 protein production in BS.  In turn, miRNA 
expression is controlled by a number of factors, including transcription factors. 
Intriguingly, Mycobacterium tuberculosis (MTB) has been shown to increase the production of 
CXCL10 and CXCL9 protein despite inhibition of CXCL10 and CXCL10 transcription and this 
mechanism has been explored in vitro [386]. IFN-γ is essential to the host defence against MTB, 
however, the ability of virulent MTB to survive within macrophages for extended periods of 
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time has led to the notion that it interferes with host signalling pathways activated by INF-γ. 
MTB has been shown in several studies to inhibit STAT1 [386, 387].  Bai et al studied the 
virulent strain of MTB Hc7Rv and its effect on IFN-γ signalling in differentiated THP-1 
macrophages. They found that MTB infection inhibited IFN-γ stimulated induction of CXCL10 
and CXCL9 mRNA, and observed that it unexpectedly enhanced the IFN-γ induced CXCL10 
and CXCL9 protein production. They found they could replicate this finding in primary human 
monocyte derived macrophages. They found that both the p38 MAPK and NF-κB signalling 
pathways were involved in both inhibition of transcription and enhanced translation. They found 
MTB blocked STAT1 binding to its cis regulatory element. They found that the inhibition of 
mRNA was mediated by the NF-κB and p38 MAPK pathways, as this inhibition was no longer 
seen once highly specific NF-κB or p38MAPK inhibitors were added. This was not seen with 
the addition of an MEK1 inhibitor. Regarding protein production, stimulation of infected cells 
with IFN-γ was found to lead to an increase quantity of protein despite inhibited levels of 
mRNA. Lysed cells contained no CXCL9 or CXCL10 protein confirming that these proteins are 
not stored intracellularly. This increased protein response could be attenuated by pre-treatment 
with BAT 11-7082 (MAPK inhibitor) or SB203580 (NF-κB inhibitor) or both, again indicating 
that MTB via NF-κB and p38 MAPK signalling inhibited IFN-γ induced transcription but 
increased translation. The study did not assess if these transcription factors influenced miRNA 
expression, but commented that as no protein was stored intracellularly the mechanism was 
likely to be secondary to more efficient translation. [386]. The similarities to our study are 
obvious, and in future work it would be interesting to investigate if these signalling pathways 
are the link between the initial IFN-γ signal, and the downstream switch resulting in more 
efficient translation, possibly via regulation of miRNAs.  
To our knowledge this approach to investigating protein regulation has not been undertaken in 
an inflammatory disease before.  Our findings show an ‘uncoupling’ in the mRNA:protein   
ratio in BS. The marked, general uncoupling between transcriptome and translatome gene 
expression changes allow us to propose a biological model by which the exaggerated 
inflammatory response in BS may be operating. 
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5.7.1 Clinical relevance of the observation 
The relevance of our findings was investigated by correlating findings with (i) the MSU 
response; (ii) clinical DAS and characteristics and (iii) medications that the BS subjects were 
taking. We did not find a correlation between the MSU skin prick response and the CXCL10 
observation. The reason for this may be that the two are unrelated. As we found low levels 
rather than high levels of CXCL10 protein in skin blister fluid, again this suggests that our 
observation may be more relevant to non-skin related manifestations. However, another 
interpretation may be that we were unfortunate in choosing subjects with a mild disease 
phenotype for the earlier experiments, and this is supported by the fact that the CXCL10 protein 
was not all that elevated in any of these subjects, and they certainly were not the more extreme 
responders in the in vitro experiments. The BS Leeds questionnaire is only a crude measure of 
disease activity, and there are currently no good biomarkers to determine disease activity or 
severity reliably. We may have had more exciting results in our skin blister study had we chosen 
ten other subjects.  
We found no significant differences in CXCL10 response in subjects taking different 
medications, although the experiment was not powered to look for this. The fact that subjects 
were on such a wide variety of medications, and that our findings were not reproduced in SLE 
or RA cohorts (who were on the same types of medications), makes it very unlikely that 
medications account for our observations. Additionally we would have expected a suppressed 
rather than exaggerated response in the medicated group if medications were influencing 
outcomes. Unfortunately there is no robust animal model for BS, and the limitation of studying 
patients who are taking medications is unavoidable, but we think it is not likely that our results 
can be explained by the effects of medications. 
CXCL10 results, both at the protein level and the protein:mRNA ratio were higher in BS 
subjects with a high DAS than in subjects with a low DAS. While results between high and low 
DAS were not significantly different, there was a trend for higher CXCL10 with increasing 
DAS, and it is possible that this would have reached significance with higher numbers. There is 
currently no reliable biomarker for BS disease activity, and clinical measurement of CXCL10, 
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possibly as part of a panel, may be clinically useful to assess disease activity of patients. It may 
be of particular use in patients with ocular or neurological disease, in contrast to mucocutaneous 
or cardiovascular disease where levels are similar to those of HCs.  
It is interesting that CXCL10 was highest in subjects with neurological disease, followed by 
ocular disease. No difference was seen between levels in HCs and those BS with limited 
mucocutaneous disease or cardiovascular disease. Where CXCL10 has been found to be 
implicated in BS, it has usually been related to those with neuro BS [388]. High level of 
CXCL10 have been found in CSF from BS [135]. CXCL10 has been implicated in neurological 
involvement of other inflammatory diseases also. For example in Multiple Sclerosis (MS) the 
both CXCL10 and the CXCR3 receptor has been described as being present on virtually all 
perivascular T cells and astrocytes associated with active lesions [389]. In addition there is an 
increased amount of CXCL10 protein in the CSF of patients with active attacks of MS [389]. 
Our study was not designed to examine the question of disease subtypes and a larger study to 
assess this would be interesting. 
5.7.2 Correlation of elevated CXCL10 protein in vitro to low 
CXCL10 observed in skin blisters 
There are several possible explanations for conflicting results between the skin blister model 
and the in vitro findings. Firstly, these are very different investigative tools. A skin blister 
contains an extensive milieu of cell types and proteins including metalloproteinases and other 
substances that degrade or take up CXC10. Therefore it is possible that CXCL10 is secreted to a 
greater extent in the blister environment in BS, but that there are also more CXCR3 receptors 
binding it, and more MMPs degrading it. It has been shown that biopsies from oral ulcers of BS 
subjects had increased numbers of CXCR3 receptors [154]. The other explanation is that 
CXCL10 is not found in high levels in the skin, and given that our findings correlated well to 
neurological and ocular disease but poorly skin or vascular disease this is an equally valid 
hypothesis.  
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5.8 Future work and potential clinical usefulness of this 
observation 
Diagnosis of BS remains largely clinical. Furthermore there is no clinically useful biomarker for 
disease activity. The condition is poorly understood and treatments are suboptimal.  As 
established from this work, the IFN-γ-CXCL10 inflammatory pathway in monocytes may 
behave fundamentally differently in BS, and could potentially be used as a tool for 
differentiating BS patients from other inflammatory conditions, or for assessing disease activity, 
or potentially to predict patients likely to develop neurological or ocular manifestations, or to 
identify potential candidates who may benefit from anti-CXCL10 monoclonal antibody therapy. 
An anti-CXCL10 monoclonal antibody has already been shown to be safe in RA patients, 
although it was only mildly effective in this disease. It may be that some patients, possibly those 
with neurological or ocular disease may benefit from this therapy. Additionally, future work 
aimed at dissecting the pathways involved, for example identifying miRNAs involved or 
transcriptional pathways that are also influencing translation, may provide us with new targets 
for treatments. 
Future work will initially be directed towards gaining a deeper understanding the potential role 
miRNAs may play.  
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6. Concluding Remarks 
BS is a multisystem disorder characterized by mucocutaneous lesions (oral ulcers, genital ulcers 
and skin pustules), arthritis and intraocular inflammation. The pathogenesis of BS is poorly 
understood but it is considered a complex polygenetic syndrome, with environmental triggers. A 
Th1 skew has been reported.  This project aimed to dissect abnormal inflammatory responses in 
BS to gain an understanding as to which pathway(s) are responsible for the phenomena.  
In Chapter 3, the hypothesis that the abnormal cutaneous inflammatory response to "non-
specific" stimulation in BS is associated with a failure of deactivation of macrophages during 
the resolution phase of inflammation was explored using human in vivo models of inflammation 
(MSU injections and skin blisters). Secondary aims were to classify other cells present as well 
as relevant cytokines in blister fluid. We studied cantharidin-induced skin blisters in 12 BS and 
12 Healthy controls (HC), analysing blister fluid cells and cytokines using flow cytometry and 
multiplex bead cytokine analysis respectively. 
Generating suction blisters over inflammatory-responses using the MSU blister model did not 
turn out to be a useful approach for obtaining inflammatory tissue from BS subjects, although 
this technique may still have a use for protocols requiring fewer cells and offers the benefit of 
directly sampling cells and fluid from the site of the MSU reaction without the need for a 
biopsy.  The cantharidin skin blister method was found to be a useful and robust model of skin 
inflammation, giving reliable volumes of fluid and adequate cell numbers for all analysis. We 
found trends but no significant differences between BS and HC with regard to our primary aim, 
assessing markers of macrophage activation/deactivation. In both HC and BS, subjects had low 
percentages of macrophages in early blisters (where neutrophils predominated) which increased 
in late blisters, and there was a non-significant trend towards BS having less deactivation in 
later blisters. However this finding was not statistically significant.  Most subjects had low HLA 
DR in peripheral blood which increased in the early blister and begun to settle in the late blister. 
It is possible that with higher numbers of participants, and by excluding BS subjects taking 
corticosteroids we may have found greater differences. Both HC and BS had high percentages 
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of neutrophils in early blisters and fewer in late blisters. Low levels of lymphocytes and natural 
killer cells were observed in both groups at all time points which made it difficult to look for 
differences between the groups with our numbers. We were surprised that we found no 
differences in any cell type or cytokine level between the two groups apart from CXCL10 levels 
which were significantly different, but that significance was lost with multiple testing 
adjustments. In vitro also led us to wonder if we had chosen subjects with quite a mild disease 
phenotype for the skin blister experiment, as these subjects had among the least dramatic rise in 
CXCL10 protein.   
The erythema surrounding blisters in BS subjects was a very interesting finding. This correlated 
with the size of erythematous responses to MSU crystals, but was not associated with any 
obvious differences in immune cells or cytokines. We reflected on what other mechanisms 
could be resulting in this erythematous response. Neuropeptides came to mind for several 
reasons, as agents that could be playing a role in this setting 
In Chapter 4, the hypothesis that the abnormal cutaneous inflammatory response may involve 
neuropeptides was explored. We applied capsaicin topically to BS and HC, and measured the 
resultant change in dermal blood flow using laser doppler imaging to evaluate if neuropeptides 
such as CGRP may play a role in the abnormal cutaneous inflammatory response in BS. The 
primary question was to assess if there was a difference in capsaicin response between HC and 
BS. We also wished to assess if subjects with a large MSU skin reaction and subjects who had 
an erythematous response to the cantharidin blisters also had an abnormal capsaicin skin test, to 
see if this could offer the possibility of a quicker and simpler test than the MSU injection. 
Finding a simpler test to replace MSU /pathergy testing would be a useful advance.  BS subjects 
who experience pathergy tend to describe an exaggerated response to any stimuli, from thorn 
pricks and nettle stings to surgical cuts and MSU injections. Therefore we were surprised when, 
contrary to our expectations, the BS cohort did not mount an exaggerated flare response to 
capsaicin. In fact the BS cohort displayed a smaller flare response than HCs. This experiment 
therefore did not find evidence of an exaggerated flare in BS subjects and did not find the 
capsaicin skin test to be of diagnostic use. Possible reasons for the smaller flare response found 
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in the BS cohort are either study limitation factors (a false negative) or else that BS subjects do 
release less CGRP upon stimulation (a true positive). The findings of this chapter may reflect a 
true representation of CGRP release in BS. CGRP differs from SP in that, in addition to 
vasodilation, there is evidence of it having anti-inflammatory properties. As discussed in detail 
in the introduction to Chapter 4, CGRP leads to less antigen presentation, inflammatory cell 
recruitment and also directly stimulates IL-10 release. A SNP in IL-10 which results in less IL-
10 protein production in the disease-associated-allele was discovered in the first two GWAS 
studies of BS.  Less IL-10 may slow down the resolution phase of inflammation, and therefore it 
is possible that if BS patients secrete less GCRP in response to insults such as MSU injections, 
then this may result in less activation of or slower activation of cutaneous anti-inflammatory 
pathways leading to a prolonged cutaneous inflammatory response, as seen following MSU 
injections. 
Chapter 5 summarizes key in vitro experiments undertaken alongside in vivo experiments. The 
IFN-γ / chemokine pathways were explored in detail in CD14+ monocyte populations in BS, 
HC and disease control subjects. Significant differences were observed in the IFN-γ-CXCL10 
pathway response in BS compared to HC and other disease controls. We found that following 
IFN-γ stimulation, monocytes from BS produced equivalent mRNA but more CXCL10 protein, 
indicating differential post-transcriptional regulation. Sucrose density gradient experiments 
suggested a role for miRNAs in this observation, as there was no difference in polysomal 
association of CXCL10 mRNA in BS and HCs.  We have discovered that BS monocytes have 
dysfunctional post-transcriptional regulation of CXCL-10 mRNA, resulting in overexpression 
of CXCL-10 protein upon IFN-γ stimulation. There is an uncoupling of the transcriptome from 
the translatome. This may contribute to the exaggerated inflammatory responses that 
characterises BS. 
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